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ABSTRACT 
Cystic echinococcosis (CE) is parasitic disease caused by cestode E. granulosus.  Turkana in 
Northern Kenya carries one of the highest CE burdens in the world.  Between 1983 and 2015 
a control programme implemented there by African Medical Research Foundation (AMREF) 
using ultrasound screening for diagnosis evaluated CE prevalence.  Several treatment options 
were available in the programme for those affected. This programme generated a vast amount 
of raw data as well as serum samples from infected patients was analysed in the first part of 
this project to assess the efficacy of treatments in Turkana.  Data analysis showed that 7.9 % 
of untreated cases achieved spontaneous cure and 34% improved without intervention. 
Chemotherapy appeared to stabilise the cysts rather than cure and increasing dose to two was 
ineffective in inactive cysts.  Surgical outcome was improved with chemotherapy from 85% to 
91% cure. 
The project also sought to undertake a detailed analysis of serum antibody responses of 
individual patients and correlate them to gross ultrasound pathologies.  Five recombinant 
antigens identified from literature to have different properties were purified and optimised.  
These were Echinococcus granulosus antigen B (EgAgB), Echinococcus granulosus 
elongation factor 1 beta/delta (EgEF-1β/δ), Echinococcus granulosus fatty acid binding protein 
1 (EgFABP1), Echinococcus granulosus heat shock protein 70 (EgHSP70) and Echinococcus 
granulosus thioredoxin peroxidase (EgTPx). Crude hydatid cysts fluid was also used for 
comparison. The optimised antigens were then assessed for differential immunoreactive 
properties towards specific total IgG and sub-classes 1 and 4 serum antibodies. 
 Significant differences in expression of IgG1 and IgG4 was found in response to some 
antigens. In simple cysts (CE1), IgG4 was highly expressed in comparison to IgG1, in response 
to HSP70 and EgEF-1β/δ while in cases where the characterised by cyst infiltration and 
x 
 
calcification (CE4) cysts, IgG1 was the prominent antibody in response to HSP70, EgEF-1β/δ 
and HCF. The best diagnostic tool was found to be expression of IgG1 in response to TPx 
which showed sensitivity of 95%. 
In follow-up, responses of total IgG towards AgB was found to be useful. It increased in all 
recurring cases, decreased in all improved cases and remained relatively constant in 
unchanging cysts. 
Use of circulating antigens rather than antibodies in diagnosis showed better results in active 
cyst.  In patients with CE1 cysts, antigen levels were seropositive for 91.1 % (31/34), in CE2 
cases 81% (34/42) of the patients, in CE3 cases 42% (9/21) and in CE4 cysts and 59 % (16/27). 
Overall hydatid cyst antigens were detected in 72.6 % (90) of the cases. 
  
xi 
 
DECLARATION 
No portion of the work referred to in this thesis has been submitted in support of an application 
for another degree or qualification of this or any other university or other institute of learning. 
All of the ultrasound scanning, clinical examinations and treatment (chemotherapy and 
surgery) was done by the AMREF Team. All the serum samples were collected by Mr. 
Eberhard Zeyhle of AMREF. These were initially stored at – 20oC at AMREF, Lokichoggio 
and subsequently at AMREF, Nairobi. Samples were then transferred to Salford and stored at 
– 20oC until use for diagnostic procedures. Ultra sound images and patient data (in a basic 
spreadsheet) was provided courtesy of Mr Eberhard Zeyhle, AMREF. Initial cloning and 
expression of recombinant antigens was done by Dr. Anthony Bodell. The stocks of E.coli cells 
harbouring the recombinant antigens were provided to the candidate for further expression of 
diagnostic antigens.  
 
  
xii 
 
Acknowledgements 
I would like to acknowledge and thank the following people and organisations for their 
contributions to this work. 
Professor Phil Craig and Professor Mike Rogan of University of Salford for the opportunity to 
undertake this work and for their supervision. 
Mr Eberhard Zeyhle of AMREF for inviting me to participate in field-work and providing 
clinical data, ultrasound images and sera samples. 
Dr Tony Bodell of University of Salford for providing stocks of E.coli cells harbouring the 
recombinant antigens and for instruction on laboratory techniques. 
Dr Alex Mastin, Dr Freya Van Kesteren, Dr Belgees, Dr Harrigan, Ms Rebecca Rushworth, 
Mrs Helen Bradshaw and the members the University of Salford Life Sciences Department for 
helpful discussions and encouragement. 
 
 
 
  
xiii 
 
COPYRIGHT STATEMENT. 
 
(i)  Copyright in text of this thesis rests with the Author.  Copies (by any process) either in full, 
or of extracts, may be made only in accordance with instructions given by the Author and 
lodged in the library of the university.  Details may be obtained from the librarian.  This page 
must form part of any such copies made.  Further copies (by any process) of copies made in 
accordance with such instructions may not be made without permission (in writing) of the 
Author. 
 
(ii)  The ownership of any intellectual property rights which may be described in this thesis is 
vested in The University of Salford, subject to any prior agreements to the contrary, and may 
not be made available for use by third parties without the written permission of the University 
which will prescribe the terms and conditions of any such agreement. 
 
(iii)  Further information on the conditions under which disclosures and exploitation may take 
place is available from the School of Environment and Life Sciences. 
  
xiv 
 
GLOSSARY 
AE  Alveolar echinococcosis  
ALBZ  Albendazole 
AMREF African Medical Research Foundation  
BamH   1 Type II endonuclease obtained from Bacillus amyloliquefaciens  
BCIP/NBT (5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium)  
cDNA   Complementary DNA  
CE   Cystic echinococcosis  
DNA   Deoxyribonucleic acid  
dNTP   Deoxynucleoside triphosophates xv  
EDTA   Ethylenediaminetetraacetic acid  
EgAgB  Echinococcus granulosus antigen B  
EgEF-1β/δ Echinococcus granulosus elongation factor 1 beta/delta  
EgFABP1  Echinococcus granulosus fatty acid binding protein 1  
EgHSP70  Echinococcus granulosus heat shock protein 70  
EgTPX  Echinococcus granulosus thioredoxin peroxidase  
ELISA  Enzyme-linked immunosorbent assay  
gDNA  Genomic deoxyribonucleic acid  
HC  Hydatid cyst  
HCF   Hydatid cyst fluid  
IgG   Total immunoglobulin  
IgG1   Immunoglobulin subclass-1  
IgG  4 Immunoglobulin subclass-4  
IMAC   Immobilised metal affinity chromatography  
IPTG   Isopropyl β-D-thiogalactopyranoside xvi  
xv 
 
LB   Luria-Bertani  
LB-amp  Luria-Bertani medium containing ampicillin  
LL   Laminate layer  
PAGE   Polyacrylamide gel electrophoresis  
PAIR   Puncture, Aspiration, Injection and Re-aspiration  
PBS   Phosphate buffered saline  
PCR   Polymerase chain reaction  
PDB  Protein data bank  
PMBC  Peripheral blood mononuclear cells  
PMSF   Phenylmethylsulfonyl fluoride  
PNPP   p-nitrophenylphosphate  
PSC   Protoscolex  
PT   Percutaneous treatment  
SDS   Sodium dodecyl sulphate  
SDS-PAGE  Polyacrylamide gel electrophoresis  
TBE   Tris base, boric acid, and EDTA  
TE   (Trishydroxymethyl) Aminomethane and EDTA  
TEMED  Tetramethylethylenediamine  
Th1   Subset helper-inducer T-lymphocyte 1 cells  
Th2   Subset helper-inducer T-lymphocyte 2 cells  
TRIS   (Trishydroxymethyl) Aminomethane  
US   Ultrasonography  
WHO   World Health Organisation 
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1 INTRODUCTION 
 
A study in 1982 found that Turkana had the highest incidence of hydatid in the world.  As a 
result, African Medical and Research Foundation (AMREF) (French, 1992) implemented a 
control programme to alleviate the problem. This programme focused on reducing the infection 
in dogs by regular praziquantel treatment and culling of stray, and on diagnosis of new cases 
for treatment via surgery of albendazole chemotherapy. Because of basic health care facilities 
surgery was often delayed for several months until surgeons from Nairobi could visit Kakuma 
hospital in Turkana. For this reason, many patients could be monitored by ultrasound scanning 
and serology during an “untreated” period. Many patients were also put on one or more courses 
of albendazole treatment without surgery and monitored for long periods of time. A final group 
of patients refused all forms of treatment because of personal beliefs, but were followed up by 
ultrasound and serology.  
For over 30 years the programme generated data relating to variations in cyst morphology.  
Many patients were diagnosed and followed-up with ultrasound scans and serological 
sampling.  Therapies included albendazole chemotherapy, surgery, PAIR. Patients were 
followed up after therapy and treatment outcomes evaluated over time. Other cases were 
followed up without treatment for periods of time due to logistical problems and clinical 
assessments.  The programme generated a vast amount of raw data as well as serum samples 
from infected patients.  The data base for full clinical information is the property of AMREF 
but a separate sub set with serological data base will be available under the university of 
Salford.  
Throughout the study it was evident that there was great variation in both hydatid cyst size and 
morphology within individual patients. There was also great variation in how each patient 
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responded to albendazole treatment. The current study was therefore designed to investigate 
cyst morphological variation in both untreated and treated individuals. Different morphologies 
are associated with pathological categories (CE1 – CE5) but since most of our cases fell in the 
category of CE1 – CE4, our study was based on those. We analysed the association of cyst 
morphology with a) age of the patient b) size of the cyst c) length of follow-up d) outcome of 
therapy and other parameters.  
Another major aim of the study was to improve field diagnosis of CE. The only method used 
in diagnosis and patient follow-up was ultrasound scanning. In this study, we assessed the value 
of recombinant antigens in detection of anti-hydatid antibodies in serum for immunodiagnosis 
and follow-up. The rationale behind this was serological studies are useful in confirming 
imaging where cystic lesions are morphologically unclear. Ultrasound imaging detects 
abdominal cysts and misses out on cysts in the lungs, bones and central nervous system.  In 
community surveys, serological studies may provide partial diagnosis of the cases missed to 
allow follow-up better imaging techniques.  
From literature we identified 5 recombinant antigens which may have differential 
immunoreactive properties towards serum antibodies in patients with different CE types.  These 
were Echinococcus granulosus antigen B (EgAgB), Echinococcus granulosus elongation 
factor 1 beta/delta (EgEF-1β/δ), Echinococcus granulosus fatty acid binding protein 1 
(EgFABP1),  Echinococcus granulosus heat shock protein 70 (EgHSP70) and Echinococcus 
granulosus thioredoxin peroxidase (EgTPx).  The antigens optimised and then assessed for 
differential immunoreactive properties towards specific total IgG and sub-classes 1 and 4 
serum antibodies in 100 patients all harbouring different cyst types. 
Another possible route towards immunodiagnosis is the assessment of circulating E. 
granulosus antigens.  These are only detectable in serum during active infection and levels 
3 
 
decrease continually after successful chemotherapy or surgical removal. In this study, we 
evaluated the relevance of E. granulosus antigens in diagnosis and long-term follow-up of CE. 
The structure of this study is set out in the following diagram.  
 
Figure 1-1:  Thesis structure. 
Chapter 2:  Literature was reviewed from key workers in the field. 
Chapter 3:  We aimed at evaluating different human and cyst factors at first presentation.  
Human factors included age and sex while cyst factors included cyst locations, numbers and 
types.  We also sought to relate cyst morphological changes to different treatment outcomes. 
Look at how cyst morphology varied with age, gender, and what different cyst stages had to 
do with those 
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Chapter 4: Five antigens with a potential to show differential immunoreactivity towards serum 
antibodies in patients with CE were purified and optimised for immunodiagnostic testing.  The 
rationale of this was that current serological methods show sub-optimal sensitivities and 
specificity.  No single antigen has been found that is suitable for all cyst sizes and types in 
different organs.  The answer might lie in using multiple antigens consecutively. 
Chapter 5:  With the antigens purified in chapter 4, we sought to compare the diagnostic value 
of different antigens and coordinate the immune responses to defined CE pathology. 
Chapter 6:  We sought to evaluate if there was a longitudinal link between antibody profiles of 
individual patients and morphological changes in cysts.  We also sought to associate responses 
of total serum IgG and IgG sub-classes 1 and 4 to disease outcome during follow-up.  Antibody 
levels fluctuate during the course of an infection depending on the rate of cyst development, 
antigenicity and sensitivity to chemotherapeutic agents.  We evaluated different antigens and 
their association with those changes as they may be useful markers for cyst fertility, viability 
or instability.   
Chapter 7:  We evaluated the relevance of the level of circulating antigen to cyst morphology.  
We also aimed to also link changes in antigen profiles to morphological changes in cysts during 
follow-up.  The rationale behind this chapter was that unlike circulating antibodies, circulating 
antigens are found in serum only when there is an active infection and continually decrease 
after successful treatment.  We assessed their usefulness in diagnosis and follow-up of active 
cysts.    
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2 Literature Review 
2.1 General Introduction 
Echinococcosis is a cyclo-zoonotic parasitic disease caused by larval stages of cestodes of the 
genus Echinococcus the order cyclophillidea.  The parasite has an indirect life cycle which 
requires two mammalian hosts.  The definitive hosts are carnivores harbouring the egg-
producing stages and intermediate hosts which include lagomorphs, rodents and ungulates 
harbouring infective metacestode stages.  Infection to humans is accidental but not uncommon 
and the World Health Organisation (WHO) has classified it as a ‘Neglected Zoonotic Disease’ 
(NZD) (Brunetti et al., 2010; McManus et al., 2012; Molyneux, 2012).  It affects wildlife, 
domestic animals as well as humans especially the marginalised poor in remote communities.  
Classification is generally based on human infection and as such, two main species are 
prevalent: Echinococcus granulosus sensu lato (the cause of cystic echinococcosis) and 
Echinococcus multilocularis (the cause of alveolar echinococcosis).  Besides the two main 
ones, other species have been shown to cause minor incidences of human disease like the 
polycystic E.oligarthrus (Zimmerman et al., 2009) and E.vogeli mostly found in South 
America (D'Alessandro et al., 2008). 
2.2 Speciation and genetic variation within Echinococcus 
Different strains or subspecies of E. granulosus have been confirmed by genetic studies with 
diversity in morphology, development and host specificity.  They are genotypically named G1 
– G10 according to the intermediate hosts in which they were first discovered (Eckert et al., 
1997; Lavikainen et al., 2003; Romig et al., 2015).  The variations in different strains include 
hook number and dimensions, host infectivity and specificity, biochemical composition, 
genetic makeup and infectivity to humans (Eckert et al., 1997).  Sheep strain G1 is the most 
common cause of infection in humans and may be responsible for more than 88% of human 
cystic echinococcosis cases (Rojas et al., 2014).  Echinococcus multilocularis which causes 
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alveolar echinococcosis in humans has long been recognised as a distinct species of 
Echinococcus.  It is characterised by multi-vesicular lesions, primarily in the liver, although 
other organs, including the lungs, spleen and brain may be affected (Bakhsh et al., 2017; 
Gottstein et al., 1985).  Intermediate hosts for E. multilocularis include small mammals 
including microtine voles Arvicola terrestris, Microtus arvalis, Microtus limnophilus (Duscher 
et al., 2006; Kotwa et al., 2019), Tibetan hares, Lepus oiostolus (Xiao et al., 2004) shrews, 
Sorex jacksonii, ground squirrels Citellus undulatus lyratus, and harvest mice, Peromyscus 
gossypinus (Smyth, 1968).  The definitive hosts are usually canids E.multilocularis has been 
found in red fox, Vulpes (Duscher et al., 2006) grey wolves, Canis lupus (Al-Sabi et al., 2018; 
Hegglin et al., 2008), coyotes, Canis latrans (Luong et al., 2018) and domestic dogs, Canis 
familiaris (Budke et al., 2005).  Three main isolates for E. multilocularis named the ‘European’, 
‘Asian’ and ‘North American’ clades have been identified with the names describing their 
geographical location (Nakao et al., 2009).   
Uni-cystic echinococcosis is caused by E.oligarthrus.  In South America, rodents are the 
intermediate host and the final hosts include wild felids including pumas, jaguars and Panthela 
onca  (Rausch et al., 1981).  It is potentially zoonotic and human cases have been reported in 
Colombia and French Guiana (D'Alessandro et al., 2008; Debourgogne et al., 2017). 
Polycystic echinococcosis is caused by E. vogeli and is characterised by growth and 
development of polycystic structures in visceral organs.  Their major intermediate host is 
usually the neotropical rodent with bush dogs being the definitive host.  It is also zoonotic with 
human incidents recorded in Paraguay and Argentina (do Carmo Pereira Soares et al., 2014).  
The human infection by E. oligarthrus and E. vogeli appear to be restricted to South America 
with twelve cases reported in 1979 rising to 106 cases by 2007 in 12 countries (D'Alessandro 
et al., 2008; Tappe et al., 2008).  
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2.3 General life cycle of E. granulosus 
As a taeniid tapeworm, Echinococcus species have an indirect life cycle involving two 
mammalian hosts through predator-prey interactions (Figure 2-1). 
 
Figure 2-1:  Lifecycles of Echinococcus granulosus.  Adapted from (McManus et al., 
2003). 
The adult tapeworm ranges in length from 3 mm to 6 mm.  Its anatomy include a head (scolex) 
and 3 segments (proglottids), an immature proglottid, a mature proglottid and a gravid 
proglottid.  The scolex is the attachment organ and has a prominent rostellum with a double 
row of 30 - 36 hooks and 4 suckers.  The gravid proglottid contains sexually mature organs and 
eggs.  Inside each egg is a 6 hook-armed embryo hexacanth (Figure 2-2).  The adult tapeworm 
lives in the small bowel of its definitive host, attached to the mucosa by its hooklets (Beyrouti 
et al., 2007). 
Traditionally, domestic dogs are the main definitive host for E. granulosus whereas foxes are 
the definitive host of E. multilocularis.  The definitive host acquires infection by ingestion of 
parasitised viscera.  Mastication, as well as the action of pepsin releases the viable 
protoscoleces from the brood capsule (Smyth, 1968).  The apical region evaginates and 
establishes by attaching to the host tissue with their suckers reaching maturity in the small 
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intestine es.  Mature E. multilocularis is found in the posterior region of the small intestines 
whereas E.granulosus is found in the anterior quarter (Thompson, 2017), perhaps due to 
different physiological requirements (Macpherson et al., 1985).  The parasite forms new 
proglottids and matures into a hermaphroditic worm.  Egg production commences after self-
insemination and the number of eggs produced per proglottid varies within species.  
Echinococcus granulosus has been shown to produce as many as 1500 eggs per proglottid 
whereas E. multilocularis produces up to 200 eggs per proglottid (Mehlhorn et al., 
1983).Gravid proglottids pass out in the faeces of the definitive host.  Each egg can survive in 
the atmosphere from between 2 days to 3 months depending on environmental conditions.  The 
egg sizes can range between 30 to 40 µm in diameter and contain an outer vitelline layer, an 
impermeable granular layer and a thin cytoplasmic layer surrounding the oncosphere (Eckert 
et al., 1983; Sarwari, 2018). 
 
Figure 2-2:  Echinococcus granulosus adult worm.  Adult form of tapeworm. E egg; H 
hook; P proglottids; S head or scolex; SO sexual organs (Tagliacozzo et al., 2011) 
Intermediate hosts acquire infection through oral ingestion of the infective viable eggs in 
contaminated soil, water, and plants.  The eggs hatch in the stomach and small intestines of the 
intermediate host by the disintegration of the embryonic blocks and release of the oncosphere 
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from its membrane(Thompson, 2017).  This disintegration and release may be assisted by 
proteolytic enzymes in the stomach or small intestines (Smyth, 1968).  Once liberated, the 
oncosphere penetrates the microvilli and migrate across the intestinal mucosa to their 
predilection site.  Oncospheric development then takes place through vascularisation, 
degeneration of the hooks, central cavity formation and development of the germinal and 
laminated layer (Heath, 1971) as shown in Figure 2-3.  Various animal species including man 
are aberrant hosts and have no role in the parasite lifecycle. 
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Figure 2-3:  Schematic drawing of a liver hydatid cyst.  BC brood capsule; DC  daughter 
cyst; GL  germinal layer; L liver; LL laminated layer; P pericyst; S protoscolex (Rogan, 
2019 unpublished). 
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2.4 Cystic Echinococcosis in humans and its public health implication 
2.4.1 Global distribution of Echinococcus granulosus and CE. 
 
Figure 2-4:  Geographical distribution of E. granulosus.  (Adapted from WHO/OIE 
(2001a); (Eckert et al., 2004) 
 
Echinococcus granulosus is the most geographically widespread of the Echinococcus species 
(Figure 2-4) occurring in Europe (Orsten et al., 2018), North America (Lavikainen et al., 2003), 
South America (Reyes et al., 2010),  Africa (Rogan et al., 2006), Asia (Chakrabarti et al., 2012) 
and Australasia (Jenkins, 2005).  The main life cycle is the domestic one which involves mainly 
domestic dogs and domestic animals namely cattle, sheep, goats and camels (Eckert et al., 
2004).  However, wild animals have also been found to be infected including jackals, hunting 
dogs, hyenas, lions and leopards (Rausch et al., 1981; Wassermann et al., 2015) and in 
herbivores wildebeest, impala, hartebeest, grants gazelle, buffalo, blue duiker (Eugster, 1978) 
waterbuck, warthog and giraffe (Wassermann et al., 2015). 
12 
 
It is predominant in areas where sheep rearing is a significant economic activity since sheep 
are the most susceptible intermediate hosts.  Other factors that feed these transmissions include 
poor sanitation, close association between domestic animals and humans as well as inadequate 
knowledge about the transmission and life cycle.  Dogs are the major definitive host for E. 
granulosus and proximity of dogs and humans especially in playful intimate contact is a driving 
factor for human infection (Chaâbane-Banaoues et al., 2016).  Dogs shed the eggs which adhere 
to their hairs, muzzle and paws and accidental ingestion of those eggs causes human infection.  
Indirect contact with the eggs through contaminated arthropods, water sources and vegetables 
may also cause infection (MacPherson et al., 1983). 
The sylvatic cycle of E. granulosus occurs between wild carnivores and wild herbivores and 
mainly involves the definitive hosts the wolf, moose and the intermediate hosts, caribou jackals 
and deer in Sri Lanka and macropods and dingoes in Australia (Himsworth et al., 2010)  
2.4.2 Cystic Echinococcosis 
Human infection with E. granulosus causes tissue cysts, a condition known as cystic 
echinococcosis, also called hydatid disease, E. granulosus echinococcosis and hydatidosis.  
Humans, though acting as intermediate hosts, are a ‘dead end host’ and rarely play a role in the 
natural life cycle following infection.  Aetiology of infection involves per-oral infection with 
E. granulosus eggs known as primary echinococcosis after which individual encapsulated cysts 
may develop in any anatomical site in the human body (McManus et al., 2017).  In the human 
host, many cysts remain sterile and may become calcified while others grow and produce 
protoscoleces and daughter cysts (MacPherson et al., 1983).  Primary cysts are commonly 
hepatic, and most patients harbour solitary cysts with single organ involvement.  Cysts may 
development in many internal organs mainly in the liver and the lungs, although E. granulosus 
can affect any organ including abdominal cavity, heart, bone, muscle, nervous system.  Liver 
cysts account for 63 – 85% of the cases while lungs were 25 – 30%.  Other locations include 
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muscles, bones spleen, kidneys, heart, thyroid, pancreas, breast, prostate and thyroid (Grosso 
et al., 2012; Kiresi et al., 2003). 
Multiple cysts may be found either in one organ or multiple organs.  They usually indicate 
secondary infection mostly resulting from primary cyst rupture.  This can either  be 
spontaneously or through induced trauma, releasing viable protoscoleces into the surrounding 
(Adewunmi et al., 2004; Pakala et al., 2016).  In Turkana, of 369 patients, 72 % harboured 
solitary cysts, 12 % had 2 cysts while 16 % had 3 or more cysts (Romig et al., 1986).  The right 
lobe of the liver is more commonly infected than the left lobe (60 – 85%) and multiple cysts 
are more likely to be in the liver (Mihaila et al., 2015).  Symptoms appear when cysts exert 
mass effect on affected organ or adjacent organs.   
2.4.2.1 Complications of hydatid cysts 
Most uncomplicated hydatid cysts are asymptomatic.  Nonspecific complications may be due 
to allergic reactions and occasional toxicity (Gelincik et al., 2007).  Symptoms can be produced 
by mass effect or complications of loss of cyst integrity.  They range from pain, jaundice and 
fever to more severe pathological manifestations including hepatomegaly, cholangitis, 
splenomegaly and portal hypertension in abdominal CE , chest pain, expectoration and 
coughing with pulmonary CE (Goumas et al., 2007; Mehta et al., 2016). Symptoms depend on 
locality and size of cysts, speed of growth and complications of rupture.  Most cysts causing 
symptoms are larger than 5 cm in diameter except when they involve the brain or eyes (Ali et 
al., 2009).  In the abdomen, where there is less restriction on growth through pressure from 
other organs, cysts may grow to several litres.  Large cyst can cause complications due to 
mechanical pressure associated with a growing space-occupying and isolated mass 
compressing the adjacent organs, causing pain (Sayek et al., 2004).  This may prove fatal 
especially if the pressure is on the diaphragm and lungs (Boudaya et al., 2014). Chronic 
inflammation of the liver may result as the cyst pushes against it in growth causing adhesion 
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to the adjacent organs, especially pronounced in infected cysts.  Cysts have been shown to 
adhere to the hepatic hilum or the retro-hepatic vena cava (Lewall, 1998).  
Secondary complications may occur due to infection, rupture or leakage of the cyst. This may 
be due to trauma or degeneration of the cyst membrane due to age or chemotherapy. Minor 
leaks may cause increased pain, flushing and urticaria while a major rupture can lead to life-
threatening allergic reaction and secondary echinococcosis  (Pakala et al., 2016) 
Incidence of biliary communication in liver cysts varies between 2 % and 42 % (Ramia et al., 
2014; Sakhri et al., 2004).  It is mostly caused by intra-cystic pressure, rupture into the bile 
duct or due to erosion of the bile duct wall due to the cyst (Ramia et al., 2014).  Cyst fluid or 
daughter cysts enter the ducts of the biliary tract leading to obstruction by daughter cysts 
resulting in cholangitis or into the bronchial tree causing expectoration of cyst fluid. (Yuksel et 
al., 2007). This usually leads to allergic reactions and complicates treatment as the use of 
scolecidal agents may cause damage to the ducts (Cooney et al., 2004).   
Cysts may become infected with bacteria and E. coli is the most common infection. The 
symptoms range from mild fever to full-blown sepsis and this has been shown to reduce the 
effectiveness of albendazole and mebendazole (Prousalidis et al., 2008).  Surgical interventions 
are cautious as there is a possibility of the bacteria killing off the cyst.  Also, if the patient’s 
health has declined significantly, there is an even higher chance of biliary communication 
(Pakala et al., 2016). 
2.4.3 Public health implication of Echinococcosis 
The disease burden of echinococcosis in endemic communities is considerable.  Direct costs 
are due to mortality among the treated and untreated patients, morbidity, direct and indirect 
costs of hospitalisation and recovery period and any residual disability or clinical sequelae 
(Piseddu et al., 2017).  Present estimates suggest that cystic echinococcosis results in the loss 
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of at least one million DALYs annually and possibly up to three million with about 200,000 
new cases diagnosed each year (Hotez et al., 2014).  Other costs are less tangible and difficult 
to calculate.  The reduced capacity to function optimally during the prodromal period, anxiety 
attached to the knowledge that one is infected as well as the real fear it creates, not just for the 
infected person but also for the wider community.  Treatment of CE requires either surgical 
interventions or long periods of chemotherapy and sometimes both (Santivanez et al., 2010). 
This can be costly and very often challenging because the most affected communities are 
usually behaviourally and/or geographically isolated from main stream health systems as they 
tend to be nomadic, semi-nomadic or transhumant communities. 
Besides the health costs, economic losses are associated with CE due to losses in livestock 
Animal death or the viscera condemnation have a direct economic impact which is calculable. 
However losses due to reduction in carcass weight, fertility rate and milk production can have 
a high degree of variability (Torgerson, 2003; Torgerson et al., 2000; Torgerson et al., 2001). 
Reports on the presence of hydatid disease in places where it had not been reported before has 
raised questions over the recent years as it appears to be increasing in global public health.  It 
may be reflective of recent spread or just better surveillance (Hotez et al., 2014).  In Turkana, 
clinical diagnosis is considerably underestimated and only reflects a small proportion of 
existing infections, usually due to variable incubation periods and misdiagnosis of clinical 
infections.  The diagnostic facilities are meagre and dependent on faith-based hospitals and 
charitable organisation.  As the rate of infection is very high, nearly every tumour seen by a 
doctor is suspected of being hydatid disease and the common consensus ‘is it's 70% correct’ 
(MacPherson et al., 1983) 
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Since most of the Turkana people do not hold down a formal job, it is difficult to calculate time 
lost from work, cost of convalescence, time taken to resume normal job and differences in cost 
due to treatment from different cyst locations.   
2.4.4 CE in Kenya  
East Africa loosely consists of 10 countries including Burundi, Rwanda, Tanzania, Uganda, 
Kenya, Somali, Southern Sudan, Eritrea, Ethiopia and Djibouti.  Echinococcosis has been 
reported in 8 of them except for Rwanda and Burundi which may be down to under reporting 
rather than absence.  It is endemic in pastoral nomadic communities but rare in agricultural 
ones.  Kenya has one of the highest infection rates in the world, mostly confined to Turkana 
County. The Maasai have a similar lifestyle to the Turkana but have a much lower preverence 
of hydatid disease (Macpherson et al., 1989; Romig et al., 2011).  However, there is a greater 
preverence of Taenia saginata among the Maasai and there is a probability that infection with 
T. saginata gives concomitant immunity, prevents superinfection and reduces parasite 
population pressure on the existing parasite (Lightowlers, 2010). 
Assessments of surgical incidence estimated 96 per 100,000per annum in Turkana (O'Leary, 
1976) and a report by French and Nelson’s  in 1982 estimated annual cases at 198 cases per 
100 000 people in the north and 19 cases per 100,000 in the south of Turkana (French et al., 
1982).  It was also found that the north harboured 3 times the number of dogs per person 
compared to the south.  Despite the extra-ordinarily high human incidence, the infection rate 
in domestic animals was much lower than would be expected.  The opposite was true for 
Maasai land where human cases are much lower than would be expected given the high 
infection rates among domestic animals (French et al., 1982; Romig et al., 2011).  This 
discrepancy may be explained by the fact that alongside domestic cycles, wild cycles have been 
reported involving jackals, wild dogs and lions as definitive hosts and wildebeests, and other 
herbivore species as intermediate hosts in Turkana communities (Macpherson et al., 1993).  
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Human factors may also play a role in influencing such variations including the fact that 
concentration of dogs in homes in Turkana is high as compared to those accompanying herds 
in Maasai land and therefore close interaction with women and children is much higher 
(Macpherson et al 1983).   
2.4.4.1 The Turkana community 
Turkana District lies on the floor of the Rift Valley in the North-West corner of Kenya.  One of 
the most important features of the district is the variability of rainfall and this determines the 
whole landscape with the possibility of drought every 3 to 10 years (Mccabe, 1987).  The 
Turkana people are nomadic pastoralists and are among the most disadvantaged of the Kenyan 
poor.  Their way of life has remained unchanged and movements are influenced not only by 
rainfall and availability of fodder for their animals but also by traditional ceremonies, many of 
which are performed in the same initiation sites around the district (Mccabe, 1990).  Rainfall 
usually falls on the higher grounds, mainly in storms, and all the seasonal rivers start flowing.  
The people move from the hills and higher grounds into the plains for celebrations, weddings 
and initiations.  At the start of the dry season, they will all move again to the higher grounds 
and the water supply will mostly be from dug up wells and residues from the dried river beds 
(Best, 1980). The Turkana people are neighboured by the Karamojong in Uganda and the 
Toposa in Sudan.  The political borders are however very vague as the way of life among the 
three tribes are quite similar regarding land use, economic and social interactions.  Insecurity 
is a serious problem since all three groups are in constant conflict and are seriously armed.  
Healthcare initiatives by the government appear to neglect these nomadic populations because 
of the logistical requirements, geographic isolation, uncertain civil status, poor 
communications, possible hostility due to lack of trust and their perceived low priority. 
On the other hand, even when there is provision of medical services, the Turkana have a distrust 
of government structures due to their possession of illegal firearms creating a barrier to the use 
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of available services. Constant movement makes access to dispensaries in villages difficult as 
groups with animals avoid farming areas. Visits to the village markets exclude the most 
vulnerable – women and children (Cohen, 2005). 
2.4.4.2 Health care provision among the Turkana 
As with most nomadic communities, the Turkana are a marginalised group due to lack of proper 
infrastructure, medical facilities as well as traditional and cultural barriers.  Most Turkana live 
in small temporary dwellings made from wood, animal skins and palm leaves and inside the 
homes live a man, his wives, children and animals. Their movement and/or settlement is highly 
influenced by rainfall which is sporadic.  Provision of continuous medical services is often 
hindered by language barriers, unpredictable relocations and low population densities resulting 
to neglect from the government and various agencies (Barkey et al., 2001). Medical provision 
in Turkana has fallen in the hands of charitable organisations as well as church groups.  The 
largest provider of medical as well as surveillance services in Turkana has been African 
Medical Research Foundation, (AMREF), who set up a centre in Northwest Turkana to 
investigate the cases of CE which were the highest worldwide.  In 1983 a control programme 
was set up in the most populated area of Turkana based around the settlement of Lokichokio. 
The main objectives of the programme were surveillance for the detection and treatment of 
hydatid patients, regulation of dog numbers, dosing with praziquantel and education of the 
local community (Macpherson et al., 1984).  Traditionally, the Turkana have two kinds of 
illnesses, one caused by “God”, which is how they regard hydatid disease, the other caused by 
“witchcraft”.  Those illnesses caused by God are treated using herbs, usually boiled and the 
infusion drunk mostly to induce vomiting.  Western medication is also treated as thus and is 
considered more potent if it induces vomiting (Loewenthal et al., 1991).  The illnesses caused 
by a witch doctor on the other hand can only be treated by a diviner or medicine man.  The line 
between the two is unclear and if a remedy does not work, the illness is re-categorised.  While 
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the Turkana people have an acceptance for western medication especially that which works 
quickly, e.g. anti-malaria medication and surgical treatment, they will resort to the traditional 
medication if they deem the medication is taking too long or is not working (Harragin , 1994).   
In general, efforts at reduction of incidence of echinococcosis in Turkana are confounded by  
a) Community ignorance of the risk factors including dog association as well as adherence 
to chemotherapy. 
b) The low priority given by the government to arid and pastoral communities due to their 
marginal contribution to the GDP 
c) Complicated human treatment which requires complex surgery or continuous 
chemotherapy,  
d) Unmanaged dog populations with many dogs being stray. Attempts to kill the strays, 
sterilise the females and deworm owned dogs have had short term results.  
e) The nomadic nature of the people complicates follow – up and supervision on 
compliance to chemotherapy. Lack of continuous government funding as well as the 
community’s failure to ‘own’ the eradication project also has negative effect on control. 
The success of AMREF among the Turkana has been mostly due to their clinics being mobile, 
their respect of the cultural ethics as well as consistency.  The local people seeing the results of 
treatment over time build trust and willingness for treatment.  However, as the projects wound 
down, the success of their control measures was rapidly being reversed especially in control of 
stray dog population.. 
20 
 
2.4.4.3 E. granulosus transmission and risk factors for human infection in Turkana 
Kenya 
One of the greatest risk factors in human CE is the behaviour of man towards domestic dogs.  
Direct contact occupationally between dogs and livestock is an important driver (Craig et al., 
1984; French et al., 1982).  The chief risk factor for dog infection is access to raw infected offal 
either through purposeful feeding or lack of restraint (Moro et al., 1999). Lacks of knowledge 
about echinococcosis as well as the presence of other acute poverty-related diseases and 
conditions are a boost for canine infection (Buishi et al, 2006). Another significant risk factor 
for both human and animal CE are water sources, shared indiscriminately between animals and 
humans (Macpherson et al., 1985).  Nomadic lifestyle dictates ownership of many dogs living 
in proximity women and children in the homestead, sometimes sleeping in the same room as 
the sheep and human giving access to intermediate hosts (French et al., 1984) 
2.5 Variation in cyst morphology, pathology and natural history of cyst development  
In many early studies in different parts of the world, patients with CE were simply listed as 
“hydatid patients”.  However, descriptions, diagnostic criteria, pathology and the outcomes of 
different treatments are highly variable (Rexiati et al., 2014).  E. granulosus is an extremely 
slow growing parasite with cysts varying significantly in size and internal structure.  The advent 
of portable ultrasound scanners has highlighted this and aided in the decision-making process 
in relation to surgical or chemotherapeutic treatment strategies.  Variability in clinical features 
and treatment outcomes points to the need for a more personalised approach to therapy (Saylam 
et al., 2013).  Ability to correctly diagnose and classify cysts allows the clinician to decide on 
whether to treat, choose the treatment option (surgery, chemotherapy or PAIR therapy), 
determine response to treatment and choose an alternative therapy where necessary and in some 
cases, identify any complications whether natural or induced (Macpherson et al., 2003). 
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Over the years, different types of classification of CE has been suggested.  Garbi’s 
classification (Gharbi et al., 1981) based it on the ultrasound morphology and structure of 
hepatic cysts in 121 patients. Five categories were proposed, from pure fluid collection in type 
I, fluid collection with split walls in type II, fluid collection with septa in type III, heterogenous 
echo patterns in type IV and thick walls in type V. These categories acted as a cornerstone for 
all other classifications and a few modifications have been added.  They form basis for 
clinicians to perform or recommend the appropriate interventions.  Ultrasound has become an 
increasingly useful tool in diagnosis as well as monitoring the progression or regression of 
cysts.  The WHO-informal working group on Echinococcosis (WHO - IWGE) have also come 
up with a standardised classification to unify and simplify diagnosis (Eckert et al., 2001) 
summarised in Table 2-1  
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Ultrasound classification of CE cysts 
Cyst status Cyst type Ultrasound Diagnostic Features 
ACTIVE CL They contain uniform clear fluid and are indicative of cysts in the early stages of 
development and usually progress to other cystic lesions.  Non-parasitic lesions 
were excluded during further observation and follow up. 
 CE1 Fertile, unilocular and bear visible cyst walls.  They exhibit snow flake signs due 
to movement of brood capsules referred to as hydatid sand.  Sizes vary from 
small < 5cm, medium >5cm <10cm, large >10cm. 
 CE2 Multivesicular and multiseptated with daughter cysts filling the unilocular 
mother cyst either partially or completely.  The daughter cysts have ‘honey 
comb’ like structures inside the wheel-like septations and contain viable 
protoscoleces. The cell walls are visible and US pictures are pathognomonic.   
TRANSITIONAL 
& ACTIVE 
CE3 Transitional cysts with cell walls detached and appearing as a floating membrane 
(“water lily sign”), indicating residual cyst fluid.  They may contain daughter 
cells anechoic in appearance that are less rounded due to reduced intra-cystic 
fluid pressure.  These are signs of a cyst degrading but may be followed by 
daughter cell production, making it active again. 
INACTIVE CE4 Inactive cysts with heterogeneous hyperechoic degenerative contents and no 
daughter cysts.  They have a ball of wool sign and US features are not 
pathognomonic in most cyst locations requiring a differential diagnosis. 
 CE5 They are characterised by a thick wall and can been either fully or partially 
calcified.  US features are not pathognomonic.   
Table 2-1:  Features of the WHO-IEWG Classification (WHO Working Group, 2003) 
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2.5.1 Anatomical/Morphological Variations 
2.5.1.1 Cystic lesion 
Cystic lesions (CL) may or may not be of parasitic origin.  They are usually small or medium 
size without any internal echoes and septations and no obvious pathognomonic signs.  
Additional diagnostic techniques are necessary for differential diagnosis.  They are circular or 
oval and contain uniform clear fluid and represent cysts in the early stages of development. 
They are active and will progress to other cystic lesions (Figure 2-5). 
 
Figure 2-5:  A hepatic sonogram shows a CL cyst. 
The unilocular cystic mass has a smooth regular and slightly echogenic wall.  
2.5.1.2 Cyst type 1 (CE1) 
These are usually fertile, unilocular cystic lesions with visible cyst walls and visible anechoic 
content (Figure 2-6).  They exhibit snowflake signs due to movement of brood capsules 
referred to as hydatid sand. High-Resolution sonogram demonstrates an echogenic layered 
appearance with a clear inner endocyst and outer ectocyst (arrows). 
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Figure 2-6:  Sonogram of CE1 cysts.  
(Subhash T., 2015,April 19)  ultrasound in hydatid disease.  Retrieved from 
http://sonodigest.blogspot.com/2015/04/ultrasound-in-hydatid-disease.html) 
 
2.5.1.3 Cyst type 2 (CE2) 
The CE2 cysts are multi-vesicular and multi-septate with daughter cells filling the unilocular 
mother cyst either partially or completely (Figure 2-7).  The septations appear wheel-like with 
daughter cysts producing honey comb-like structures.  They contain viable protoscoleces, the 
cell walls are visible and US pictures are pathognomonic.  They have variable sizes Small < 
5cm, medium >5cm <10cm, large >10cm. 
         
Figure 2-7:  Pelvic scan showing a CE2 cyst. (Subhash T., 2015, April 19) 
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2.5.1.4 Cyst type 3 (CE3) 
These are transitional cysts with cell walls detached and appearing as a floating membrane, 
indicating residual cyst fluid (Figure 2-8).  They may contain daughter cysts and are less 
rounded due to reduced intra-cystic fluid pressure.  These are signs of a cyst degrading but may 
be followed by daughter cell production, making it active again. 
Figure 2-8:  Sonogram of Cyst Type 3(CE3). The sonogram shows a large complex with 
detached endocyst layer echogenic structure b) collapsed hydatid cyst with detached 
endocyst.  
In recent years it has been suggested that the C3 classification could be subdivided into C3a 
and C3b with C3a being as described above and C3b referring to collapsing daughter cysts in 
a semi-solid matrix (Brunetti et al. 2010). (Subhash., 2015,April 19)  ultrasound in hydatid 
disease.   
2.5.1.5 Cyst type 4 (CE4) 
These are inactive cysts with heterogeneous hyperechoic degenerative contents and no 
daughter cysts (Figure 2-9).  They have a ball of wool sign and US features are not 
pathognomonic in most cyst locations requiring a differential diagnosis. 
a b 
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Figure 2-9: Sonogram of a CE4 cyst.  The figure shows a solid mass with multiple 
hypoechoic structures with evidence of a fusing inactive cyst.  
(Subhash, 2015,April 19)  
2.5.1.1 Cyst Type 5 (CE5) 
These are considered inactive calcified cysts (Figure 2-10).  They are characterised by a thick 
arch shaped wall and can been either fully or partially calcified.   
 
Figure 2-10:  Sonogram of a CE5 cyst.  It depicts a rounded mass with echogenic rim 
calcification casting distal shadowing.  
(Subhash, 2015)  ultrasound in hydatid disease.   
Classifications are also made based on cyst size where Cyst size < 5cm is classed as small (s), 
5-10cm as medium (m), 10cm – 15cm as large (l) and > 15 cm as very large (v.l) (Guarnera et 
al., 2004). 
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2.5.2 Natural history of CE and variation in cyst development 
The period between oral egg infection and development of first symptoms in CE infection is 
difficult to establish due to the slow growing nature of hydatid cysts.  The rate of growth may 
vary according to cyst location and age of patient.  Cyst growth is slow thus initial primary 
infection is asymptomatic and may remain so for many years, sometimes never manifesting at 
all (Ammann et al., 1996) .  Other cysts may develop and size may range between 1 cm and 15 
cm (Gahukamble et al., 1991; Romig et al., 2011) though larger cysts have been reported 
(Nadeem et al., 2006). In Turkana, most cysts range between 1cm and 10 cm diameter in 
patients with an average size of 10.2 cm (SD ± 4.9) though Romig et al., (1986) found that 16 
% measured ≥ 16 cm. The rates of growth of the cysts vary greatly in different host species and 
among different human populations.  Slow growth is observed among indigenous people in 
Alaska compared to the Turkana in Kenya (MacPherson et al., 1983; Wilson et al., 1968)  
Most initial infections involve unilocular hepatic cysts which may remain asymptomatic for 
many years whereas pulmonary cysts become symptomatic due to compression of the lung 
tissue which causes chest pains (Karaoglanoglu et al., 2001).  Abdominal cysts are usually 
diagnosed incidentally during medical check-up for other illnesses, routine health check, or 
due to trauma/fall where the cysts rupture causing anaphylactic shock. 
On diagnosis, it is difficult to establish when the infection happened. In children, the infection 
can only be as old as the child while in adults it is difficult to establish time of infection based 
on imaging alone. The cyst rate of growth can however be calculated in consequent follow-up 
though rates of growth have been known to vary among different communities and age groups.  
Rates of growth can therefore be used as an indicator of time of infection as well as disease 
prognosis if left untreated.  There are few studies on untreated cysts due to ethical reasons but 
in some cases, patients have refused treatment or treatment was not readily available. Estimated 
growth in published studies vary between 0 and 2.9 cm per annum in hospital treated cases and 
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between 6.7 and 7.2 by mass ultrasound screening.  Most of the cases show no cyst growth at 
all and in some cases even spontaneous cure/disappearance of the cyst (Romig et al., 1986).   
From the many longitudinal ultrasound studies that have been carried out, it is clear that not 
only are there differences in the internal structure of cysts from individuals (WHO-IEWG 
classification), but also that the structure of cysts within the same individual can change in both 
untreated patients and those treated with albendazole. The natural history of cyst development 
therefore can involve both growth of the cyst and internal modifications which are usually 
perceived as progressively or degenerative.  Cysts with a CE1 classification may progress to 
CE2 or CE3 and ultimately to CE4 or CE5 (classified as inactive).  It is important to note that 
this progression is not necessarily linear, and cysts may revert back to previous forms or remain 
unchanged at each stage for long periods (Solomon et al., 2017).  Whilst the changes in cyst 
morphology during chemotherapy are understandable, those that occur in untreated patients are 
less well understood but may have an immunological basis (Rogan et al., 2015) (Table 2-2). 
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Phase of 
Development 
Morphology Developmental events Approximate time 
post-infection 
Immunological events 
Establishment 
 
Oncosphere to small 
hydatid cyst (<2mm). 
Surface membrane 
changes and formation of 
the laminated layer 
0 - 1 month Initiation of antibody 
response and cellular 
infiltration – highly effective 
at parasite killing 
Established 
Maturing 
 
Sterile cyst with germinal 
and laminated layers 
Growth - Increase in size 
of cyst (2-20 mm) and 
laminated layer. Cysts 
may become fertile 
(produce protoscoleces) at 
the end of this phase. 
 
1 – 12 months Detectable IgG to a range of 
antigens. 
Formation and thickening of 
host adventitial layer. 
Cytokine activity largely of 
Th2 type. Lack of fertility 
may be affected by antibody 
or cellular attack 
Established Stable 
 
 
Large fertile cysts greater 
than 1 cm. Growth rate 
increases   variable 0.2 - 
3cm/year.  WHO 
Classification Type 1. 
Growth rate variable 0-
3cm/year. Well-developed 
pericyst. 
1 year + Detectable IgG to a range of 
antigens. Antibody levels 
may fluctuate over time.  
Generally modulated 
cytokine response (Th2 or 
mixed). Well-developed 
adventitial layer. 
Established 
Unstable 
 
Cysts generally greater 
than 10cm. Internal 
reorganisation including 
collapse of cyst wall or 
formation of daughter 
cysts. 
WHO Classification 
Types 2 and 3. 
3 years + Antibody profile variable. 
May involve IgG1. Cytokine 
profile more Th1 or mixed. 
Cell population in adventitial 
layer may contain high 
numbers of macrophages 
(Th1) or Eosinophils (Th2). 
Established 
Degenerative 
 
* 
WHO Classification 
Types 4 and 5. 
3 years + Often reduction in antibody 
response in calcified cysts. 
Infiltration of cyst cavity 
with leucocytes may be 
accompanied by elevated 
antibody levels. 
Table 2-2:  Re-evaluated phases of parasite development/immunity (Rogan et al., 2015). 
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2.6 Diagnosis of CE 
Human hydatid disease is usually diagnosed by the clinicians only when advanced and 
symptomatic cases present themselves requiring immediate intervention.  Four major reasons 
for seeking medical help include, a) When large cysts exert mechanical pressure on the tissues 
and organs affecting general functions and maybe causing pain, b) When a trauma causes 
rupture of the cyst consequently resulting to an allergic reaction, c) when other symptoms 
including eosinophilia or other allergic phenomena are present and d) incidental finding during 
surgical, imaging or body scanning for other conditions.  Many asymptomatic infections are 
diagnosed during active surveillance campaigns which are now conducted even in the very 
remote communities where CE is endemic.  
2.6.1 Imaging 
Imaging techniques that can identify space-occupying lesions in internal organs are available 
and many of them have been used in diagnosing CE.  These include X rays, Magnetic 
Resonance Imaging/Computerised Tomography (MRI/CT) scans as well as ultrasound.  
Ultrasound is the most common imaging technique used for diagnosing CE.  It is safe, painless, 
non-invasive, easy to perform and relatively inexpensive after the initial cost.  It can determine 
the number, size, location and condition of the cyst and also gives instant results which can be 
permanently recorded (MacPherson et al., 1983). Portable ultrasound machines are now 
particularly in use for diagnosis of asymptomatic cases during routine epidemiological mass 
screening.  They give satisfactory results for abdominal localisations showing between 93–
98% (Carmena et al., 2006; Macpherson et al., 2003).  Imaging is also a useful tool in follow 
up of patients, allowing the clinician to continuously assess changes in size, morphology, 
development or regression which in turn influences the choice of treatment. (WHO 
WorkingGroup, 2003).  Many asymptomatic patients stay symptom-free for many years 
requiring no otherwise risky intervention (Wang et al., 2003).  Despite its great value as a 
31 
 
diagnostic tool, ultrasound is not always ideal for diagnosis of extra abdominal cyst locations, 
determining cyst complications for example infection or visualising liquids within the cyst 
(Golzari et al., 2013).  Other imaging techniques are in use for diagnosis and follow-up of CE 
including computerised tomography, (CT) and magnetic resonance imaging (MRI.  They are 
especially useful in the diagnosis of extrahepatic cysts especially lung and bone cysts, calcified 
cysts, monitoring therapy and recurrences (Gougoulias et al., 2010). They also give better 
clarity in small cysts (>1 cm in diameter) (Bukte et al., 2004) through differential diagnosis.  
While these advanced techniques are precise and accurate in diagnosis of CE, they are very 
expensive and require technical expertise that is not readily available in the endemic areas.  
They are mostly useful in passive surveillance when the patient is already in hospital whereas 
portable ultrasound scanners allow active surveillance making screening campaigns possible 
even in the very remote communities where CE is endemic (MacPherson et al., 1987) 
2.6.2 Serology 
Early diagnosis of echinococcosis greatly improves treatment outcome (Wen et al., 2019).  The 
asymptomatic nature of early infection necessitates large scale surveillance of populations at 
risk (Zhang et al., 2006).  Today, primary diagnosis of hydatid disease is based on US images 
in line with the current classification system of hydatid cysts.   
Serological studies are useful in confirming US imaging where cystic lesions presented are 
morphologically unclear and in community surveys since US mostly detects abdominal cysts 
and may miss out on lung cysts, bones or CNS.  Serology may provide partial diagnosis for 
some of those cases missed and allow a follow-up with better imaging techniques (Rogan et 
al., 1997).  
Any CE treatment requires long term follow up and monitoring to determine cure or relapse.  
Imaging provides some information on morphological changes in cyst structure, but these are 
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not pathognomonic in some cases.  It is also not possible to predict disease outcome in 
heterogeneous cysts in terms of the parasite stability/ instability or in transition from non-viable 
to viable.  Potential to link the US images to immunological markers is needed especially 
during the cyst stages that are “silent” post-treatment when the cyst changes may go undetected 
(von Sinner et al., 1991). 
Many serologic techniques have been evaluated and reviewed for diagnosis of CE(Jiang et al., 
2001; Liu et al., 1993; Mamuti et al., 2004; Mohammadzadeh et al., 2012; Santivanez et al., 
2012), usually based on detecting host immune responses to CE infection especially antibodies, 
cellular responses and to a lesser degree circulating antigen. 
 
2.6.2.1 Antibody detection 
A wide range of specific antibody production against protoscoleces, the germinal layers and 
the transforming oncosphere have been investigated for their diagnostic value. Different classes 
and subclasses of antibodies have been assessed for serodiagnosis of CE using various parasite 
antigen preparations. The most frequently used source of antigen is E.granulosus hydatid cyst 
fluid (HCF).  It is antigenically rich and has been shown to contain more than ten immune-
precipitable antigens derived from the parasite (Li et al., 2010; Siracusano et al., 1991).  
Hydatid cyst fluid (HCF) is a complex mixture of glycoprotein, lipoproteins, carbohydrates 
and salts (Oriol et al., 1971).  About 60 % of this is host material and the rest is from 
metacestodes metabolism (Zhang et al., 2003).  Crude extracts of native antigens exhibit poor 
diagnostic performance due to variability in antigen quality from different sources, locations 
and parasite genotypes (Zhang et al., 2011).  Crude HCF is highly immunogenic with 
sensitivity between 75 to 95 % but is difficult to standardise.  It also has limitations in 
specificity as it crossreacts with other cestode infections (89%), nematode infections (39 %) 
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and trematode infections (30%) (Eckert et al., 2004).  To improve its diagnostic value, crude 
HCF has been purified into antigen 5 (Ag5) and antigen B  (AgB)  for ELISA and 
immunoblotting for detection of total IgG / IgG subclasses or other Ig isotypes (IgM, IgE, IgA) 
in human sera (Khabiri et al., 2006; Virginio et al., 2003). 
2.6.2.2 Recombinant technology 
Other parasite tissues including protoscolex and adult somatic antigens have been investigated 
for their potential use in serodiagnosis in human CE.  In their crude form, they have shown 
little promise due to poor sensitivity and specificity (Jiao et al., 2013; Severi et al., 1997).  Some 
of the antigens explored are associated with adult excretory and secretory products(Carmena 
et al., 2005) oncosphere antigens (Chow et al., 2004) as well as carbohydrate-rich laminated 
layer of the E.granulosus metacestode (Diaz et al., 2011; Taherkhani et al., 2007).  Diagnostic 
performance of CE antigens has been greatly improved by recombinant proteins (Kordafshari 
et al., 2015; Zhang et al., 2007) . 
Antigenicity and the immune responses against immunodiagnostic antigens are complex and 
trying to establish a “one fits all” situation is difficult.  In virtually all studies evaluating the 
effectiveness of different antigens in diagnosis, each preparation has been screened against 
“clinically proven cases” but as stated previously, clinical cases represent an extensive range 
of possible cyst morphologies.  In addition, in the case of recombinant antigens, different 
authors have used different expression systems making comparisons more difficult.   
In this thesis we assess the relative antibody profiles of clinically distinct CE cases against a 
panel of E.granulosus recombinant antigens produced in the same expression vector. 
2.6.2.2.1 Recombinant antigen production and standardization 
Sensitive diagnostic tools are important in clinical diagnosis, epidemiological surveillance and 
infection control.  Current serological methods in CE diagnosis show sub-optimal sensitivity 
and specificity and standardising the use of available antigens has proved difficult.  
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Antibody levels have been shown to fluctuate in the course of an infection. Changes in immune 
responses depend on the cysts rate of development, antigenicity, transmission dynamics and 
sensitivity to chemotherapeutic agents (Barnes et al., 2012; Daeki et al., 2000).  Different 
antigens have been associated with those changes and their use as markers for cyst fertility, 
viability or instability assessed by different authors (Carmena et al., 2004; Jiao et al., 2014; 
Ortona et al., 2004).  However, no single diagnostic antigen has been found that is suitable for 
all cyst sizes and classifications in different organs.  
Hydatid fluid and its components such as antigen B have been the main antigens used in 
diagnosis. Crude hydatid fluid has high sensitivity but limitations arise with specificity while 
antigen B has good specificity but limited sensitivity (Zhang et al., 2011).  In addition to cyst 
fluid antigens, other studies have looked at other parasite tissues such as protoscoleces, 
laminated layer and excretory-secretory products for use as diagnostic antigens but optimum 
sensitivities and specificities have not been achieved thus far (Carmena et al., 2006; Sarkari et 
al., 2015).  Shortcomings of using native antigens include variability in antigen quality when 
sourced from different locations and sources. Hydatid fluid from sheep, cattle and horses all 
vary in antigenicity and even cysts fluid from the same genotype and host species can show 
variations (Gottstein et al., 1987).  
Many molecules from E. granulosus have been cloned and produced as recombinant proteins. 
Use of recombinant antigens reduces the variability in antigenicity although even they can 
show variation depending on the expression system used (Sadjjadi et al., 2009).  We identified 
4 antigens from literature which may have different properties and appeared to have differential 
immunoreactive properties towards serum antibodies in patients with CE (Carmena et al., 2006; 
Zhang et al., 2003).  Elongation factor 1 (EF-1β/δ) is a 24 – 31 kDa protein found in both the 
protoscoleces and hydatid cyst fluid (Siracusano et al., 2012; Vuitton, 2004; Zeghir-Bouteldja 
et al., 2017) and is thought to be useful in parasite translation and elongation (Kamaishi et al., 
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1996).  Its expression is reported to be highly correlated to presence of allergic reactions with 
a higher response to IgE than IgG and may therefore play a role in allergic reactions in CE 
cases.   Ortona et al. (2004) and Rigano et al. (1995) reported a correlation to IgG4.  Presence 
of EF-1β/δ human auto-antibodies in CE patients was demonstrated by Mori et al. (1986)and 
the homology to EF-1β/δ may suggest their possible role in parasite immune evasion.  High 
levels of serum antibodies in response to EF-1β/δ antigen for example have been recorded in 
patients with calcified cysts while lower titres were recorded in patients with active cysts 
(Margutti et al., 1999).  Elevated levels of this protein in hydatid cyst fluid mayn be indicative 
of a degenerating cyst.  The higher percentage of humoral immune responses to EF-1β/δ 
observed in CE patients with calcified cysts than in patients with active cysts suggests that the 
protein is released into the hydatid fluid after the degeneration of PSC and indicates its possible 
use in immune-surveillance of CE.  Furthermore, EF-1β/δ may play a key role in the allergic 
disorders (urticaria, itching, and anaphylactic shock) that often complicate the course of CE 
(Margutti et al., 1999; Siracusano et al., 2008). 
Thioredoxin peroxidise (TPx) has been isolated from protoscoleces and hydatid cyst wall but 
is absent in cyst fluid (Manzano-Román et al., 2015; McManus et al., 2003).  In the early stages 
of development, the cyst is surrounded by cells from host immune responses including 
macrophages, eosinophils and neutrophils (Margutti et al., 2008).  This is accompanied by 
production of highly reactive oxygen species (ROC) not just from the host but also from the 
metabolic activities of the cyst.  These ROCS can cause protein oxidation and lipid 
peroxidation leading to cyst breakdown (Wang et al., 2018).  TPx is thought to be an enzymatic 
scavenger helping the parasite escape oxidative damage by removing H2O2 (Salinas et al., 
1998).  Similar levels are expressed throughout the parasite lifecycle in both active and inactive 
cysts (Li et al., 2004) found making it a valid antigen for diagnosis. 
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E. granulosus fatty acid binding protein 1 (EgFABP1) is a developmentary regulated protein 
characterised in the larval stages of E. granulosus.  Their roles may be provision of fatty acids 
from the host to the parasite for membrane synthesis and metabolic pathway (Alvite et al., 
2001).  The homology to other protein families like retinol binding protein and interstitial 
binding proteins suggest their role in transport and storage of lipids (Jones 1994).  Strong 
immune responses of FABP1 to larval stages of E. granulosus have been recorded  (Porfido et 
al., 2012) an indication that they may be an early marker of asexual reproduction (Alvite et al., 
2001)  
Heat shock protein 70 (HSP70) are highly conserved proteins whose roles include stabilising 
misfolded proteins, stress responses and protein translocation (Mayer et al., 2005).  Increased 
levels of HSP70 are usually a sign that an organism is exposed to stress (Hogervorst et al., 
1992; Kaufmann, 1990).  It has been found to be a dominant immunogen in parasitic infections 
including leishmaniasis, oncocerciasis and schistosomiasis (Maresca et al., 1994). 
EgAgB is a 120–160 kDa polymeric protein that dissociates in to 8, 16, and 20–24 kDa subunits 
under reducing conditions. The biological role of EgAgB includes inhibition of neutrophil 
chemotaxis, inducing apoptosis of immune cells and triggering of non-protective Th2 
responses (Zhang et al., 2011).  EgAgB belongs to a multigenic family with five other defined 
genetic groups: EgAgB1, EgAgB2, EgAgB3, EgAgB4, and EgAgB5 (Chemale et al., 2001; 
Fernández et al., 1996).  These subunits share sequence identity of between 44% and 81%.  
Similar antigens have been found in E.multilocularis species and genus Taenia (Carmena et 
al., 2006), giving rise to cross-reactivity.  Native EgAgB has sensitivity of between 60% to 
85% in ELISA test (Carmena et al., 2006).  In one study using ELISA test, EgAgB recombinant 
antigen showed a sensitivity of 74%, 96%, 90%, and 56% in patients with CE1, CE2, CE3, and 
CE4/CE5 cyst stages, respectively(Li et al., 2010).  
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After purification, the antigens showed a good immune response towards a pool of positive 
sera and poor responses towards negative sera.  This was a good basis for the next two chapters 
where these antigens were used for diagnosis and follow-up of confirmed CE patients. 
2.6.2.3 Antigen detection 
Many inconsistencies are associated with serodiagnosis based on antibody detection due to 
crossreactivity with other helminths producing false positives (Craig, 1986).  Other limitations 
include low responses in patients (Macpherson et al., 2003; Siracusano et al., 2008) and 
variation in responses with cyst type, cyst size and location (Hernandez-Gonzalez et al., 2008; 
Piccoli et al., 2013) and failure to distinguish between past and present infection, making it 
difficult to assess the efficacy of a treatment. 
Circulating antigens are only found in sera during an active infection and decline rapidly on 
disease resolution either through surgery or effective chemotherapy (Chandrakesan et al., 2003; 
Sadjjadi et al., 2009) and may be a better method of immunodiagnosis of CE as well efficacy 
of treatment.  Sensitivity of assays detecting circulating immune complexes and circulating 
antigens vary between 33 – 85% with better results obtained from a field coagulation test 
(Ghorbanpoor et al., 2006; Parija et al., 1997).  Just like in antibody detection various factors 
affect sensitivity and specificity.  These include nature of cysts where intact and small cysts do 
not release as much antigen and are therefore more difficult to detect whereas large, rapidly 
growing and fertile cysts have shown superior sensitivity (Lightowlers et al., 1995). In one 
experiment, the assay also showed superior results in liver cysts compared with kidney and 
lung but also showed crossreactivity with visceral leishmaniasis (Sadjjadi et al., 2009). 
2.7  Treatment of echinococcosis 
Although it is estimated that 1 million people suffer CE at any time and 3.6 million DALYs 
are lost (Hotez et al., 2014), it is a disease of the neglected poor communities and as such 
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receives very little attention in developed countries. This explains why clinical management 
procedures over the years still have inadequate evaluation on efficacy, effectiveness, rate of 
relapse, rate of adverse reaction and cost.  Also, why there is no advancement in development 
of new drugs. 
At infection, the patients are asymptomatic, and the cysts are small.  The rate of growth has 
been shown to be different in different communities, organs as well as age groups (Mufit et al., 
1998; Romig et al., 1986).  Onset of clinical symptoms depends on size of cyst, organ infected, 
localisation of cyst in that organ, number of cysts and the pressure on surrounding tissue 
(Eckert et al., 2004).  Abdominal cysts can remain asymptomatic for long periods of time 
whereas lung and bone cysts cause pain quite early after infection and are diagnosed earlier in 
the infection process. There is also the possibility of cyst rupture due to trauma which can cause 
anaphylactic shock or may lead to dissemination of protoscoleces resulting in secondary 
hydatidosis (Svrckova et al., 2018) 
At present, four treatment modalities are used namely Surgery, PAIR, Chemotherapy and 
watch and wait. Evidence in choosing any of the treatment options remains controversial due 
to insufficient carefully designed clinical studies. 
2.7.1 Surgery. 
Surgery remains the treatment of choice and is performed on a high proportion of patients 
because of its potential to cure completely.  It has been shown to be very successful in cases of 
simple cysts located in less risky organs.  Surgery is indicated for solitary, large, superficial 
cysts that are likely to rupture, infected cysts, those in vital organs and the ones exerting 
substantial mass effect (Brunetti et al., 2010). Open surgical procedures may be conservative, 
involving removing the parasite foci and leaving the pericystic membrane in situ while a more 
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radical surgical approach sees the complete removal of both cystic materials along with the 
pericystic membrane (Akbulut et al., 2010) 
It is counter-indicated in multiple cysts in multiple organs, in patients with high surgical risk 
and may prove impractical in areas with inadequate expertise and facilities in which situations 
alternative options of treatment are considered.  Surgical patients experience more risk of 
complication but lower relapse rate about 2% to 25% and this is greatly reduced by pre and 
post operational chemotherapy (Khuroo et al., 1997). 
2.7.2 Puncture Aspiration Injection Re-aspiration (PAIR) 
Puncture Aspiration Injection Re-aspiration (PAIR) was introduced in the mid-80S. It involves 
percutaneous puncture of the cyst under ultrasonographic guidance, aspiration of a substantial 
portion of the cyst fluid, injection of a parasiticidal solution and re-aspiration of the cyst fluid 
content after 5 - 20 min (Macpherson et al., 2003). A few ml of aspirate is first tested 
biochemically for sodium, potassium, chloride, calcium, proteins and glucose (Filice et al., 
1997; Solbiati et al., 1985)  and bilirubin in case of liver cysts and also parasitologically to 
assess for cyst viability (Filice et al., 1997). A parasiticidal solution,  95% ethanol is then 
injected into the cyst, approximately an equivalent of one- third of the amount aspirate, and re-
aspirated after 5 - 20 min (Ormeci, 2014).  Ethanol has been shown to be effective a few min 
after contact (Bean et al., 1985) 
It minimally invasive technique usually preceded and followed up by chemotherapy, with 
albendazole (Park et al., 2009).  Complications with PAIR can range from 28% when used 
alone and reduced to 5-10% when used alongside chemotherapy (Filice et al., 2000).  
There exists a risk of anaphylactic shock and/or spillage leading to dissemination of parasite 
and consequent implantation and secondary CE. This can be minimised by advances in imaging 
techniques as well as use of finer needles and catheters and about one per cent of the patients 
experience anaphylaxis or spillage (Dziri et al., 2004). Used together, PAIR and chemotherapy 
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showed efficiency as good as peri-cystectomy in hepatic CE with shorter hospital stay (Akhan 
et al., 2014; Filice et al., 1997).  A shortcoming of PAIR may be incomplete evacuation of the 
cyst content which may become an abscess, become infected or recur (Sayek et al., 2004). 
Modified forms of PAIR, percutaneous evacuation (REVAC) and percutaneous puncture 
drainage and curettage which include concomitant removal of entire cyst content have been 
described (Gabal et al., 2005; Zerem et al., 2005).  It involves insertion of a bore catheter into 
the cyst, infusing scolecidal agents and aspirating again until there complete wash out of the 
contents with the cyst is completely collapsed and consequently removing the entire endocyst.  
These techniques are indicated for multivesicular cysts, infected cysts, patients with several 
small cysts as well as pregnant women(Gabal et al., 2005). Protoscolecidal agents include 
hydrogen peroxide, cetrimide, chlorhexidine, hypertonic water and alcohol (Filice et al., 1997). 
The guidelines on scolicidal concentration are different in different setting and achieving 
optimal concentrations is difficult (Belghiti et al., 1986).  Contraindications for PAIR are cysts 
communicating with the biliary tree, cysts in a risky or inaccessible location and calcified or 
solid cysts, young patients under 3 years old and inaccessible and ruptured cysts (Sayek et al., 
2004). 
2.7.3 Chemotherapy 
Chemotherapy with benzimidazole compounds was initially recommended for inoperable cysts 
and patients with multiple cysts (John, 2003).  Today it is routinely used as a drug of choice 
for pre and post-surgery as well as an alternative to surgery in uncomplicated cysts 
(Macpherson et al., 1986) and its use has increased over the years.  Benzimidazole anthelmintic 
(BZD) including methylcarbamate compounds mebendazole (MBZ) and albendazole (ABZ) 
have been used for treatment of CE in humans for decades (Davis et al., 1986).   
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However, problems persist in determining the optimal administration period either as an 
adjunct perioperative therapy or on their own as this is still not clearly defined. Other 
limitations include the high cost of the drugs, side effects as well as efficacy not being optimum.  
Benzimidazole anthelmintic are not readily soluble in water and this influences absorption and 
limits their bio-availability leading to erratic therapeutic success (Lanusse et al., 1993).  To 
achieve high plasma concentration of these compounds, they need to be dissolved in gastro-
intestinal fluids (GI fluids), pass through the intestinal mucosa into the bloodstream and sustain 
an effective concentration around the parasite.  Poor GI absorption is problematic in sustaining 
systemic availability in enterally administered BZD (Davis et al., 1986; Sadjjadi et al., 2009).  
Albendazole has a better GI absorption rate than mebendazole after oral administration and has 
replaced mebendazole as the drug of choice (John, 2003; Vuitton, 1997). 
The benzimidazole compounds work by inhibiting tubulin polymerization, cellular transport, 
energy metabolism and waste excretion in the parasite.  As a consequence, the formation of 
new microtubules is stopped disrupting cell division, the energy reserves are progressively 
depleted and the waste products accumulate inside the cells eventually resulting in parasite 
death (Gottschall et al., 1990).  
Effective chemotherapy is still lacking, and extensive studies are still being done on the drugs 
available.  Mebendazole was the first drug tested for efficacy in echinococcosis and it is still in 
use as an alternative drug to albendazole which is now the “first intent” drug (Nakaya et al., 
1998).  The recommendation for the use of mebendazole is a daily dosage of 40 – 50mg/kg 
body weight divided in 3 doses and given postprandially during a fat rich diet. Absorption of 
mebendazole is suboptimal and average blood levels of < 10 µg/ml does not produce 
therapeutic effects invivo (Macpherson et al., 1986; Marriner et al., 1986). Severe adverse 
effects are relatively frequent due to the high dose. They include disturbance of hepatic 
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function, depression of the bone marrow and glomerunephritis (Bekhti et al., 1987; Bryceson 
et al., 1982; Kung'u, 1982).  Therefore, a shift from mebendazole to albendazole has resulted 
from good commercial availability in most countries, better bioavailability, easier 
administration as well as overall better efficacy (Brunetti et al., 2009; John, 2003). 
Albendazole, given in two divided doses a day has shown to be more efficient than 
mebendazole. Variabilities exist in duration of treatment and is determined by ultra sound 
based follow-up which may result in repetitive treatment (Stojkovic et al., 2009). Cyclic 
albendazole treatment at the dosage of 10 – 20 mg/ kg of body weight /day, divided in to 2 
doses is administered continuously for 28 days postprandially. The patients are then given a 
“washout period” of 10 – 15 days when no medication is administered before starting a second 
dose when applicable (Steiger et al., 1990).  Effectiveness of albendazole is still quite low and 
only 8 – 20 % of patients show complete cure or significant decrease of cyst size(Davis et al., 
1986; Todorov et al., 1990). Factors affecting therapeutic results of BZD may include age of 
patient, location of cyst, age of cyst, the morphology of cyst and the immune responses of the 
patient (Horton, 2018; Stojkovic et al., 2009).  
Benzimidazole compounds are generally well tolerated but their prolonged use in treatment of 
echinococcus causes adverse reactions.  When they occur, adverse effects include 
gastrointestinal disturbances, hepatotoxicity, alopecia and leukopenia.  Monitoring 
aminotransferases as well as blood counts is recommended during chemotherapy (Nahmias et 
al., 1994).  Both drugs are contraindicated for early stages of pregnancy due to high risk of 
embryo toxicity and teratogenicity (Bradley et al., 2001). There are great intra and inter-
individual variations in BZD pharmacokinetics and ideally levels of albendazole sulfoxide and 
mebendazole in plasma should be monitored (Eckert et al., 2001) though this is not always 
possible in the endemic areas. 
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Praziquantel (PZQ), a derivative of pyrazinoisoquinolone is an effective antihelmintic which 
has been routinely used against a wide range of parasite in both humans and animals (Cioli and 
Picamattocia, 2003).  It has better bioavailability than albendazole and mebendazole and peak 
plasma levels reached after 1–3 hours after oral administration (Mandour et al., 1990).  Relative 
bioavailability of PZQ increases if administered of food (Castrol et al., 2000).  
Praziquantel is generally well tolerated with incidences of adverse effects around 10–15% King 
and Mahmoud., 1989). Side effects include abdominal pain, nausea, dizziness, diarrhoea, 
anorexia and headache.  Studies of PZQ in monotherapy have shown unsatisfactory results. A 
study by Piens et al. (1989) where 30 patients were treated with PZQ,  9 CE patients showed 
no difference in cyst viability after  two 10-day courses of 75 mg/kg/day separated by between 
3 weeks and a control group untreated group. However, it was found to be effective in 
preventing relapses. 
The benefit in using PZQ in combination with ABZ in chemotherapy for CE has been 
evidenced (Cobo et al., 1998) particularly where there has been a cyst content spillage during 
surgery.  It may also reduce the risk of disease recurrence and the dosage needed therefore 
reducing adverse effects. (Kern., 2003). 
 
2.7.4 Watch and wait  
Mass screening has proved that cysts do spontaneously disappear, rupture, collapse or remain 
unchanged for many years. In transitional cysts (CE3), degenerating cysts (CE4, CE5) and also 
in small cysts, watch and wait may be recommended with careful follow up every 3-6 months 
for a minimum of 2 years (Piccoli et al., 2014). 
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2.8 Follow – up and evaluation of treatment and disease progression  
Follow up - on patients either after treatment or for monitoring untreated cases is commonly 
done using imaging and serology.  This is important in treated cases because spillage during 
surgical removal or PAIR is common and recurrence causing secondary echinococcosis and 
may not become apparent until months or years after treatment. For patients with 
uncomplicated inactive cysts, expert consensus is that they are left untreated and are closely 
monitored using the ‘‘watch-and-wait’’ approach as there is a possibility of self-cure or 
remaining unchanged (Piccoli et al., 2014). 
2.9 Clinical and epidemiological significance of cyst variation 
The WHO-IGWE cyst classification, relating to variation in cyst structure was produced to 
evaluate treatment options.  The complex nature of cyst location, size and internal structure 
means that no one intervention approach is suitable for all cyst types.  Brunetti et al. (2010) 
recommended a stage-specific approach as shown in Table 2-3 below.  Variation in cyst 
morphology and classification has also been deemed to be useful for epidemiological purposes.  
The predominant cyst type in a community may be indicative of when the infection occurred. 
According to natural history, it is assumed that CE4 and CE5 cysts are older than CE1 cysts.  
In communities where CE1 cysts dominate, transmission from dogs is likely to be more recent 
than in communities where CE4 and CE5 cysts predominate (Craig et al., 2007; Polat et al., 
2003). 
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WHO Surgery Percutaneous Drug Suggested Resources 
CE1  
  
  
  
  
 <5   cm ABZ PAIR  Optimal  
Minimal  
 ✓  ✓  
>5 cm PAIR + Albendazole  Optimal  
CE2  
  
   ✓  
Albendazole  Optimal    
 ✓  
  
 ✓  
  
  
   
Minimal  
 
CE3a  
  
  
  
  
  
  <5 cm Albendazole  Optimal  
 ✓   ✓  PAIR  Minimal  
  
  
  
  
>5 cm PAIR + Albendazole  Optimal  
PAIR  Minimal  
CE3b     Non-PAIR  Optimal  
 ✓   ✓   ✓  
Non-PAIR PT  Minimal  
CE4  
      
Watch and Wait  Optimal  
CE5     
Watch and Wait  Optimal  
Table 2-3:  Suggested approaches to uncomplicated hepatic cysts. 
2.10 Aims and Objectives 
In the information presented above shows that the morphology of hydatid cysts can vary 
considerably between patients, requiring different approaches to treatment.  However, the 
variation in cyst morphology can also impact on diagnosis of CE about specific antibody 
detection tests which are frequently used to confirm the parasitic nature of the lesion in 
community screening.  The observed transitions from one cyst type to another are indicative of 
disease progression or regression both during albendazole therapy and in untreated patients.  
However, the changes observed by ultrasound scanning represent gross morphological events 
and do not reflect underlying immunological variation that may be of use in the follow-up of 
patient progress. 
The Echinococcus intervention programme in Turkana, Kenya run by AMREF generated over 
30 years of data relating to cyst morphologies in different age and sex classes.  It followed up 
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many patient’s therapy with sequential ultrasound scans and serological sampling, with and 
without albendazole.  The main objective of the project was to establish a better understanding 
of the factors that influence morphological variation in cysts.  The specific aims of this project 
were therefore: 
1.  To evaluate age and sex differences in cyst presentation at first detection. 
2.  To relate morphological changes to different treatment options. 
3.  To evaluate the relevance of cyst morphology to antibody profiles in relation to 
immunodiagnostic antigens. 
4.  To link morphological changes in cysts to antibody profiles during long term follow-up of 
individual patients with and without albendazole therapy 
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3 TURKANA SURVEILLANCE AND OUTCOMES OF 
THERAPEUTIC APPROACHES  
The surveillance, the laboratory and clinical teams sometimes accompanied by the University 
of Salford personnel,  created a contemporaneous log of data between 1983 and 2015.  This 
was during the active years of African Medical Research Foundation (AMREF) hydatid control 
programme in Northern Turkana.  In this chapter, we aimed to analyse and interpret the 
surveillance data.  We also assessed the outcomes of different interventions and evaluated 
responses to treatment for CE patients.  
3.1 Introduction 
A study in the 1970s revealed that surgical incidence of hydatid disease was an estimated 96 
per 100,000 per annum in Turkana (O'Leary, 1976).  Another by study estimated annual cases 
at 19 per 100,000 in the south of Turkana 198 cases per 100 000 people in the north making it 
the highest in the world (French et al., 1982).  Bases on these findings, AMREF started a 
hydatid control programme in the north of Turkana in 1983. 
Morbidity attributable to CE occurs in all age-groups and disease have been described in 
patients below 1 year old (Tanki et al., 2018) and a man over 80 years (Lopez-Marcano et al., 
2017).  At infection, patients are asymptomatic and the cysts small.  The rate of growth varies 
in different communities, organs as well as age groups.(Sarkar et al., 2016).  Onset of clinical 
symptoms depends on size of cyst, organ infected, localisation of cyst in that organ, number of 
cysts and the pressure on surrounding tissue (Usluer et al., 2010). Abdominal cysts can remain 
asymptomatic for long periods of time whereas lung and bone cysts cause pain quite early after 
infection and are diagnosed earlier in the infection process (Song et al., 2007).  There is also 
the possibility of cyst rupture due to trauma which can cause anaphylactic shock or may lead 
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to dissemination of protoscoleces resulting in secondary hydatidosis (Castanares-Zapatero et 
al., 2009) 
In humans, hydatid cysts develop with great variability in size, location and among different 
human populations (Moro et al., 1999).  Slow growth is observed among indigenous people in 
Alaska compared to the Turkana in Kenya, (Gottstein et al., 1985; MacPherson et al., 1983).  
Cysts undergo different rates of growth and development or degeneration and calcification 
sometimes remaining dormant for long periods of time.  The factors influencing these 
variations are not well understood but they lead to complicatios in diagnosis and clinical 
management (Stojkovic et al., 2016).  
3.2 Treatments and interventions 
Four treatment modalities were used in the patients diagnosed in Turkana namely Surgery, 
PAIR, Chemotherapy and watch and wait.  Evidence in choosing any of the treatment options 
remains controversial and the clinician decided what treatment was suited for each patient.  
Factors influencing these decisions included symptoms, patient history as well as availability 
of resources (Horton, 2018).  In the absence of written guidelines, the interventions in Turkana 
were explained by the medical officer (Dr. Wangomb’e, personal communication, June 2018).  
3.2.1 Surgery  
Cystectomy or endo-cystectomy was performed on the patients who had large cysts, cysts with 
daughter cysts and the cysts with complications.  It involved open surgery where the cyst was 
opened and the hydatid material removed including laminated layer and germinal layer. A 
protoscolicide (95% ethyl alcohol) was then used to treat the pericyst cavity before suturing 
the patient.  The tissue around the cyst was neither entered nor resected as the operations were 
carried out by a general surgeon in a rudimentary hospital.  Hospital stay was on average 9 
days (range 6 – 17 days). 
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3.2.2 PAIR (Puncture – Aspiration-Injection-Re-aspiration),  
A less invasive form of surgery was also used for treatment of large cysts. The procedure 
involved, (i) per-cutaneous puncture of the cyst under ultrasonographic guidance (ii) aspiration 
of a substantial portion of the cyst fluid, (iii) injection of a parasiticidal solution (95% ethanol; 
approximately an equivalent of one- third of the amount aspirated), (iv) re-aspiration of the 
cyst fluid content after 5 min.  It was sometimes preceded and followed up by chemotherapy 
with albendazole. 
3.2.3 Chemotherapy (Albendazole)  
Treatment with albendazole was used on patients with inoperable cysts, multiple cysts in two 
or more organs, high-risk surgical cases, those who refused invasive treatment.  In some 
situations, surgical treatment was not possible due to logistical problems and chemotherapy 
was offered as an alternative till surgery was possible.  Where deemed necessary, cyclic 
chemotherapy with albendazole was given.  The dosage of 10 – 20 mg/ kg of body weight /day 
divided into 2 doses and administered continuously for 28 days postprandially.  The patients 
were then given a “washout period” of 10 – 15 days when no medication was administered 
before starting a second dose when applicable.  Some patients came to the medical centre to 
have their medication administered to prove compliance.  At the beginning of the study, 
guidelines on the number of courses to be administered were lacking and some patients 
received up to 8 courses of albendazole.  The guidelines provided some limits where inoperable 
cases received a maximum of 4 doses, pre-surgical cases had one dose 6 week before surgery 
and post-surgical prophylaxis cases received up to 3 courses.  Some patients had more than one 
cyst and the treatment regime given was determined by this among other factors including age, 
weight as well as willingness of the patient to adhere to long term treatment.  
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3.2.4 Watch and wait 
Many patients were followed up with no interventions either indefinitely or until it became 
necessary and possible to intervene. This was due to limitations in term of resources, personnel 
and patient reluctance to treatment and comorbidities.  Other reasons included adverse effects 
of treatment, the fact that some cysts remained unchanged either in size or nature while others 
self-cured.  Some people remained untreated for prolonged periods of time as they were not 
available for treatment.  Cases that had received intervention in the past were considered watch 
and wait if enough time had elapsed from previous intervention. In this study, this was 6 months 
since the previous chemotherapy treatment and 1 year since the last surgical procedure. 
3.2.5 Follow - up 
Follow-up on patients either after treatment or for monitoring untreated cases was done via 
imaging.  This was to assess efficacy or cure as well as disease progression or regression.  In 
surgical patients, it was used to monitor healing and residual cavity reabsorption after endo-
cystectomy.  Post-chemotherapy, patients were followed up to monitor cyst changes in size and 
morphology.  In untreated patients, follow – up was important in monitoring the natural history 
of the disease, which included cyst type and growth rate.  
3.3 Study design 
The research and medical team from AMREF carried out a surveillance and treatment 
programme between 1983 and 2015. All residents of North Turkana were invited to participate 
in a community-based CE screening programme, which incorporated abdominal 
ultrasonography and a questionnaire.  The participants who received a CE-positive diagnosis 
upon abdominal examination had a blood sample taken for testing and were requested to 
complete an epidemiological questionnaire.  They were then directed to the local mission 
hospital where a hydatid treatment unit had been established and partly funded by AMREF.   
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A second assessment was done at the hospital to determine the best therapeutic pathway for 
each patient in accordance with the guidelines set by African Medical Research Foundation 
and the Ministry of Health for Turkana County.  The questionnaire was completed by everyone 
who participated in the study with parents giving consent for children below 18 years of age.  
The general information gathered included age, gender, location and medical history.  In 
addition, potential factors influencing infection including occupation, previous infection, 
frequency of contact with dogs and source of water were collected.  A Turkana – English 
translator was employed where necessary though most people spoke Swahili.  
3.4 Study area and Climatic Factors 
The study area (Figure 3-1) covered 40,000 km2 which stretched from the Uganda Rift Valley 
escarpment east of the 34°E to 35°E longitude.  To the north, it bordered the Kenya/Sudan 
boundary and to the south the Lokichar main road  The area is hot, dry and has an annual 
rainfall of 575mm. The rainfall peaks are found in November and March-April (data from the 
Meteorological Station, Lokichokio). The surveillance was done during the dry season when 
most people were found in an accessible area.  
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Figure 3-1:  Study Area.   
The area shaded blue shows the North of Turkana where the surveillance took place (Romig et al., 
2011) 
3.5 Ethical considerations 
At the beginning of each screening session, informed consent was obtained from all adults 
participating in the survey and from a parent for each participating child.  To maintain 
confidentiality, each participant was assigned a unique identification number which was also 
used in follow-up.  Participation was voluntary, and individuals were not obligated to remain 
in the study.  The study was reviewed and approved by the African Medical Research 
Foundation Hydatidosis Control Program and the Kenya Ministry of Health.  With regards to 
53 
 
this PhD project, written consent was obtained from AMREF authorising the use of the 
database and serum samples for further research.  This was submitted for ethical approval 
through the University of Salford. 
3.6 Screening for hydatid cysts 
In the field surveillance of CE, diagnosis and classification was carried out using a portable 3.0 
MHz real-time linear ultrasound scanner (Siemens Healthcare Limited, Surrey UK).  This was 
powered by a 1 kW portable electric generator equipped with an accurate measuring gauge.  
Most patients were screened standing up using liquid paraffin as a transducing medium ().  The 
cysts were categorised accordig to the guidelines of World Health Organization Informal 
Working Group on Echinococcosis (WHO-IWGE).  They were classified as active (CL, CE1 
and CE2), transitional (CE3), or inactive (CE4 and CE5) based on their appearance (Figure 
3-2).  Due to the long term nature of this study, C3 cysts were not sub-divided into C3a and 
C3b as this only became standard many years into the study.and is now considered to be a 
useful approach.  Where possible, cyst sizes and numbers were recorded and monitored in 
subsequent visits even after completion of therapy, cure or untreated cases. 
 
 
Figure 3-2:  Classification of Hydatid Cysts:   
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Key:  CL – Active, uniform nuclear fluid, no clear cyst walls; CE1 – Active, unilocular fluid-filled cyst; CE2 – 
Active, with daughter cysts; CE3 – Transitional cyst with collapsing wall; CE4 – degenerative contents and 
inactive with hyperechoic fluid; CE5 – inactive calcified cyst (WHO-IWGE, 2003). 
3.7 Statistical Analysis 
In community surveys, data from interviews and ultrasound scans were entered in Excel and 
analysis and figures made using SPSS statistical package version 23 (SPSS Inc Chicago, IL), 
R statistical software version 2.15.2 (R Development Core Team, 2012) and (GraphPad Prism 
version 6, SanDiego - CA USA). Descriptive statistics were used to assess the frequencies in 
both demographic, human factors and follow-up periods.  
Associations between the demographic and human factors and cyst morphologies were done 
using Chi square test. Where these associations were significant, ordinal multiple regression 
was done to describe them. 
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3.8 Results 
Over 50,000 people were screened during the AMREF programme which ran from 1983 to 
2015.    A simple flow chart showing how patients were recruited in the study is shown in 
Figure 3-3 
Figure 3-3:  Patient recruitment by AMREF in Turkana 
3.8.1 Screened Population  
During the running of the programme, 2369 patients from a cross-section of locations in the 
North of Turkana County were diagnosed as having CE using ultrasound imaging. During the 
running of the programme, 2369 patients from a cross-section of locations in the North of 
Turkana County were diagnosed as having CE using ultrasound imaging.  Majority of patients 
were identification and recruitment from patient files supplied from AMREF surveillance 
study. These patients were seen and treated in Kakuma Mission Hospital.   Other patients were 
from Kakuma main hospital and Lopading sub-County hospital.  Of these, 299 had had a 
previous surgical procedure to treat CE and were considered as a re-infection or a recurrence.  
                                              
                     
          . 
 50 000  
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        . 
 47 631  
                 
        . 
 751        432          
    . 
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       . 
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            . 
 1229  
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The Mean ± SE age of patients at diagnosis was 28.53 ± 0.325 and a male: female ratio of 1: 
2.3.  Other demographic factors are summarised in Table 3-1 below.  
 
Attribute Characteristic n Percentage 
Gender Male 606 29.3  
Female 1463 70.7 
Previous Surgery Yes 299 17.2  
No 1740 82.8 
Cyst Number Single 1431 60.7  
Multiple 931 39.3  
2 cysts 611 25.8 
Multiple Cysts 3 - 5 cysts 222 9.4  
6 - 8 cysts 61 2.6  
> 8 cysts 28 1.2 
Cyst Type CE1 777 33.4  
CE2 604 26  
CE3 240 10.3  
CE4 677 29.1  
CE5 29 1.2 
    
Table 3-1:  Characteristics of hydatid patients at first diagnosis.  
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3.8.1.1 Proportion of Infections during the years of surveillance 
The surveillance programme was run in phases of 3 years beginning in 1983 to 2015.  There 
was a break in active surveillance between 2004 and 2011 where only clinical diagnosis was 
done on self-referring symptomatic patients.  To assess longitudinal changes in infection 
proportion for different age groups during the 25 years of active surveillance, the number 
primary infections was analysed, and the cases stratified in to 8 age groups.  Primary infection 
was assumed if there was no previous history of CE infection.  The hypothesis explored was 
that the infection dynamics did not change with time and were there was no variation in 
infection proportions in different age groups.  Figure 3-4 shows the proportion of new cases 
divided up according to age groups during each phase of the surveillance. 
 
Figure 3-4:  Changes in proportion of infection in different age groups over the years 
Throughout the years of active surveillance, the children below 4 years did not show much 
fluctuation in proportions of infection 1.6 ± 0.7 %. This was also the case with those over 55 
at 2.76 ± 1.46 %.  The proportion of infection in other age groups varied at diagnosis over the 
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years.  The proportion of infection in older children in the age-bracket 5 – 12 showed marked 
fluctuations and declined from between 19 - 21%  at the start of the surveillance to between 10 
-15 % by the end.  The proportions of infection in this age bracket continued to fall during the 
years of passive surveillance.    
Infection proportions in the 5 -12 years age group was 18.5% at the start of the program, 
gradually increasing to 21.7 by the 9th year of surveillance.  This trend reversed in the following 
years with fluctuations of between 10 and 16%.  There was only one symptomatic case during 
the years of passive surveillance and when the field diagnosis resumed, the proportions come 
down slightly from 15.3% to 13.3%.  
Among the 13 – 17-year olds, there was gradual increase in infection proportions in the first 9 
years of surveillance.  These decreased sharply by the 12th year and remained relatively low at 
around 7%.  In similarity to the younger groups, there was only one symptomatic case in the 
years of passive surveillance and infection proportions had declined further when active 
surveillance was resumed. 
The group with the highest number of cases at the start of the program was in the 18 – 25 years 
age group.  There was 29.5% in proportion in this age group, rising to 30.2% 6 years after the 
start of the programme. By the ninth year, the number had declined sharply to 18% and despite 
fluctuations over the years, the proportion declined to 12.4% by the end of the first phase of 
active surveillance. Four symptomatic cases were diagnosed and treated during the 7 years 
period of passive surveillance.  This age group appeared to be the most susceptible group and 
on restarting the field diagnosis, the proportion had increased from 12.4% to 18.6% in the 
asymptomatic population.  The proportion of infection fluctuation was also high 19.96 ± 6.44 
%. 
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The second highest proportion of infection at the start of the surveillance programme was 
among the 26 – 35-year olds at 21.8%. unlike the younger group, there was a decline in the 
proportion of cases in the first 6 years of study.  This was followed by an increase in proportions 
in the years that followed with the highest proportion being in the 7th -12th year at which this 
group had the highest proportion of new cases. B There was gradual decline and by the end of 
active surveillance, this group accounted for 17% of all the cases. The break in active study 
had the greatest negative impact in this age group as on restart there was a 5% increase in 
proportion of cases affected. The highest number of symptomatic self-referring cases (39.3%) 
during the passive years was also found in this group.  This group had highest number of cases 
and greatest variation in infection proportion at 22.63 ± 7.16%. 
Age group 36 – 45 years saw the proportion of new cases increase gradually for 15 years in a row. At 
the start of surveillance, the proportion was 12% increasing gradually to 27% in 15 years.  By the 13th 
year of the program the proportions the highest number of new cases (26.9%) was in the 36 – 
45 years age group.  With slight fluctuations, it remained in between 22 – 27% throughout, even after 
the surveillance break. There was 14% proportion of symptomatic cases needing treatment during the 
inactive years 
The 46 – 55 years age group had few cases at the start of study and the proportion of infection declined 
for the first 9 years of active surveillance from 6.2% to 0.7%.  The proportions then increased gradually 
to 18.8% in the next 12 years at the end of active surveillance.  During passive surveillance, 18 % of 
the cases seen were in this age group. On return to field diagnosed, the proportion had declined to 9.5%.   
A similar trend was seen in those over 46 years old.  
The difference in infection over the years was significant among the 13 – 17-year olds (p 
=0.016), 18 – 25-year olds (p < 0.001), 36 – 45-year olds (p = 0.002) and 46 – 55 age group (p 
< 0.001).  There was increase in mean age at first diagnosis from 25.4 to 31 years during the 
years of active surveillance between 1983-85 and 2010-2015. 
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Figure 3-5:  Change in infection proportion in years of Surveillance 
There was an opposite trend in infection proportions among the cases under 20 and those over 
20 years (Figure 3-5).  At the start of the program, infection proportion between people under 
20 and those over 20 was 35% and 65%. The trend showed an initial increase in persons under 
20 and decrease for persons older than 20 years. This trend peaked in 1988-1989 with almost 
similar rates of infection. The number of younger infections started declining in younger cases 
compared to the older cases to 8% and 92% by 2005. After a 7-year break from active 
surveillance, the rate of infection among the young had increased to 29% and reduced to 26% 
in  the next 3 years of surveillance.  
3.8.1.2 Differences in infection between genders at diagnosis 
The participants diagnosed as infected with CE were categorised according to gender as well 
as age groups.  The differences between male and females at diagnosis is shown in. Figure 3-6.  
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Figure 3-6:  Gender differences according to age group at first diagnosis.  
There was a great variation between genders in different age groups. In children below 5 years, 
more males than females were infected, but the trend changed in older cases.  In the pre-
pubescent age group of 6 – 15, the gap in infection between male and female became eminent 
and increasingly so with the child bearing age of 16-25 years and child rearing years of 26-45 
years.  This difference reduced in the later years of 46 – 65 and almost returned to similarity 
with childhood years later in life, in the over 65 years. 
Children less than 4 years old had a female to male ratio of 1:1.88.  This was the only age group 
where males diagnosed were significantly more than female (p < 0.000).  All other cases had a 
higher number of female infections than male. The age groups that showed significant 
differences were 5 – 12 years old, (p = 0.05), 26 – 35 age group, (p<0.001). 
The highest number of infections was among women between 36 and 45 years, also the highest 
number of males diagnosed belonged to this age group.  Just under 18% of the patients were 
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children under 13 years of age with the youngest being 15 months old and 13.4 % were over 
the age of 46 with the oldest in this study was 63 years old.  
3.8.1.3 Cyst locations at first diagnosis  
Overall, 3119 cysts were detected via ultra sound imaging over 32 years of surveillance. Of 
these, 2775 cysts were in what are generally referred to as common sites and they accounted 
for 93 % of all the cysts. Most liver and kidney cysts were solitary but in all other organs, more 
than 50 % of the cases had multiple organ involvement ranging from 2 to 5 organs.  Table 3-2 
shows the differences in single and multiple infections according to organs. In patients 
diagnosed with cysts in the right liver lobe, 72.1% had solitary cysts, 18% cysts in a different 
lobe or organ concurrently, 6.5% harboured cyst in 3 different organs etc.  
Affected Organ n Single cyst  
n  (%) 
Cysts in 2 organs n  
(%) 
Cysts in 3 organs 
n  (%) 
Cysts in 4 organs 
n  (%) 
Cysts in 5 organs 
n  (%) 
R Liver 1458 
(52.6) 
1051 (72.1) 262 (18.0) 95 (6.5) 40 (2.7) 10 (0.7) 
L Liver 387 
(14.9) 
167 (43.2) 130 (33.6) 39 (10.1) 41 (10.6) 10 (2.6) 
Kidney 66 
(1.9) 
44  (70.6) 4 (6.1) 7 (10.6) 1 (1.5) 10 (15.5) 
Spleen 128 
(4.6) 
60 (46.9) 29 (22.6) 18 (14.1) 12 (9.3) 9 (7) 
Omentum/Mesentery 409 
(14.7) 
133 (32.5) 144 (24.1) 80 (21.4) 42 (12.1) 10 (3.1) 
L Abdomen 330 
(11.6) 
131 (39.7) 80 (24.2) 70 (21.2) 39 (11.8) 10 (3.0) 
Table 3-2:  Predilection sites of cysts at first diagnosis in common organs 
The most common organ involved was the liver harbouring 66.5 % (n = 1885) with the right 
lobe harbouring 52.6 % (n=1458) and the left lobe 14.9% (n=387).  Most of the cysts in the 
right liver lobe were single cysts (72.1%, n=1051) but those in the left lobe were mostly 
coinfections with other organs.  Apart from the right liver lobe and the kidneys, less than half 
of the cysts found in other organs were single cysts.  
Most multiple organ infection was found to involve both lobes of the liver with or without any 
other organ involvement (187 cases).  In 2 cases both lobes and the kidneys were involved, in 
15 patients both lobes and the spleen, in 68 patients both lobes and the omentum and in 52 
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cases both lobes and the lower abdomen.  In other cases, only the right lobe was involved in 
multi-organ infection.  Coinfection between right lobe and the omentum/mesentery was found 
in 212 cases while with the lower abdomen with was found in144 cases.  In cases where 2 
organs were involved, only 43 patients did not have hepatic cysts and in infection involving 3 
organs only 4 did not have liver involvement.  All cases with more than 3 organs infected had 
a hepatic cyst. 
The mesentery/omentum had the highest number of extra hepatic cysts with 409 (14.7 %).  
Unlike the liver, single cysts accounted for only 32% (n=133) with high coinfection with the 
liver and the lower abdomen.  Coinfection without hepatic involvement was found in 29 cases 
where the other organ was the lower abdomen, 3 cases with the spleen and 1 with the kidney.  
The kidneys had the second highest percentage of single cysts (70.6) though the number of 
patients was small compared to the 3 main organs. There were 42 cases of right kidney infection 
while the left kidney had only 11 cases.  In 8 cases, the cysts in the left kidney were solitary. 
Between them, the lower abdomen, the liver and the omentum/mesentery accounted for 92.8 
% of all the cysts found during imaging to have multiple organ involvement.   
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3.8.1.3.1 Cysts in rare locations 
Non-common locations of hydatid cysts infections are considered to be cysts found in other 
body organs apart from the ones described above.  The cases in this study are summarised in 
Figure 3-7 below. 
 
Figure 3-7:  Rare locations of hydatid cysts 
In Turkana, 175 cysts fell in this category with the highest number being found in the 
ovaries/uterus 29.9% (n = 52), thigh 11% (n = 20), neck 10.3% (n = 18) and knee 6.9% (n = 
12).  Of interest in this group was the number of cases where the rare location was the primary 
cyst.  In 86% (152) of the cases, there no other organ involved, 18 cases had 2 organ 
involvements, 1 case had 3 organs infected and 4 cases the patients had 4 or more cysts 
elsewhere in the body.   
3.8.1.4 Factors associated with cyst type at diagnosis 
Data from patient history and questionnaire was compiled to find associations between gender, 
age and pervious treatment with cyst morphology.  A summary of these demographic and 
human factors and their association to different cyst types at diagnosis were analysed and 
described in Table 3-3. 
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Factor Characteristic χ 2 df p value 
Age CE1 195.534 108 0.000*** 
 
CE2 144.916 108 0.031** 
 
CE3 135.649 108 0.000*** 
 
CE4 188.741 108 0.000*** 
 
CE5 171.736 108 0.001** 
Gender CE1 0.034 1 0.448 
 
CE2 0.714 1 0.215 
 
CE3 1.275 1 0.149 
 
CE4 1.933 1 0.091 
 
CE5 0.149 1 0.442 
Previous Surgery CE1 18.429 1 0.000*** 
 
CE2 23.308 1 0.000*** 
 
CE3 4.655 1 0.031** 
 
CE4 2.644 1 0.062 
 
CE5 0.865 1 0.275 
***significant at 1% and ** at 5%   
Table 3-3:  Factors associated with cyst types at diagnosis 
Age was associated with CE1, CE3, CE4 and CE5 cyst types at 1% level and with CE2 cyst 
type at 5% level. Gender was not while previous surgery showed significant association with 
CE1 and CE2 cysts at 1% level, CE3 at 5% level and CE4 at 10 % level.  The relationships 
were further investigated and reported below. 
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3.8.1.4.1 Relationship between age and cyst types at first diagnosis 
At primary diagnosis, cysts were described according to cyst type.  The differences in cyst 
types at diagnosis with age were assumed to be indicative of length of time from infection.  A 
total of 2757 cysts were characterised according to cyst type and age at diagnosis (Figure 3-8).   
Of these, 826 (31.2 %) were CE1 cysts, 782 (28.3 %) CE2 cysts, 270 (9.8 %) were CE3, 779 
(28.2) were CE4 and 30 (1.1 %) were CE5. 
 
Figure 3-8:  Cyst types at first diagnosis with age 
Key: Red is representative of CE1 cysts, olive of CE2 cysts, light green of CE3 cysts, blue represents 
CE4 cysts and pink represents CE5 cysts. 1 rectangle represents 2 yrs 
 
In children below 12 years, the predominant cyst type was CE1 accounting for 63.4 % of all 
cysts in this age group.  This was the highest proportion in any age group and accounted for 
26.1 % of all CE1 cysts.  There was a gradual decrease with little fluctuations in proportion of 
patients with CE1 cysts with age.  Among those between 46 and 55 years CE1 cysts accounted 
for 21% of all the cyst types.  The proportion of CE2 cysts was lowest among children under 
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12 years and adults over 55 years old.  This was significantly different to all other age groups 
which had a mean proportion of 33.7% and SD = 4.3. Unlike CE1 whose proportion reduced 
with age, CE2 cysts appeared stable with few fluctuations. The proportion of CE2 cysts 
fluctuated very marginally and remained very similar in for the ages between 13 and 24 years 
old. This number increased again between 26 and 45 coming down again from 45 to the oldest 
age group. Infection with CE2 was similar in the very young and the very old.   
Compared to the numbers seen with the rest of the cysts, very few CE3 cysts were diagnosed. 
Over 87 % were found in the cases older than 18 years old with a third in the those 36 – 45-
year olds.  Recent classification methods have divided CE3 and some CE4 cysts into CE3a and 
CE3b and there may have been mis-categorisation.  In the cases diagnosed as CE4 cysts, 94% 
were over 18 years old.  The youngest child with a CE4 cyst was 3 years old indicating that the 
rate of cyst change from CE1 to CE4 can be less than 3 years.  Over 40% of newly diagnosed 
cases in the over 55 age-group had CE4 cysts a complete reversal of what was seen in the 
children under 4.  Similarly, the highest percentage of those in the age group 45 – 55 had a 
disproportionately large number of CE4 cysts compared to other types as well as other groups. 
Overall, age was shown to be associated with cyst type according to the regression model 
shown in Table 3-4. 
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Cyst Type Estimate Std Error df sig 95% Confidence Interval 
Lower Bound Upper Bound 
CE1 -0.012 0.003 1 0.000*** -0.017 -0.006 
CE2 0.015 0.003 1 0.000*** 0.009 0.020 
CE3 0.002 0.004 1 0.673 -0.006 0.010 
CE4 0.005 0.003 1 0.062 0.000 0.010 
CE5 0.042 0.012 1 0.000*** 0.019 0.066 
***significant at 1% and ** at 5%  
Table 3-4:  Contribution of age to cyst morphology at diagnosis 
The results showed that there was a strong association between age and cyst type.  There was 
a significant and negative relationship between CE1 cyst types with age and older cases were 
less likely to be diagnosed with CE1 cases.  Conversely there is a strong significant positive 
coefficient CE2 and CE5 cyst types indicating that older cases were highly likely to be 
diagnosed with CE2 and CE5 than were younger cases. The association with CE4 was and CE3 
were not significant. 
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3.8.1.4.2 Relationship between age and cyst numbers at first diagnosis 
Cyst numbers at first diagnosis varied with age.  The number of cysts per person ranged from 
1 to more than 8. The cyst numbers increased with age though most cases harboured solitary 
cysts (Figure 3-9).  All children below 3 years had a single cyst.  The youngest case with 6 – 
8 cysts was 10 years old and the oldest person was 50 years old.  The highest number of 
infections with 8 or more cysts was seen among 43 – 50 years old with the youngest being 19 
years old and the oldest 54 years old.   
 
Figure 3-9:  Number of cysts with age group 
Key:  red represents 1 cyst, olive depicts cases with 2 cysts, Light cases with 3 - 5 cysts, blue 
depicted cases with 4 – 8 cysts and pink more than 8 cysts was shown in colour. 
 
Overall, cyst numbers varied significantly with age (χ2= 595.69, p < 0.000).  Infection with 
multiple cysts increased gradually with age with though most of the patients only ever 
harboured one cyst.  The highest number of cysts recorded in one individual was 14 in 5 
different organs and 3 different cyst types. Overall, age was shown to be associated with cyst 
type according to the regression model shown in Table 3-5. 
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        95% Confidence Interval 
Cyst Type Estimate Wald Sig. Lower Bound Upper Bound 
1 Cyst 0.473 0.452 0.501 -0.907 1.854 
2 cysts 2.060 8.513 0.004** 0.676 3.444 
3-5 cysts 3.786 27.935 0.000*** 2.382 5.190 
>8 cysts -4.641 40.411 0.000*** -6.072 -3.210 
***significant at 1% and ** at 5%  
Table 3-5:  Contribution of age to cyst sizes at diagnosis 
The results showed that there was a strong association between age and cyst numbers for 
multiple cysts.  There was a significant and positive relationship between for 2 to 5 cysts with 
age and older cases were more likely to be diagnosed with multiple cysts.  Conversely there is 
a strong significant negative coefficient with more than 8 cysts indicating that older cases were 
less likely to be diagnosed multiple infections than were younger cases. The association with 
CE1 cysts was not significantly associated with age.   
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3.8.2 Evaluation of therapeutic approaches 
Patients diagnosed with CE during surveillance were directed to the local mission hospital.  
The hospital had a working relationship with the surveillance project and free treatment was 
offered.  A second assessment was done at the hospital to confirm field analysis.  Confirmed 
CE patients received one of four approaches, chemotherapy, surgery, PAIR or watch and wait.   
Due to the fragmented nature of the data in terms dosage, cyst locations and duration of 
treatment, analytical parameters were established to assess a vast amount of data.  Descriptions 
of outcomes were appropriated to provide enough differentiation for analysis and summarised 
as below.  
 a) Cysts not operated on  
Cured was recorded where  
• Cyst contents had degenerated from active and transitional cysts (CE1, CE2, CE3) to inactive 
and calcified cyst types (CE4 or C5)   
• The cyst was clinically assessed as disappeared.   
• There was complete detachment of cyst membrane  
Improved cases were registered where   
• There was partial degeneration of cyst content and the classification moved from active to 
transitional cyst type (CE1 or CE2 to CE3).   
• There was reduction in cyst diameter by 10 % or more   
• There was partial detachment of cyst membrane, loss of daughter cysts or appearance of 
calcification  
No change was recorded where there was no visible change in appearance, or the size had 
reduced by less than 10 % of the size of the original cyst  
A deteriorated cyst described a cyst which had   
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• Grown bigger in size,   
• Reverted to an active cyst (CE1 or CE2) from transitional and inactive (CE3 and CE4) 
• Had not changed in size or morphology but had become infected usually bacterial infection 
and causing secondary abscess.  
b) Pair Cases 
Cured  was recorded for those that showed cysts disappearance or complete obliteration of the 
internal structures of the cyst mostly leaving just a thin echogenic linear scar 
Inactive was recorded where cysts showed partial obliteration or calcification of the cyst 
contents. Also, for cysts that showed a folding of the endocyst with significant size reduction 
and absence of daughter cysts 
Regenerating Was recorded where cysts appeared to be regaining their original size and 
morphology or progressing to active types from inactive.  
c) Cysts operated on   
Cured was recorded where  
• Cysts were no longer visible  
• Cysts had collapsed completely.  
c) Recurrence was recorded where a cyst was found in the residual cavity of one that had been 
previously operated.  
Notes  
• All patients whose compliance to chemotherapy was inadequate were excluded from data 
analysis.   
• Analysis excluded lung cysts which could not be assessed by ultrasound. In patients harbouring 
multiple cysts, each cyst was treated individually   
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• Time was measured from the end of the last dose of chemotherapy or the date 
of surgery.   
3.8.2.1 Results in followed-up untreated patients 
A total of 432 patients harbouring 751 cysts were followed up for between 6 and 38 months 
with 1788 observations being made.  A survivorship curves for different outcomes are 
described Figure 3-10 
 
Figure 3-10:  A survivorship curve for untreated patients. 
The age groups of the followed-up patients varied between 3 years and 55 years with a mean 
of 31.8 years and a standard deviation of 14.2 years.  Other factors are described in Table 3-6. 
Patients were considered untreated if they did not receive any intervention after diagnosis, had 
received chemotherapy but a period of 6 months had lapsed since the last dose or had received 
a surgical intervention but a period of 1 year had lapsed since the last surgical procedure. 
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Factor Characteristic n % 
Gender Female 577 76.80 
  Male 174 23.20 
Previous Surgery Yes 29 0.90 
  No 722 99.10 
Cyst Nature Multiple cysts 480 63.91 
  single cyst 271 36.09 
Cyst Type CE1 237 31.60 
  CE2 136 18.13 
  CE3 156 20.80 
  CE4 206 27.47 
  CE5 15 2.00 
Follow - up 06-12 months 191 25.47 
  13 - 18 months 163 21.73 
  19 - 24 months 136 18.13 
  25 - 30 months 124 16.53 
  31 - 36 months 104 13.87 
  37 - 38 months 32 4.27 
Cyst Size Large 204 27.2 
 
Medium 348 46.4 
 
Small 21 2.8 
  Very Large 177 23.6 
    
Table 3-6:  General description and follow-up period of patients that were untreated 
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The time elapsed in months between a paired first and last observation either before treatment 
or patient’s last attendance was recorded.  Cyst type at the start and the end of follow up were 
also noted.  The outcome of cured, improved, no change or deteriorated was recorded at the 
end of follow-up (Table 3-7). 
Cyst Type Change n (%) Mean and (S.D) 
of Follow-up Period 
95 % Confidence of Follow-
up Period 
CE1 Cured 18 (7.6) 18.44 (10.6) 13.15 – 23.74 
Improved 89 (37.6) 19.09 (10.1) 18.01 -26.49 
No change 110 (46.4) 20.26 (8.9) 18.57 – 21.96 
Deteriorated 20 (8.4) 22.25 (9.05) 18.01 – 26.49 
CE2 Cured 4 (2.9) 18.44 (10.6 13.15 – 23.74 
Improved 61 (44.9) 19.01 (10.1) 16.8 – 21.44 
No change 65 (47.8) 20.26 (8.9) 18.57 – 21.96 
Deteriorated 6 (4.4) 22.5 (9.8) 18.01 – 26.49 
CE3 Cured 25 (16.1) 20.42 (9.7) 16.52 – 24.33 
Improved 28 (18.1) 23 (9.3) 19.38 – 26.62 
No change 89 (57.4) 20.38 (8.6) 18.56 – 22.21 
Deteriorated 13 (8.4) 20.46 (6.9) 16.24 – 24.68 
CE4 Cured 10 (4.9) 16.2 (8.8) 9.85 – 22.55 
Improved 62 (30.1) 19.68 (9.4) 17.29 – 22.04 
No change 98 (47.6) 20.91 (9.0) 19.1 – 22.72) 
Deteriorated 36 (17.5) 24.08 (7.9) 21.42 – 26.75 
CE5 No change 11 (78.6) 24.55(7.8 19.26 – 29.83 
Deteriorated 3 (21.4) 21.67 (10.2) -3.83 – 47.16 
     
Table 3-7:  Outcomes of untreated patients over time 
The highest proportion of cured cases was seen in CE3 cysts where 16.1 % of the cases were 
cured in an average of 20 months. The second-best cure results was in the CE1 group with 7.6 
% of the cases considered cured in the shorter period of time on average 18.4 months. 
Noteworthy is the fact that CE3 cases achieved better cure rate than CE4 cysts. Patients with 
CE2 cysts showed the lowest rate of cure without intervention at 2.9 % but greatest rate of 
improvements at 45%. The greatest proportion of cysts remained unchanged both in 
morphology and size (49.7%) and few cysts deteriorated compared to other outcomes (10.1%). 
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The association between outcome, follow-up period and cyst type were analysed and tabulated 
in Table 3-8. We sought to find out if there was any association between the cyst type and the 
cyst condition at the end of follow-up otherwise named outcome. 
Factor Characteristic χ2 df p value 
Outcome CE1 17.434 3 0.001*** 
 
CE2 8.444 3 0.038** 
 
CE3 33.224 3 0.000*** 
 
CE4 17.536 3 0.001*** 
 
CE5 7.996 3 0.046** 
Follow-up Period  CE1 10.244 5 0.069 
 
CE2 2.155 5 0.827 
 
CE3 5.948 5 0.311 
 
CE4 2.221 5 0.818 
  CE5 11.197 5 0.048** 
***significant at 1% and ** at 5%   
Table 3-8:  Association between outcome and cyst type in untreated patients. 
Overall, paired before and after results  showed that 10.4 % (n=78) of the cysts got worse by 
either progressing to CE1 or CE2 cyst from CE3 or CE4 cysts or by growing larger or causing 
clinical symptoms. Another 32% (n = 240) improved with no intervention either by regressing 
from an active CE1 or CE2 to a CE3, CE4 or CE5 cyst. Nearly half of all the cases (49.7 %, n 
= 373) showed no clinical or morphological difference. In 7.9 % (n=59) of the cases, cysts were 
not visible or were calcified CE5 inactive cysts in consequent imaging. Association between 
disease outcome and the cyst type at the start of follow-up was analysed using chi square and 
the results tabulated in Table 3-8.  There was significant association in disease outcome at 5% 
level for CE2 and CE5 and at 1% level for CE1, CE3 and CE4. There was also an association 
with CE5 at 5% levels.  
To assess the type of relationship this association had an ordinal regression model was done 
and the results tabulated in Table 3-9. 
77 
 
 
Cyst Type Results Estimate Std Error sig 95% Confidence Interval 
Lower Bound Upper Bound 
CE1 Follow-up -0.009 0.009 0.310 -0.026 0.008 
 
Cured 0.038 0.305 0.902 -0.560 0.636 
 
Deteriorated -0.726 0.325 0.025** -1.362 -0.090 
 
Improved 0.476 0.174 0.006** 0.135 0.817 
CE2 Follow-up -0.009 0.011 0.417 -0.029 0.012 
 
Cured -1.077 0.536 0.044** -2.127 -0.026 
 
Deteriorated -0.042 0.334 0.901 -0.695 0.612 
 
Improved 0.311 0.207 0.132 -0.094 0.716 
CE3 Follow-up 0.006 0.010 0.553 -0.014 0.026 
 
Cured 0.930 0.289 0.001*** 0.362 1.497 
 
Deteriorated -0.458 0.328 0.163 -1.100 0.185 
 
Improved -0.819 0.233 0.000*** -1.275 -0.363 
CE4 Follow-up 0.005 0.009 0.565 -0.013 0.023 
 
Cured -0.551 0.367 0.133 -1.270 0.167 
 
Deteriorated 0.871 0.256 0.001** 0.369 1.373 
 
Improved -0.018 0.189 0.924 -0.388 0.352 
CE5 Follow-up 0.038 0.029 0.190 -0.019 0.096 
 
Cured -0.534 1.055 0.613 -2.602 1.535 
 
Deteriorated 0.229 0.666 0.731 -1.075 1.533 
 
Improved -21.345 0.000   -21.345 -21.345 
***significant at 1% and ** at 5% 
Table 3-9:  Contribution of cyst type to outcome in untreated cases 
Cured cases were significantly likely to be CE3. There was a reverse relationship between 
cured cases and CE2 cysts. Improved cases were positively related to CE1 and negatively 
related to CE3. Deterioration was positively related to CE3 and CE4 but negatively related to 
CE1. All other outcomes had no significant relationship to cyst type. 
3.8.2.1.1 Changes in cysts sizes in untreated patients 
Data from 32 patients, harbouring 49 cysts whose sequential ultrasound images were available 
was analysed for changes in cyst size over 12 months. A paired first and last observation of 
cyst diameter was taken.  The difference in cyst sizes was summarised in Table 3-10 
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Change in Size Number 
Mean ± SD of Cyst Diameter (mm) 
Start Finish 
Reduced 5 - 24 % 7 109 ± 27 96 ± 15 
Reduced 5% to increased 6% 13 100 ± 14 103 ± 16 
7 - 30% increase 12 92 ± 7 111 ± 8 
>31 % increase 10 48 ± 28 113 ± 19 
Collapsed 5 56 ± 71 72 ± 84 
Disappeared 2 ------  
Table 3-10:  Changes in cyst size in untreated patients over 12 months of follow-up 
After 12 months of follow – up, 7 cysts showed reduction in size of between 5 and 24 %, 13 
cysts remained within ±5 % of the size at diagnosis, 12 cysts increased by between 7 – 30 % 
and 10 cysts increased over 20 %. A further 5 cysts collapsed, and 2 cysts were no longer 
visible on ultrasound scans. The greatest increase was in a 12-year-old girl who had a cyst that 
grew from 4 to 135mm in 12 months but overall average growth of 24 mm in diameter. There 
was no significant difference between sexes or age-groups. Although 22 cysts (46 %) of the 
cysts grew by 7% or more, other cysts remained the same, reduced in size, collapsed or 
disappeared without any intervention.   
3.8.2.2 Chemotherapy results 
Chemotherapy with albendazole was administered to patients harbouring 1229 cysts.  The 
mean age of the patients that underwent chemotherapy was 27.4 years, SD = 14.5 years range 
2 – 63 years. Other attributes recorded for the patients that received chemotherapy are 
summarised in Table 3-11.  
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Attribute Characteristic n Percentage 
Gender Male 260 21.2 
Female 969 78.8 
Previous Surgery Yes 198 16.1 
No 1031 83.9 
Cyst Number Single 536 43.6 
Multiple 680 55.3 
Cyst Type CE1 248 20.2 
CE2 319 26.0 
CE3 204 16.6 
CE4 452 38.8 
CE5 6 0.50 
Follow-up Period 3-6 months 429 34.9 
6 -9 months 441 35.9 
9 - 12 months 359 29.2 
Number of Courses 1 Course 928 75.5 
2 Courses 194 15.8 
3 or more Courses 107 8.70 
    
Table 3-11:  Attributes of the patients that underwent chemotherapy 
To analyse the chemotherapeutic outcome, a paired first and last observation of cyst 
morphology either before treatment or patient’s last attendance was recorded and all the 
observations between the two disregarded. The factors above were assessed for association 
with outcomes of chemotherapy and the results tabulated in Table 3-12.  
Factor χ2  df  p-value 
Age 1041.654  174  0.000*** 
Gender 7.819  3  0.050** 
Cyst Number 6.473  6  0.372 
Number of courses 44.305  6  0.000*** 
Follow-up Period 18.618  6  0.005** 
Cyst Type 23.890a  15  0.067 
      
***significant at 1%  and ** at 5%  
Table 3-12:  Factors associated with outcome of chemotherapy 
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The attributes that had significant associations with chemotherapeutic outcome were age and 
number of courses of treatment at 1% level and gender and follow-up period at 5% level. 
CE1 Cysts 
Albendazole treatment was given to 248 cases of CE1.  The patients were then followed up for 
3 – 12 months post treatment and the outcome summarised in Figure 3-11 to Error! Reference 
source not found.below. With one course of treatment the most significant changes were seen in 
the first 6 months post-treatment. In this period, cure was achieved in 7.6% of the cases, 15% 
of the cysts got worse, 31% improved and 46% remained the same. In the subsequent months 
of follow-up, over 70% of the cysts did not change further but a further 4 cases were cured.  
Overall, cure was achieved in 11 (4.5%) of all CE1 cases that had 1 dose of chemotherapy.  In 
63.6%of the cured cases, it was achieved in the first 3 months after the end of treatment while 
another 27.3% achieved cure within 9 months of treatment. Of the 58 CE1 cases that improved 
29 (50%) were recorded 3 months post-treatment, 21 (36.2%) between 6 and 9 months and 8 
(13.8) improved between 9- and 12-months post-treatment.  In the cases of deteriorating cysts, 
22 were recorded of which 63.6 % (n=14) were recorded in 3 – 6 months post-treatment, n=4 
(9.1%) deteriorated 6-9 months post-treatment and another 4 (9.1%) got worse 9 – 12 months 
post-treatment . Overall, 1 dose of chemotherapy caused changes shortly after administration 
and a few patients were cured.  but majority of the cysts returned to original status within a 
year.  The outcome of 1 dose of chemotherapy in patients with CE1 cysts was highly significant 
(p<0.001) as was follow-up period (p<0.001). 
A total of 22 CE1 cysts received 2 courses of chemotherapy and followed up after the second 
dose over 12 months.  Seven were followed up for 6 -9 and 4 for 9 – 12 months.  In this group, 
1 case was considered cured after 9 months.  Overall, there were 9.1 % cured cysts, 36.4% had 
shown improvement and 45.5% had not changed. One cyst showed deterioration. 
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Figure 3-11:  Outcome of 1 dose chemotherapy on CE1 cysts 
 
 
Figure 3-12:  Outcome of 2 doses chemotherapy on CE1 cysts 
 
 
Figure 3-13:  Outcome of 3 or More doses of chemotherapy on CE1 cysts 
n=9 
n=12 
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The outcome of 12 CE1 cases that received 3 or more doses of chemotherapy, followed up 
from the date of their last dose was assessed for a year.  All were followed up for 6 - 9 months. 
Overall, 3 cases improved and 9 showed no change. In this group, there were no cure or 
deterioration of cysts.  
CE2 Cysts 
CE2 cyst responses to different courses of chemotherapy were analysed and the outcomes are 
summarised in Figure 3-14 to Figure 3-16 below. 
A total of 222 cases of CE2 cases treated with one dose of albendazole and followed up for 3 
– 12 months post treatment.  Of these, 100 cases were followed up for 6 months.  In this time, 
9 cysts (9 %) were cured, 9 (9 %) of the cysts improved,  70 (70 %) cysts showed no changes 
and another 12 (12%) got worse. In the next three months, another 50 cysts were followed up.  
In this group, 9 (18%) cysts were cured, and 9  (18%) cysts improved, a third of the cysts 31  
(62%) did not change and 1 cyst got worse. A further 72 cysts were followed up for between 9 
- 12 months. In this group, there was 2 (2.8%) other cysts got cured, 9 (12.5%) improved, 59 
(81.9%) did not change and 2 (2.8%) deteriorated.  A total of 48 cases of CE2 cysts received 2 
courses of chemotherapy and were followed up for 12 months after they completed the second 
dose. Ten for were followed up for 6 months, 33 for 6 -9 months and 5 for 9 - 12 months. The 
greatest improvement was seen 3 -6 months post-treatment with 50 % of the patients showing 
improvement, a higher number than the ones that did not change who were at 30%. Only one 
cyst got worse in this group.  A year after chemotherapy, 7 (50%) of the cases were considered 
improved, 6 out of 14 cases remained the same and 1 cyst got worse.  
Sixteen CE2 cases treated with 3 or more doses of chemotherapy were followed up for 12 
months.  In the first 3-6 months, there were no cured cases but 2 (12.5%) deteriorated and 2 
(12.5%) improved. Two thirds (75%) showed no change. Another 23 cases were followed up 
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for 6 – 9 months. In this group, 1 (4.3%) was considered cured, 2 (8.7%) deteriorated, 5 (21.7%) 
improved and 15 (65.2%) did not change. A further 9 cases were followed up for 9 – 12 months 
and every case in this group showed no change. 
 
Figure 3-14:  Outcome of 1 dose of chemotherapy CE2 cysts 
 
Figure 3-15:  Outcome of 2 doses of chemotherapy 
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Figure 3-16:  Outcome of 3 or More doses of chemotherapy 
 
CE3 cysts 
A total of 131 cases with CE3 cysts were treated with one dose of albendazole and followed 
up for 3 – 12 months.  Of these, 37 cases were followed up for 3 – 6 months, 37 were followed 
up for 6-9 months and 57 cases for 9 – 12 months. In the cases followed up 3-6 months, 5 
(13.5%) were cured, 1 deteriorated and 1 improved while 30 (81.1%) did not change. After 6-
9 months of follow-up, there were no further cured cases and 1 (2.7%) case deteriorated.  
Improvement was recorded in 11 (29.7%) of the cases and 25 (67.6%) did not change.  A 
further 57 cases were followed up for 9 – 12 months. In this group, 1 (1.8%) case was cured, 1 
case deteriorated 5 (8.8%) of the cases improved and 50 (87.7%) did not change.  
A total of 58 cases of CE3 cysts received 2 courses of chemotherapy. A total of 24 were 
followed up for 3 – 6 months, 8 were followed up for 6 – 9 months and 26 were followed up 
for 9 – 12 months.  Of the 24 followed up for up to 6 months, cure was achieved in 2 (8.3%) 
cases, another 3 (12.5%) cases deteriorated, 4 (16.7%) improved and 15 (62.5%) did not 
change.  In the cases followed up for 9 – 12 months, there were no cured cases, 1 case 
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deteriorate, 13 (50%) improved and 12 (46.2%) did not change. Overall, 31 (53.4%) of the 
cysts did not change, 56.6% improved or were cured and 6.9% of the cysts got worse.  
Fifteen cases of CE3 cysts received 3 doses of chemotherapy. Six cases were followed up for 
3 – 6 months and none of them changed. Nine cases were followed p for 9 – 12 months and 
only one improved. The other 8 did not change. No cysts were found to have cured or 
deteriorated. 
A summary of the outcomes to different doses is shown in Figure 3-17 to Figure 3-19. 
  
 
Figure 3-17:  Outcome of 1 dose of chemotherapy on CE3 cysts 
 
Figure 3-18:  Outcome of 2 doses of chemotherapy on CE3 cysts 
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Figure 3-19:  Outcome of 3 or More doses of chemotherapy on CE3 cysts 
 
CE4 Cysts 
A total of 346 cases of CE4 cysts, treated with one dose of albendazole were followed up for 3 
– 12 months post treatment. One hundred and eighteen were followed up for 3 - 6 months.  In 
this time, 7 (5.9 %) of the cysts were cured, 6 (5.1%) of the cysts improved 102 (86.4%) showed 
no changes and 3 cysts (2.5%) got worse. Another 159 cysts were followed up for 6 - 9 months 
and in this group, a further 5 (3.1 %) of the cysts were cured, 25 (15.7%) of the cysts improved, 
122 (76.7%) did not change and 7 (4.4%) cysts deteriorated.  Another 69 cysts were followed 
up for 9 -12 months.  I this group, 6 (8.7%) of them were cured, 21 (30.4%) improved, 1 (1.4%) 
got worse and 41 (59.4%) remained the same.  Overall, 18 (5.2%) cysts were cured by the end 
of the follow-up, 52 (15%) improved, 265 (76.6%) had not changed and 11 cysts (3.2%) had 
got worse.   
A total of 74 cases of CE4 cysts received 2 courses of chemotherapy. Twenty-three were 
followed up for 3 – 6 months, 16 for 6 – 9 months and 35 for 9 - 12 months. Two (8.7%) cysts 
were cured in 3 – 6 months, 10 (43.5%) improved, 10 did not change and 1 cyst deteriorated. 
In 6 – 9 months post-treatment, there was no cured cyst nor was there deteriorating cyst. Six 
(37.5%) improved and 16 (62.5%) did not change. In 9 -12 months post-treatment, there were 
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no cured cysts, 5 (14.3%) deteriorated, 10 (28.6%) improved and 20 (57.1%) did not change.  
The sample size was small, and this may explain some of the variations, but the trend was 
similar to the CE3 cases after 2 doses of chemotherapy. The number of cases that got worse 
increased with time from 1 at 6 months to 5 in 12 months.  Overall, 37.8% showed cure or 
improvement, 54.1 % of the cysts did not change and 8.1 % got worse.  
Thirty-two CE4 cysts received 3 doses or more of chemotherapy before follow-up.  Two were 
followed up for 3 – 6 months and of these, one was cured and one improved. Another 10 were 
followed up for 6 – 9 months. In this group, 2 more achieved cure, 1 deteriorated, 1 improved 
and 6 (60%) did not change. A further 20 cysts were followed up for 9 – 12 months.  There 
was no 10% cure rate, 10% improvement and 80% did not change. Overall, 28.1% were cured 
or improved, 3.1% got worse and 68.8% did not change. 
A summary of the outcomes to different doses is shown in Figure 3-20 to Figure 3-22 below. 
 
Figure 3-20:  Outcome of 1 dose of chemotherapy on CE4 cysts 
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Figure 3-21:  Outcome of 2 doses of chemotherapy on CE4 cysts 
 
Figure 3-22:  Outcome of 3 or More doses of chemotherapy on CE4 cysts. 
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Overall assessment 
Overall, 928 cysts were treated with one dose of albendazole and the outcome assessed for 
periods between 3 – 12 months and results summarised in Figure 3-23 to Figure 3-25  
 
Figure 3-23:  Outcome of 1 dose of chemotherapy overall 
 
Figure 3-24:  Outcome of 2 doses of chemotherapy overall 
 
Figure 3-25:  Outcome 3 or more doses of chemotherapy overall 
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Of those, 347 were followed up for 6 months post treatment. Cure was realised in 28 cases 
(8%), improvement in 49 cysts (14.1%), 243 cysts remained the same (70%) and 27 cysts got 
worse (7.8 %).  Another 330 cysts were followed up for 6 months. Less cured cases 17 (5.2%) 
but number of improved cases increased to 18.5% (n = 61). A similar proportion to those in the 
3 month group did not change (72.7%) and fewer cysts deteriorated at 3.6 %. Nine months post 
treatment, 98 cysts were followed up. In this group, 1 more cysts was cured, 17 (17.3 %) 
improved, there was no change in 72 (73.5 % ) cysts and 8 (8.2 %) cysts deteriorated.  A further 
153 cysts were followed for 12 months. There was no deterioration of cysts in this group and 
121 (79 %) did not change. Of the 21 % that got better, 5.2% (n = 8) were cured and 15.8% 
(n=24) had improved. Overall, 54 cysts (5.8 %) were cured, 151 cysts (16.3%) improved, 676 
cysts (72.8%) did not change and 47 cysts (5.1%) got worse. 
One hundred and ninety three patients received 2 doses of chemotherapy and follow-up began 
after completion of the second dose. Among them, 58 cases were followed up for 3 months 
during which 6 cysts (10.3 %) were cured, 19 cysts (32.7 %) improved, 28 (48.2 %) cysts 
remained the same and 5 (8.8%)cysts got worse. In the next three months, 66 cysts were 
followed up. In the six months post treatment, 2 cysts were cured, 21 (32.7%) improved, 37 
(48.2%) did not change and 6 (8.6%) cysts got worse. In the group that was followed up for 6 
months, there was an overall cure rate of 4.7%, improvement rate of 34.7 %, unchanging cysts 
were 51.8% and 8.8% were cysts that got worse. Among 107 cysts that received 3 doses of 
chemotherapy, 24 were followed up for 3 months. In this time, 1 case was cured, 3 cases 
improved 18 cases did not change (75.5%) and 2 cases got worse. Six months post treatment, 
of the 45 cysts followed, 2 were cured, 10 improved, 3 got worse and 30 did not change. There 
was cure in another 2 cysts after 9 months from chemotherapy and none at 12 month timepoint. 
The general outcome of the cases that received 3 courses of chemotherapy was 4.7 % cured, 
15 % improvement, 75.7% that did not change and 4.7 % that got worse.  
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Giving a second dose of chemotherapy in CE1 cases improved the outcome from 25% to 43.5 
% and a third had even better outcome where 73% of the cases were either cured or improved. 
A similar outcome was seen in CE3 cysts though the percentage was lower where 1 course 
achieved 24.2 % improvement or cure, 2 courses achieved 39% and 3 courses showed 52% 
cure or improvement.  A second dose also showed improvement of outcome in CE3 and CE4 
cysts, but a third dose showed none  
Outcome (%) Number Cured Improved No Change Deteriorated 
Untreated (n = 75) 10.7 45.3 36.0 8.0 
1Course of Chemotherapy (n = 928) 5.8 16.3 72.8 5.1 
2 Courses of Chemotherapy (n = 193) 4.7 34.7 51.8 8.8 
3 or more Courses  (n = 107) 4.7 15.0 75.7 4.7 
Overall (n = 1229) 5.5 19.0 69.7 5.6 
Table 3-13:  Comparison of Outcomes. 
Disregarding the number of courses of therapy, length of follow-up and cyst type, 68 out of 
1229 (5.5 %) were cured, 234 (19%) improved, 857 (69.7 % did not change and 69 (5.6 %) 
deteriorated. 
An example of a survivorship curve for outcome of 1 dose of chemotherapy over time is 
described below (Figure 3-26) 
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Figure 3-26:  A survivorship curve for outcome of 1 dose of chemotherapy on CE4 cysts 
 
Comparing this outcomes with the untreated cases in the first 12 months of follow-up, there 
was a better outcome overall among the untreated cases compared to the ones that received 
chemotherapy (Table 3-13).  Almost twice of untreated cases self-cured compared to those that 
received any amount of chemotherapy and almost three times in the ones that showed 
improvement . It is however noteworthy that the clinicians recommended therapy based on the 
changes in the cysts and the tendency was to treat those cysts that show signs of deterioration 
and leave those are stable or improving untreated.  On the basis of this, the results of 
chemotherapy may indicate that deteriorating cysts may become stabilised by chemotherapy 
thus stopping further regression into active and larger cysts.  The number of courses of 
albendazole given was at the discretion of the clinicians.  The results of 3 or more courses were 
effective on CE1 and CE2 cysts but showed no further benefit in CE3 and CE4 cysts.  In 
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summary, increasing the number of courses given had beneficial effects on cases that had CE1 
and CE2 cysts but not CE3 and CE4 cysts (Figure 3-27).   
 
Figure 3-27:  Beneficial outcomes of different doses of chemotherapy 
Giving one dose of chemotherapy to CE1 patients achieved improvement in 25.4% of the  
cases.  In patients that received 2 courses of chemotherapy, this improvement was seen in 
43.5% and in those that received 3 courses, the number of improved cases increased further to 
73.5%. A similar trend was found in patients harbouring CE2 cysts although these 
improvements were better in CE1 and CE2 case. This beneficial outcome with increase in 
dosage was not found in CE3 and CE4 cases where the rate of cure decreased after the second 
dose.  
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3.8.2.3 Responses to PAIR 
Three hundred and sixty cysts underwent PAIR and were followed-up for 6 – 12 months. The 
mean age of patients that underwent PAIR was 24.5 years, S.D 15.5 years and ranged between 
3 and 65 years.  Other attributes recorded before surgery are summarised in Table 3-14. 
Factor Characteristic n Percentage 
Gender Female 204 78.2 
  Male 57 21.8 
Previous Surgery No 255 97.7 
  Yes 57 2.3 
Cyst Nature Multiple cysts 96 36.8 
 
Single cyst 165 63.2 
Cyst Type CE1 186 71.3 
 
CE2 16 6.1 
 
CE3 10 3.8 
 
CE4 49 18.8 
Table 3-14:  Attributes of patients treated with PAIR 
Those that showed cysts disappearance or complete obliteration of the internal structures of the 
cyst mostly leaving just a thin echogenic linear scar were considered cured. Other cysts showed 
partial obliteration or calcification of the cyst contents and were considered inactive. Inactive 
was also recorded for cysts that showed a folding of the endocyst with significant size reduction 
and absence of daughter cysts. Other cysts appeared to be regaining their original size and 
morphology or progressing to active types from inactive and were recorded as regenerating 
cysts. Analysis of the outcome of PAIR sought to find out which cyst type had responded best 
to treatment and a summary is shown in Figure 3-28 
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Figure 3-28:  Proportions of Outcome of Pair in Different Cyst Types 
The highest number of cysts that underwent PAIR was in the CE1 group with 186 cases which 
was 71.3 % of all cases.  Of these, 25 (13.4%) were considered cured, 123 (66.1%) were 
inactive and 38 (20.4%) were regenerating cysts.  CE1 cysts consisted of 73.5 % of all cured 
cysts, 72.4 % of all inactive cysts and 66.7 % of all regenerating cysts. There was no statistical 
significance between CE1 and outcome (χ2(2) = 0.772, p = 0.680).  Compared to CE1 cysts, 
there were few cases of CE2 cysts that underwent PAIR (6.1%, n = 16).  Two cysts (12.5%) 
from this group attained cure, 2 (12.5%) cysts regenerated by the end of follow-up and 12 cysts 
(75%) were considered inactive.  Similar to CE1 cysts, there was no association between CE2 
and outcome (χ2(2) = 0.265, p = 0.876).  Only 10 CE3 cysts underwent PAIR. Of these, 1 (10%) 
cyst was considered cured, 6 (60%) were inactive and 3 (30%) regenerated. There was no 
association between cyst type and outcome in CE3 cysts ((χ2(2) = 0.275, p = 0.872).  In CE4 
cases, 49 patients underwent PAIR.  There was a 12.2 % cure rate in this group, 59.2% (n= 29) 
had inactive cysts while 28.6% (n = 14) of the cysts showed regeneration by the end of the 
study.  Like all other cyst types, there was no association between the cyst type and outcome 
(χ2(2) = 0.275, p = 0.872).    
n=12 n=59 n=185 n=20 
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3.8.2.4 Surgical Cases 
Three hundred and seventy-eight cases harbouring 556 abdominal cysts underwent surgical 
endocystectomy. The mean age 27.5 years, SD 13.1, range 3 -60 years.  Other patient factors 
at surgery are shown in Table 3-15. 
Factor Characteristic n Percentage 
Gender Female 438 78.8 
  Male 118 21.2 
Previous Surgery No 528 95.0 
  Yes 28 5.0 
Cyst Nature Multiple cysts 336 60.4  
Single cyst 220 39.6 
Cyst Type CE1 218 39.2  
CE2 85 15.3  
CE3 68 12.2  
CE4 185 33.3 
Intervention Surgery 475 85.4 
 Surgery & Chemotherapy 81 14.6 
Table 3-15:  Attributes of patients who underwent endocystectomy 
Post-surgical follow-up was done by ultrasonography to monitor the recovery of the residual 
cavity for between 8 months to 1 year. Recurrence was recorded where there was presence of 
a live cyst at the location of a previously treated one.  Twenty-eight cases (5%) had had surgery 
before and were either recurrences or reinfections.  Surgery without chemotherapy was 
performed on 457 cases while in 103 cases surgery was accompanied by chemotherapy prior 
and after.  In all cases, accompanying surgery with chemotherapy reduced the rate of recurrence 
though this was not significant (χ2 = 0.158, p=0.408).  This reduction was greatest in cases 
under 18 years of age and in children between the ages of 5 and 12 accompanying surgery with 
chemotherapy reduced recurrence rate from 28.4% to 10%.  Patients over 46 years old who 
received chemotherapy with surgery had a higher rate of recurrence than those who received 
surgery alone as well as those that remained untreated. Overall, cases who did not receive 
chemotherapy before and after surgery had a cure rate of 86.9% (397) and a recurrence rate of 
13.1% (60) while those that did had a cure rate of 93.5%  (n = 101/108) with a recurrence in 
6.5 % (7)cases (Figure 3-29).  The overall cure rate was 89.1 % recurrence rate was 11.9%.  
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Figure 3-29:  Outcome of surgical treatment with and without chemotherapy. 
  
n=103 n=457 
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3.9 Discussion 
Surveillance data, collected and analysed effectively, is a robust tool in defining the problem, 
providing a rationale for intervention strategies, evaluating the success of the control program 
and quantifying the infections in human (Craig et al., 2006). In CE, Infections are more of a 
measure of prevalence rather than incidence because cyst growth in humans can be slow and 
is variable (Seimenis, 2003).  The clinical diagnosis of CE is usually only representative of a 
small proportion of the infection because most people are asymptomatic and can remain so for 
many years (Herrador et al., 2016) 
From the start of the study, there were noticeable differences in the ratio of infection between 
the sexes with females being more infected than males.  The ratio varied between age groups, 
but the youngest and the oldest age groups showed little or no difference.  The greatest 
differences were seen in the post-pubertal and childbearing ages where the ratio was nearly 
1:3. Some of the factors contributing to these differences may be immunological and/or 
cultural.  The highest infections were found in women between 18 – 35 years old.  Immunity 
may be reduced in childbearing and breastfeeding women who are also culturally unequally 
exposed to dogs.  Egg viability after shedding from dogs is temperature dependent.  In the 
sunlight, it is lost within 3 hours, in the huts after 48 hours and in water may remain viable for 
up to 300 hours (Wachira et al., 1991).  In the heat of the day, family dogs lay inside the houses 
increasing proximity to women compared to men who spend their days out in the pastures with 
the animals.  Studies have suggested a presence of sexual dimorphism that makes female 
cellular immune responses inferior to male ones(Giefing‐Kröll et al., 2015; Klein et al., 2016) 
a fact that has been demonstrated in experimental murine infections  (Bubb et al., 2012).  This 
dimorphism was also recognised in medicine in that males and females often respond 
differently to drug therapy (Sherman et al., 1995) 
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At infection, cysts are small and unilocular. Some go on to develop in size as well as 
morphology while others have the development arrested at some stage and may remain in that 
state for long periods of time (Rogan et al., 2015).  Variations of cyst sizes with cyst stages 
showed that most of the small to medium sized cysts were CE1 and CE2 types while CE3 and 
CE4 tended to be larger. The rate of growth has been estimated to be between 0 – 3cm per year 
(Eckert et al., 2004) although some cysts were observed to remain the same size after 14 years 
of follow-up (Acarli, 2004).  In this study, the rates varied considerably between subjects.  
Differences were observed even with cysts in the same subject and same organ and the average 
increase was 24 mm in a year. Possible explanations for the variation maybe parasite related 
according to genotype as well as levels of virulence or host related with variations in immune 
responses (Rosenzvit et al., 1999).  However the genotype of the infecting species have been 
shown to be mainly E.granulosus sensu stricto.  Other infecting species are E. Canadensis and 
E.orteppi.  The infecting species has similar patterns in Kenya (Mulinge et al, 2018), China 
(Shang et al 2019 ) and Iraq (Salam Jumaah Hammad et al, 2018). 
It is proposed that cysts become symptomatic on reaching 10 cm diameter (Larrieu et al., 2001)  
but in Turkana, many larger cysts were observed with the subjects reporting no pain.  
Following up on cyst structural changes is important in keeping track of morphological changes 
as some cysts may remain stable for many years and undergo a sudden change.  It is also 
essential in monitoring therapeutic results.  Changes in cyst type over time followed the natural 
progression which supported the WHO classification (Brunetti et al., 2010; WHO Working 
Group, 2003) in both chemotherapy-induced and natural progression.  In the cases that were 
followed up without treatment and CE1 cysts were observed, they either progressed to CE2 or 
remained the same, CE2 cysts progressed to CE3 or did not change, CE3 cysts progressed to 
CE4 mostly although some transitioned back to CE2 cysts and most CE4 and CE5 cysts 
maintained the initially observed stages but a few retrogressed and went the other way. 
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Variations in cyst types with age were observed with CE4 cysts being seen more in older cases.  
The differences in cyst types at diagnosis with age are assumed to be indicative of length of 
time from infection.  These variations are also useful in following the natural history of cyst 
development where internal modifications can be perceived as progressively or degenerative. 
The increase in average age at diagnosis over the years may indicate fewer new infections and 
provide evidence that the control program was working 
Cysts numbers also increased with age and most of the younger cases diagnosed had a single 
cyst.  Multiple cysts were most likely to depict multiple exposures with a single cyst infection 
each time.  This was evidenced by the observation that most paediatric cases only harbour 1 
cyst.  However, the possibility of multiple infections in one exposure was a possibility as it is 
difficult to establish when the infection occurred.  On the other hand, many patients with 
multiple cysts had similar cyst types and sizes, even in different organs which may be indicative 
of infection at the same time or that cyst development stopped at a certain stage. Many 
untreated followed up cases showed no changes over long periods of time with cysts at every 
stage of development. This has been observed in other studies (Chihai et al., 2016; Piccoli et 
al., 2014)  
Advancements in both serological and imaging techniques allow for screening of large 
numbers of populations at risk as the majority of infected cases are usually asymptomatic. 
Therapeutic strategies in diagnosed CE are determined by the clinicians depending on available 
options.  The evidence base that would assist in such decisions is lacking, a problem further 
complicated by the setting where CE is endemic and limitations in the availability of resources.  
Guidelines from WHO exist (Group, 2003), but there is no standard medical management and 
clinicians determined treatment initiation, dose and duration.  One of the dilemmas facing 
clinicians faced with CE cases especially in the endemic areas where cases are many is whether 
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to treat or not.  Here we aimed at assessing the outcome of chemotherapy treatment and 
compare the results with those of untreated groups in different cyst types 
Many of the cases diagnosed were not offered immediate therapy (watch and wait) especially 
if they were asymptomatic.  One major reason for this was logistical as more were diagnosed 
than could be treated.  Others did not seem to require it as their life was not impacted by the 
infection through compromised organ function or discomfort. Clinicians can decide not to treat 
as all treatment comes with risk (Ammann et al., 1996; El-Mufti et al., 1993).  Regular follow-
up was considered enough in asymptomatic cases and this proved a logical decision as with 
time, some cysts calcified and became inactive while others remained stable or improved with 
time.  Other patients refused treatment even when it was offered, a decision that was respected 
by the clinicians and long-term follow-up with imaging was done instead.  
At infection, cysts are small and unilocular. They may remain so for long periods of time or 
may change in morphology and increase in size (Pedrosa et al., 2000). In this study, the 
development in most cysts seen appeared to have been arrested at a different stage and 
remained stable for long periods.  Factors influencing this are unknown and monitoring cysts 
is important as clinicians base their decisions and therapies on observed changes.  Questions 
on efficacy of chemotherapy have been raised with some authors contend that with time, E. 
granulosus will self-resolve and disappear.  Some have even suggested that changes seen after 
treatment are spontaneous and not therapy induced (John, 2003).  In this study, the outcome in 
untreated cases seemed better than those that underwent chemotherapy. However, the number 
was too small for fair comparison and only the stable cysts were left untreated. The fact that 
over 10 times more patients were treated might indicate that although spontaneous cure does 
occur cysts are most likely to progress, and intervention becomes necessary at some point.   
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In this study as with other publications, responses of cysts to albendazole varied widely even 
in the same patient, further complicating evaluation.  Symptomatic patients and those with 
cysts showing progression or size increase through time were offered chemotherapy as 1st 
choice of treatment.  Use of chemotherapy for treatment of CE has gained traction since its 
efficacy was first published 40 years ago (Morris et al., 1983; Saimot et al., 1983; Vachon et 
al., 1985).  Since then, many case studies have been published.  There are better imaging 
techniques usable in the field allowing regular follow-up on both untreated and treated cases. 
In our study, chemotherapy seemed to cause stability to the disease more than cure it.  After 1 
cycle of chemotherapy, nearly 6 % were cured, 16 % improved, 72.8% did not change and 5.1 
% deteriorated. After 2 cycles, 4.7 % were considered cured, 34.7 % improved, 51.8% 
remained the same and 8.8% of the cysts got worse.  For the cases that received 3 courses of 
chemotherapy, 4.7 % were cured, 15.6 % improved, 75 % did not change and 4.7% got worse. 
Increasing the number of doses of chemotherapy, a patient had from 1 to 2 did not have the 
expected effect in increasing cure rate.  Possible reasons may have been lack of compliance or 
reduced bioavailability since the recommendation is to have the medication with a fatty meal 
which is difficult in Turkana due to poverty.  However, improved cases doubled after second 
dose compared to those who received one dose.  The third dose did not seem to have a big 
impact on the cysts.  Treatment was offered to the cases that had symptomatic and progressive 
cysts and chemotherapy appeared to stabilise them stopping further progression in morphology 
and size. The rate of cure after chemotherapy in cysts that were treated with chemotherapy 
compared to that of surgery was small.  However, improvement of cysts to asymptomatic types 
and sizes allowed for continued follow-up without further treatment if that cyst stability was 
maintained.  Other studies have found similar therapeutic results where after 12 months of 
evaluation.  Cure was found in 7 – 30 % of the cysts, significant size reduction in 12 – 50 % 
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and no morphological changes no 20 – 50%  (Horton, 1997; Nahmias et al., 1994). Results 
from WHO showed 39 % favourable response (Saida, 2011). 
Intermittent treating was used in nearly all the cases in this study and 15 patients had their 
treatment terminated due to jaundice.  Questions exist on whether continuous treatment is a 
better option. Although albendazole is well tolerated in most patients, increase in hepatic 
enzyme levels occur in 20% of the cases though few are severe (Todorov 1995) and they return 
to normal on cessation of treatment.  The rationale for “dry out” period was to allow recovery 
before the next round of therapy and protect liver function ((Davis et al., 1989; Hao et al., 
1994).  However, a 20 year study in Rome using continuous treatment showed no increase in 
side effects (Franchi et al., 1999).  The rises in hepatic enzymes during treatment are considered 
to be caused by drug toxicity.  However, Rigano et al. (1995) found them to be useful 
immunological markers for albendazole efficacy and other studies concurred (Eckert et al., 
1995; Mufit et al., 1998).  It is now believed that the changes result from immune responses to 
the cyst after it has been damaged by chemotherapy.  Liver function test should continue to be 
monitored for idiosyncratic drug reactions but with less concern over changes that may be 
indicative of efficacy (Morris, 1987).  On the other hand, intermittent dosing has been argued 
to cause tolerance and reduce efficacy in subsequent doses and cysts have been known to 
increase in size during the rest period (Junghanss et al., 2008).  This may explain some of the 
deterioration of cysts seen in this study.  Overall there is a need to improve efficacy. In Turkana, 
the ease of administration of chemotherapy, coupled with the fact that the available hospital 
amenities are rudimentary, better efficacy would greatly improve outcome and reduce the need 
for surgery.  Suggestions include increasing drug concentration and sustaining higher blood 
level (Morris et al., 1990; Naseri et al., 2016), albendazole administration with a fatty meal 
increased plasma levels 5 fold (Lange et al., 1988; Pawluk et al., 2015) and double dosing of 
albendazole with praziquantel (Homeida et al., 1994; Torabi et al., 2018). Praziquantel in E. 
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granulosus has been shown to be most effective on cysts that are not fully developed like those 
released from daughter cysts making it very useful after surgery (Al Karawi et al., 1992). 
Another advantage of this combination therapy is that the 2 drugs interact increasing plasma 
concentration for both but the safety of using praziquantel with multiple dosage lacks evidence 
(Hong, 2018).  Other adverse effects of using albendazole include alopecia and bone marrow 
depression causing neutropoenias or aplastic anaemia although all are reversible (Bakhsh et al., 
2017; Steiger et al., 1990).  Albendazole is also teratogenic and its use in pregnancy is counter-
indicated (Choi et al., 2017; De Silva et al., 1999).  WHO recommendations are for a 3 – 6 
cycles of 28 days and 14 days breaks, or a 3 to 6-month continuous cycle (Brunetti et al., 2010).  
As a conservative surgical procedure, PAIR aims at evacuation and sterilisation of cyst 
contents.  When first introduced in 1986, fear was that the cysts may puncture once pierced or 
that injecting a sclerosant into a cyst that had biliary communication may cause ascending 
cholangitis, (Filice et al., 1990; Yaghan et al., 2004).  In practical use, with precautions in place, 
PAIR is safe and has been used as standard treatment for cysts between 5 – 15cm in diameter 
in many centres  replacing open surgery in many cases (Wen et al., 2019).  Sclerosants used 
include hypertonic saline, alcohol and cetrimides with suggestions of albendazole also included 
(de Reuver et al., 2018).  Used alongside chemotherapy, PAIR has proved to have greater 
clinical efficacy, less recurrence rates and less complications compared to surgery (Khuroo et 
al., 1997; Silva et al., 2015).  Recommendation for chemotherapy is to use for 1 month post-
surgery to prevent reactivation or recurrence from accidental damage (Eckert et al., 2001).  The 
average stay in hospital was 4 days (range 2 – 7 days) which shorter than surgery whose average 
hospital stay was 9 days. Recurrence is not uncommon over long periods of follow-up and this 
study was only done for 6 months.  However, in studies where longer follow-up was possible, 
the results were still favourable after 5 years (Craig, 1994) but evaluation on allergic reactions 
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and secondary echinococcosis still require further evaluation  allergic reaction was reported in 
0.63% (Filice et al., 1997) 
Surgical procedures for CE range from radical transplant to conservative partial pericystectomy 
(da Silva, 2015). Surgery has the capacity to eliminate the disease and treat complications 
associated with it.  It is however associated with higher morbidity and mortality both during 
and post operation compared to other forms of treatment.  (Manterola et al., 2016). 
In this study, surgical treatment of CE was performed on very large cysts that caused significant 
morbidity.  Conservative partial pericystectomy was performed to reduce complications related 
to more radical surgery and the number of days in hospital.  Surgical cases considered cured at 
the end of follow-up were 88% (493/560) and 12% were considered as recurrences as the cysts 
appeared in the residual cavity.  This is similar to other studies where conservative surgery was 
done (Chautems et al., 2003; Jerraya et al., 2015; Kapan et al., 2004; Sielaff et al., 2001).  Other 
postoperative sequelae were not adequately followed up, but 1 patient died on the operating 
table and another one 3 days after surgery due to surgical complications.  
There are frequent recurrences especially with conservative surgery as the residual cavity is a 
potent source of daughter cysts and has a likelihood of dispersion to multiple sites often with 
the disease being more extensive than before (Georgiou et al., 2015).  Post-surgical recurrence 
may result from spillage of protoscoleces or inadequate treatment of the cyst during surgery.  
Radical surgical procedures show lower recurrence rates, but the rate of mortality 
increases(Pang et al., 2018).  These drawbacks are exacerbated by poor facilities in a disease 
that generally infects the marginalised poor in developing countries. 
Recurrence is not an early complication and its incidence is difficult to establish as it is 
dependent on quality and length of follow-up.  Follow-up in this study was a maximum of 12 
months and the rate of recurrence may have increased over the years.  Recurrence may be local 
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to the organ, regional or distance.  The question of whether a new cyst is a recurrence, or a new 
infection persists especially if the monitoring is inadequate. Recurrence occurs between 2 – 
20% of the cases (Velasco-Tirado et al., 2017).  The time it takes for the cyst to recur after 
endocystectomy varies from a few months to several years (Eckert et al., 1995; He et al., 2015).  
Differentiating between residual cavity and recurrence may not be clear during imaging (He et 
al., 2015) and follow-up should continue until the whole cavity has been reabsorbed and 
invisible. Other complications of surgery include exudates from the residual cavity, incisional 
fistula and excess bile secretion (Cirenei et al., 2001). 
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Limitations  
The study as indeed the data was very fragmented due to difficulties associated with collecting 
longitudinal data from different sources.  Measurement of the outcomes was limited to short 
periods due to inability to have a regular follow-up on the transhumant subjects who moved 
freely in and out of the control area.  The difficulty of working with unregulated retrospective 
data collected by different people over long periods of time was also problematic to analyse.  
It was impossible to determine that the samples had been constantly stored at – 200C as power 
outage is a common occurrence in Turkana as well as Nairobi where samples were stored for 
a long time.  Even in the presence of a generator, it is possible that the samples thawed a few 
times. 
Another problem encountered in follow-up was similarity in names where it was difficult to 
determine if it was a repeat patient or first diagnosis. This was reduced by use of patient 
numbers instead of names. However, this was only useful where the patient brought their 
records and its possible that there was duplication.  A different method of patient identification 
like fingerprinting may be more useful in the future. 
2.9  Conclusion  
This study gives better under understanding of the effectiveness of existing approaches.  This 
longitudinal study shows that there is considerable variation in the development of cysts.  The 
spontaneous disappearance of 3 cysts and the collapse of 3 others have implications both for 
the selection of patients for surgery and the assessment of chemotherapy.  Surgical removal of 
asymptomatic cysts should only proceed after a period of observation to establish cyst growth.  
This is especially pertinent in Turkana where the fertility of the cysts and the subsequent 
incidence of dissemination at surgery resulting in widespread inoperable disease are high 
(McPherson 1985).  Although 66% of the cysts grew during the period of observation, 34% 
remained static, collapsed, or disappeared.   
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Controlled trials are needed to determine the efficacy of drugs such as albendazole in 
continuous treatment as opposed to intermittent.  
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4 RECOMBINANT ANTIGEN PRODUCTION AND 
STANDARDIZATION 
Sensitive diagnostic tools are important in clinical diagnosis, epidemiological surveillance and 
infection control.  We identified 5 antigens from literature which may have different properties 
and appeared to have differential immunoreactive properties towards serum antibodies in 
patients with CE (Carmena et al., 2006; Zhang et al., 2003).  Elongation factor 1 (EF-
1β/δ).Thioredoxin peroxidise (TPx), E. granulosus fatty acid binding protein 1 (EgFABP1), 
Heat shock protein 70 (HSP70) and EgAgB.  After purification, the antigens showed a good 
immune response towards a pool of positive sera and poor responses towards negative sera.  
This was a good basis for the next two chapters where these antigens were used for diagnosis 
and follow-up of confirmed CE patients. 
4.1.1 Serum samples and patient information  
Serum samples were obtained from Mr Eberhard Zeyhle of the African Medical & Research 
Foundation (AMREF) which has run a hydatid control program in Northwest Turkana between 
1983 and 2015.  The study involved mass ultrasound screening of the nomadic Turkana people 
for Cystic Echinococcocus (CE) infection.  Treatment was given when required and patients 
were then followed-up for as long as was possible and/or necessary.  For each positive case, 
information was gathered on age, gender, medical history and cyst type.  At each screening a 
serum sample for any positive case was taken, labelled, bagged together and stored in freezers 
at -20°C and a sample of these was transported to the UK after obtaining necessary permits.   
4.1.2 Recombinant antigen purification   
3.1.2.1  Protein Expression  
Five recombinant antigens of Echinococcus granulosus origin were used in this study.  Stocks 
of Escherichia coli BL21(DE3) cells harbouring the recombinant pET19b EgFABP1, 
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EgEF1β/δ, EgHSP70, EgTPx and EgAgB plasmids had previously been synthesised by Dr. 
Tony Bodell (University of Salford) and stored as frozen glycerol stocks (10%).  These antigens 
were cloned, purified and standardised for use in this study by the researcher.  
Briefly, for each recombinant antigen, a frozen scraping from glycerol stocks (10%) was 
inoculated in 10 ml of Luria-Bertani (LB) (Thermo Fisher Scientific, Runcorn, UK ) medium 
and supplemented with ampicillin (100mg/ml) to generate a starter culture.  This was then 
grown overnight at 37°C in an incubator with a shaker (200rpm).  The following day 500 ml 
conical flasks containing 200 ml LB-amp were seeded with the overnight cultures at a 1:50 
dilution and grown to mid logarithmic phase.  Cultures were then induced with isopropyl β-D-
thiogalactopyranoside (IPTG) at a concentration of 0.4mM (100mM stock) and incubated 
shaking at 37°C (200rpm) for 4 hours.    
The 200ml cultures were processed using 50 ml falcon screw cap tubes to obtain pellets by 
centrifugation (5 min at 5000g), and pellets were inverted and left to air-dry.  The pellets were 
re-suspended in BugBuster protein extraction reagent (His-Bind Purification Kit, Novagen, 
Watford, UK ) using 5ml of 1X reagent per gram of wet cell paste.  The cell suspensions were 
shaken vigorously on a rotating platform for 20 minutes at room temperature, and subsequently 
centrifuged (16,000g for 20min at 4°C).  The supernatants were transferred to a new tube and 
a 1 ml aliquot was analysed by SDS-PAGE/Coomassie blue staining.  The remaining soluble 
cell lysates were subsequently purified by Immobilised Metal Affinity Chromatography 
(IMAC) as per the manufacturer’s instructions (Novagen, Watford, UK)    
3.1.2.2 SDS PAGE analysis  
Presence of purified target proteins was confirmed on 12.5% tris-glycine gels using the 
Laemmli (1970) system.(add ref)  Stacking buffer (0.5M Tris.HCl, pH 6.8), separating buffer 
(1.5M Tris.HCl, pH 8.8), Sodium dodecyl sulphate (10% w/v), 40% Acrylamide solution 
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(acryl: bis, 37.5:1, pH 8.8), 10% Ammonium persulphate and 0.04% Temed.  Sample buffer 
(100 mM Tris-Cl pH 6.8, 4% (w/v) sodium dodecyl sulphate, 0.2% (w/v) bromophenol blue, 
20% (v/v) glycerol, 200 mM DTT (dithiothreitol) was used at a 1:1 ratio (v/v) with purified 
recombinant proteins and loaded on gels at 10 µl per well.    
The gels were stained in Coomassie blue stain (0.1% Coomassie Blue, 10% Glacial acetic acid 
[v/v], 50% Methanol [v/v], 40% H2O [v/v]) and incubated covered on a rocking platform set 
at low speed at room temperature for 1 hour.  Gels were de-stained twice (7% glacial acetic 
acid [v/v], 12% methanol [v/v], 81% H2O [v/v]) for 1 hr and 3 hours respectively using fresh 
de-stain.  Protein bands were visualised using a G-Box imaging system (Syngene, Cambridge 
UK) and molecular sizes estimated using SeeBlue Plus2 pre-stained standard marker 
(Invitrogen, Paisley, UK). Protein sizes were calculated using the protein sequences inputted 
into the online Expasy available at: http://www.expasy.ch/tools/.   
3.1.2.3 Western Blotting   
Proteins separated under reducing conditions were transferred onto nitrocellulose membranes 
using an Iblot semi-dry system as per the manufacturer’s instructions (Invitrogen, Paisley, UK).   
The blots were subsequently blocked in phosphate buffered saline (PBS) (0.3%) Tween20 and 
5% dry milk powder (blocking buffer), covered and incubated at room temperature on a rocking 
platform set at low speed for 1 hour.  The membranes were washed three times in washing 
buffer 0.1% PBS T20 for 3 minutes per wash.    
Using an anti-histidine detection system, the nitrocellulose blots were incubated with 
polyclonal mouse anti-histidine primary antibody (Novagen Watford, UK) diluted in blocking 
buffer at 1:2000, covered and placed on a rocking platform set at low speed for 1 hour at room 
temperature.  Blots were washed three times and incubated in anti-mouse secondary antibody 
112 
 
conjugated to alkaline phosphatase (Sigma, Dorset, UK) at a dilution of 1:16,000 in 0.3% PBS 
T20.   
Subsequently, the membranes were washed three times and then covered in 5-Bromo-4-
chloro3-indolyl phosphate/Nitro blue tetrazolium substrate buffer (NBT/BCIP - BCIP 0.15 
mg/ml, NBT 0.30 mg/ml, Tris buffer 100 mM and MgCl2 5mM, pH 9.25–9.75), until they had 
developed, and bands were visible.  The reactions were stopped with deionised water and blots 
were viewed in a G-box imaging system (Syngene, Cambridge UK).  Protein concentration 
determined using Bradford Assay  
3.1.3 ELISA ASSAYS   
All enzyme-linked immunosorbent assays (ELISA) were performed as described by Wen and 
Craig (1994).  Optimum antigen concentrations for well coating and sera dilutions were 
predetermined by checkerboard titration (Voller et al., 1976). Total IgG was determined using 
direct ELISA and IgG subclasses were determined using indirect ELISA (Figure 3-1).  
 
Figure 3-1:  Direct and Indirect ELISA.  
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3.1.3.1  Standardization of Immunodiagnostic Reagents  
To determine the optimum working concentrations for different antigens and antibodies, highly 
responding positive controls and low responding negative controls were screened to assess the 
level of total IgG antibody responses and determine a cut-off point for diagnosis.   
3.1.3.1.1 Standardisation of recombinant antigens and crude HCF  
To determine the optimal dilution for diagnostic use, checkerboard titrations were performed 
using sheep hydatid cyst fluid (HCF) and recombinant antigens against human serum 
antibodies.  
A plate for crude sheep hydatid cyst fluid (HCF) and each pre-prepared recombinant antigen 
was set-up as follows:  The first row of each immunolon microtiter plate (Thermo Fisher 
Scientific, Runcorn, UK ) was coated with of HCF or recombinant antigen diluted in carbonate 
bicarbonate buffer (Sigma, Dorset, UK)) (0.05M) at pH 9.6.  Each column was serially diluted 
across the plate from the neat concentrations determined by Bradford assay in 3.1.2.3 above.  
The plate was incubated overnight at 4 0C and washed three times with phosphate buffered 
saline (PBS) (0.1%, pH7.2) Tween20 (0.05%) (PBS) to remove any non-bound antigen. 
Nonspecific binding sites were blocked with PBS (0.3% pH 7.2) containing skimmed milk 
(5%) and Tween20 (0.05%). Both positive and negative serum samples were diluted 1:25 with 
PBS (0.3% pH 7.2) containing skimmed milk (5%) in Tween20 (0.05%) and pipetted in the first 
row followed by serial dilutions to 1/1600. A final row with no sera had PBS (0.3% pH 7.2) 
containing skimmed milk (5%) in Tween20 (0.05%) only was used a control. The plates were 
incubated for 1 hour at room temperature, the liquid was discarded, and the wells washed (x3) 
with PBS to remove any non-bound serum. A secondary antibody, goat anti-human IgG whole 
molecule conjugated to alkaline phosphatase (Fc specific; Sigma, Dorset, UK)) was diluted to 
1: 16,000 in PBS (0.3%)–T and added to each well (100 μl). The liquid was discarded, and the 
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wells washed (x3) with PBS.  A chromogen p-Nitrophenylphosphatase (Sigma, Dorset, UK)) 
dissolved in (1M) diethanolamine (Sigma, Dorset, UK) and Magnesium Chloride (Sigma, 
Dorset, UK)) solution (0.5mM, pH 9.8) was added to each well and the plates were left to 
incubate at room temperature for a pre-determined time. The optical densities were measured 
at 405nm after 15 minutes, 20 minutes and 45 minutes, using an automatic microplate reader 
(Multiskan Ascent FC, Thermo Fisher Scientific, Runcorn, UK ). Optimal dilution was 
determined at the point where the positive control began to titrate out ensuring maximum 
binding with lowest dilution of antigen possible.  
3.1.3.1.2 Single antibody detection (Direct) ELISA assays  
Optimum working concentrations were pre-determined from the above experiment on 
standardisation of recombinant antigens and crude HCF.  They were REgAgB - 5.6µg/ml, 
REgEF-1β/δ- 6µg/ml, REgHSP70 - 87.5µg/ml, REgFABP1- 33.25µg/ml and REgTPx - 5.3µg/ml 
and HCF-1.5 µg/ml.  Immunolon microtitre (immunolon B) plates were pre-sensitised with 
crude parasite antigen (HCF) and recombinant antigens with the above working concentrations. 
The plates were then washed three times with phosphate buffered saline (PBS) (0.1%, pH 7.2) 
Tween20 (0.05%) (PBS), to remove non-bound antigen.  Non-specific binding sites were 
blocked with PBS (0.3% pH 7.2) containing skimmed milk (5%) in Tween20 (0.05%) (200ul) 
per well and the plates were covered and incubated at room temperature for 1 hr. The blocking 
buffer was discarded, and the plates were washed (x3) with PBS.  Individual patient sera 
including negative and positive controls was diluted to 1:200 with PBS (0.3% pH 7.2) 
containing skimmed milk (5%) in Tween20 (0.05%) and pipetted in duplicate to each well (100 
μl). The plate was incubated for 1 hour at room temperature and washed (x3) with PBS.  The 
antibody, goat anti-human IgG whole molecule conjugated to alkaline phosphatase (Fc 
specific; Sigma, Dorset, UK) was diluted to 1: 16,000 in PBS (0.3%) and added to the wells at 
100 μl per well and the plates were covered and incubated for a further 1 hr at room 
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temperature. The liquid was discarded, and the wells washed (x3) with PBS. A chromogen, 
pNitrophenylphosphate 5mg (Sigma, Dorset, UK)) dissolved in (1M) diethanolamine (Sigma, 
Dorset, UK)) and Magnesium Chloride (Sigma, Dorset, UK) solution (0.5mM, pH 9.8) was 
added to each well and the plates were left to incubate at room temperature for a pre-determined 
time. The optical densities were measured at 405nm after 15 minutes, 20 minutes and 45 
minutes, using an automatic microplate reader (Multiskan Ascent FC, Thermo Fisher 
Scientific, Runcorn, UK).  
3.1.3.1.3 Double antibody detection (Indirect) ELISA assays  
Subclasses of IgG (IgG1 and IgG4) antibody detection ELISA assays were performed using 
previously standardise protocols (Lawn et al., 2004) and working concentrations of antigens 
calculated from the standardisation of recombinant antigens and crude HCF. These subclasses 
have been shown to be the predominant antigens in helminth infections e.g. filariasis, 
schistosomiasis, cysticercosis and echinococcosis (Restrepo et al., 1998; Siracusano et al., 
2008).  
Using 96-well immulon B4 micro-titre plates, crude HCF (1. 5 µg/ml) and recombinant 
antigens were coated at different optimum working concentrations pre-determined by 
checkerboard titration. These were (REgAgB - 5.6µg/ml), (REgEF-1β/δ- 6µg/ml), (REgHSP70 
- 87.5µg/ml), (REgFABP1- 33.25µg/ml) and (REgTPx - 5.3µg/ml) (Table 3-1) and were 
incubated overnight at 4°C.  The plates were washed three times with phosphate buffered saline 
(PBS) (0.1%, pH 7.2)-Tween20 (0.05%) (PBS). Non-binding antigens and non-specific binding 
sites were blocked with PBS (0.3% pH 7.2) containing skimmed milk (5%) in Tween20 (0.05%) 
(200ul). The plates were covered and incubated at room temperature for one hour and washed 
three times with PBS. Individual patient sera samples, including negative and positive controls 
were diluted to 1:50 with PBS (0.3% pH 7.2) containing skimmed milk (5%) in Tween20 
116 
 
(0.05%). Each sample (100ul) was pipetted in duplicate into mapped wells and incubated for 
one hour at room temperature.  Monoclonal anti-human IgG1 or IgG4 antibodies raised in mice 
(Abcam, Cambridge UK) were diluted to 1:5000 in PBS (0.3%) and added to each well (100 
μl). The plates were covered and incubated for one hour at room temperature. The antibody 
was removed from each well and the wells washed (x3) with PBS.  Goat anti-human IgG whole 
molecule tertiary antibody conjugated to alkaline phosphatase (Sigma, Dorset, UK)) was 
diluted to 1: 16,000 in PBS and added to each well (100 μl). The plates were covered and 
incubated for one hour at room temperature, followed by a final wash (x3) with PBS.  
Chromogen p-Nitrophenylphosphate (Sigma, Dorset, UK)) dissolved in (1M) diethanolamine 
(Sigma, Dorset, UK)) and Magnesium Chloride (Sigma, Dorset, UK)) solution (0.5mM, pH 
9.8) was added to each well and the plates were left to incubate at room temperature for a pre-
determined time.  The optical densities were measured at 405nm after 15 minutes, 20 minutes 
and 45 minutes, using an automatic microplate reader (Multiskan Ascent FC, Thermo Fisher 
Scientific, Runcorn, UK). 
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4.1.3 Results and Discussion 
The preparation of the recombinant antigens Echinococcus granulosus antigen B (REgAgB), 
Echinococcus granulosus elongation factor 1 alpha beta (REgEF-1β/δ) Echinococcus 
granulosus heat shock protein 70 (REgHSP70), Echinococcus granulosus fatty acid binding 
protein 1 (REgFABP1), and Echinococcus granulosus thioredoxin peroxidase (REgTPx) under 
investigation was achieved by cell culture of the recombinant antigen pET vectors previously 
prepared by Dr A. Bodell. The pET plasmid expression vector structures were based on the 
work carried out in the 1970’s by Herbert Boyer and his post-doctoral scientists derived from 
their pBR322 plasmids (Greene et al., 1978).  
Solubilisation of the crude proteins and purification was achieved using IMAC technology via 
affinity chromatography specific to histidine extensions of the protein sequences. The fine 
purification steps were followed using the standard procedures described by 
Merck4Biosciences with their HisBind Purification Kit. Imidazole elution afforded the proteins 
in high levels of purification and the protein concentrations were determination by the Bradford 
Assay (Bradford, 1976) method.  Table 4-1 shows the neat concentration levels achieved from 
the IMAC purification stage and the working concentrations that were then found to be 
optimum ELISA checker board experiments and later single and double antibody ELISA’s. 
Antigen  Neat concentration Working concentration 
Hydatid cyst fluid 400 µg/ml 1.5 µg/ml 
rEgAgB 90 µg/ml 5.6µg/ml 
rEgEF-1β/δ 95µg/ml 6 µg/ml 
rEgHSP70 1.4mg/ml 87.5 µg/ml 
rEgFABP1 532µg/ml 33.25 µg/ml 
rEgTPx 85µg/ml 5.3 µg /ml 
Table 4-1:  Antigen concentrations of the recombinant IMAC isolated proteins. 
The recombinant fusion proteins EgEF-1β/δ, EgHSP70, EgFABP1, EgTPx and EgAgB were 
partially characterised using SDS-PAGE and a 1mM Tris-glycine 12.5% gel. The molecular 
118 
 
weights were determined by comparing with the SeeBlue® plus2 pre-stained protein standard 
marker from Invitrogen, loaded in one lane of the gel. 
The qualitative purification of each protein was observed by visualisation using a G-box 
imaging system. The number and density of the blue stained protein bands and the pseudo-
quantitative evaluation of the recombinant protein sizes were calculated using the online 
Expasy Peptide mass calculator (Gasteiger et al., 2003), available from 
http://www.expasy.ch/tools/.  shows the Coomassie stained gel of non-reduced blots for 
purified proteins in Panel 1 as well as their immune reactivity with pooled positive and negative 
sera (Figure 4-1). 
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C  
Figure 4-1:  Non-reduced blots for purified proteins  
Key:  Panel 1 Lane M, SeeBlue® Plus2 pre-stained protein standard 4–250 kDa; anti-
histag assay; Lane 1, purified recombinant histag-fusion protein; lane 2, negative control. 
Panel 2: pooled sera assay: lane 1, pooled hydatid patient sera; lane 2, normal sera; a) 
EgFABP1; b) EgEF-1β/δ; c) EgHSP70; d) EgTPx; target proteins shown with arrow 
head. 
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4.1.4 Titration curves between human sera and crude HCF 
The determination of the most effective working concentration of crude HCF was carried out 
using a checkerboard titration (Voller et al., 1976).  
A pool of highly responding positive sera and another of low responding negative sera was 
used to work out optimal working concentrations. The optimum dilution was the point where 
there was maximum binding of HCF at the lowest dilution of antigen.  
 
Figure 4-2: Titration of native HCF. 
A titration of HCF against positive and negative human sera antibodies using antihuman total 
IgG conjugated antibodies was performed (Figure 4-2). 
The results show that the human sera dilutions at 1:25, 1:50 and 1:100 all retain relative 
plateaus above the O.D. of 4.0 with similar HCF concentrations (25µg/ml to 1.5µg/ml). The 
HCF antigen concentration of 1.5µg/ml and the dilution 1:100 for sera were used for all 
proceeding work and identified as the optimal concentrations for sample experiments.   
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4.1.5 Titration Curves of Recombinant Antigens  
A similar checkerboard titration method was used to assess the optimal concentration of 
recombinant antigens. This second checkerboard ELISA’s were undertaken to assess the 
reactivity’s of the IMAC purified positive and negative recombinant proteins derived from the 
clones: pET19b-EgTPx-2Cb; pET19b-EgFABP1-C10; pET19b-EgEF-1β/δ; pET19b-
EgHSP70-C10; and pET19b-EgAgB and were compared to crude HCF.  
Each recombinant protein was examined against the positive and negative antihuman total 
IgG conjugated human sera antibodies, shown separately in Figure 4-3 to Figure 4-7 
  
Figure 4-3:  Titration curves for recombinant antigens TPx  
 
 
 
  
Figure 4-4:  Titration curves for recombinant antigens HSP70  
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Figure 4-5:  Titration curves for recombinant antigens EF-1β/δ 
  
Figure 4-6:  Titration curves for recombinant FABP1  
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Figure 4-7: Titration curves for recombinant antigens AgB.  
Antigens reactivity were tested against positive and negative human sera using antihuman 
total IgG conjugated antibodies.  The titration curves for the positive sera responses were 
used to determine the working concentrations used in subsequent experiments.  The reactivity 
of the recombinant proteins examined were lower compared to HCF. At the highest sera 
concentration, HSP70 starts with a response below an O.D. of 0.8. FABP1, TPx and EF-1β/δ 
all start with an O.D. of around 1.15, at the highest concentration.  
Antigens reactivity were tested against positive and negative human sera using antihuman total 
IgG conjugated antibodies.  The titration curves for the positive sera responses were used to 
determine the working concentrations used in subsequent experiments.  The reactivity of the 
recombinant proteins examined were lower compared to HCF.  At the highest sera 
concentration, HSP70 starts with a response below an O.D. of 0.8. FABP1, TPx and EF-1β/δ 
all start with an O.D. of around 1.15, at the highest concentration. 
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4.2 Discussion 
Use of recombinant antigens in diagnosis of helminthic infections reduces cross reactivity and 
consequently the number of false negatives (Li et al., 2004; Ricciardi et al., 2015).  In diagnosis 
of CE, no one antigen shows satisfactory results in either diagnosis or follow-up.  In this study, 
we sought to explore the idea that perhaps the answer lies in using multiple antigens 
consecutively.  Four potentially differentially immunoreactive antigens with towards serum 
antibodies in patients with CE (Manzano-Román et al., 2015; Ortona et al., 2004) were purified 
and optimised for immunodiagnostic testing along with the commonly used HCF and AgB.  
Mouse monoclonal antibodies have exhibited high specificity for human IgG (Welling et al. 
1985 and Kameny.,1987) demonstrated these characteristics.  Working concentrations of 
antigens were determined using highly positive sera and low responding negative sera 
described in checkerboard ELISA experimental protocol 3.1.3.1.  Optimal concentrations of 
antigens were taken when the lowest amount of antigen exhibited maximal binding.  The lowest 
dilution of positive sera where the optimal concentration of antigen had the highest binding 
just before it began to titrate out was determined in the checkerboard ELISA with 
considerations to background noise and quantity of sera available.  Working concentrations 
used in this study are summarised in Table 4-1. 
Working dilutions of conjugates was based on manufacturers recommendations. These were 
verified and modified where necessary. Optimal concentrations were checked for each new set 
of sera, conjugates and reagents and new antigen preparations.  
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5 IMMUNO-SEROLOGICAL PROFILES IN HUMAN CYSTIC 
ECHINOCOCCOSIS 
5.1 Introduction 
Human cystic echinococcosis (CE) is a re-emerging zoonotic disease among the rural poor.  It 
causes considerable morbidity and mortality in many parts of the world, particularly in 
underdeveloped regions. Pathology is typified by long term growth of unilocular fluid filled 
cysts which may contain thousands of protoscoleces (Macpherson et al., 2003; Thompson, 
2015).  E.granulosus is the only parasite known to produce lesions in so many anatomical sites. 
(Kiresi et al., 2003).  WHO based classification of hydatid cysts on morphology and contents 
and placed them into five groups from CE1 to CE5.  This formed the basis for clinicians to 
perform or recommend the appropriate interventions (Macpherson et al., 2003) and to define 
whether patients show active disease CE1 – CE2, transitional CE3 or stable/cured disease CE4 
– CE5 (Brunetti et al., 2009; Lissandrin et al., 2016).  These definitions are not clear cut as a 
dead cyst may harbour active CE2 cysts containing viable daughter cysts (Taherkhani et al., 
2007). 
Accurate early diagnosis of CE leads to cheaper management and better treatment outcomes 
(Velasco-Tirado et al., 2018) Today, diagnosis is based on clinical assessment, imaging and 
serology.  Imaging techniques including ultrasonography (US), computed tomography and 
magnetic resonance imaging have been widely used in diagnosis of CE and the modality most 
helpful depends on size of cyst and affected organ (Wen et al., 2019) In areas where CE is 
endemic, the high cost of computed tomography and magnetic resonance imaging make them 
inaccessible and ultrasound is the main diagnostic method.  Use of ultra sound revolutionized 
the diagnosis of intra-abdominal CE in individual cases of human infection, with sensitivity 
and specificity between 93–98% (Vicary et al., 1977; Wen et al., 2019), giving the clinicians 
information on the number, size, location and condition.  The advantages include its portability, 
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lack of ionizing radiation, painless, harmless and non-invasive.  Also, instant results which can 
be permanently recorded.  Ultrasound is ideal for abdominal localizations where visualising 
the internal structures of the cysts provides conclusive diagnostic information in active cysts 
especially CE1 and CE2 (Macpherson et al., 2003). 
Ultrasound is not always ideal for some cyst locations and may miss out on cysts in the lungs, 
bones or CNS (Shambesh et al., 1999).  Other diagnostic techniques are therefore necessary 
for confirmatory testing.  Serological studies are useful in community surveys and may provide 
partial diagnosis for some of those cases missed. They also allow a follow-up with better 
imaging techniques as well as confirming US imaging where cystic lesions presented are 
morphologically unclear (Brunetti et al., 2018; Rogan et al., 1997). In addition, when 
community studies are carried out, greater numbers of people are screened, and serological 
responses can be useful in identifying suspect cases not picked up by ultrasound screening 
(Shambesh et al., 1999).  Torgerson et al (2009) suggested using a highly sensitive test to pick 
out all the initial cases, followed by a highly specific test to confirm the results.  
Immunodiagnostic tests for CE using E.granulosus hydatid cyst fluid antigen for primary 
screening has good sensitivity between 75 to 95 % and is ideal for primary testing but it has 
many inconsistencies due to cross reactivity with other helminths producing false positives 
(Craig, 1986). Other diagnostic variations arise due to patients showing low responses 
(Macpherson et al., 2003; Siracusano et al., 2008), variation in responses with cyst type, cyst 
size (Hernandez-Gonzalez et al., 2008; Piccoli et al., 2013) and location (Zhang et al., 2006).  
To improve sensitivity and reduced the problem of cross reactivity with other helminths 
significantly, use of IgG subclass detection and recombinant antigens which can be mass 
produced and easily purified has been applied (Sarkari et al., 2015; Virginio et al., 2003). 
Sensitive assays, such as enzyme-linked immune-sorbent assay (ELISA), immunoblotting and 
immuno-fluorescence, have replaced the classical tests such as immuno-electrophoresis, 
127 
 
indirect hemagglutination.  The efficiency of the assay is dependent on the quality of antigen 
used (e.g. crude, purified or recombinant,) as well as the characteristics of the sera (e.g. 
confirmed cases, suspected cases, low responders or high responders  (Paul et al., 2001) 
This study sought to compare the diagnostic value of HCF with 5 recombinant antigens and 
correlate the immune responses to defined CE pathology. 
The aim of this chapter was to evaluate the relevance of cyst morphology to antibody profiles 
in relation to immunodiagnostic antigens. 
The hypothesis was that different antigens are associated with different stages of cyst 
development. 
 
  
128 
 
5.2 Materials and methods 
5.2.1 Serum samples 
Samples from 100 ultrasound confirmed CE cases were selected for this study.  All the patients 
were untreated and harboured single abdominal cysts. All sera samples originated from 
Turkana (Kenya) and had been collected during mass screening between 2002 and 2005 and 
had been stored in a freezer at 200C. The freezer was battery powered in the field and contents 
were transferred to an electric powered freezer as soon as that was possible.  There is a 
possibility that the samples went through at least 3 freeze – thaws between the field and arrival 
in Salford. In all batches tested, there were high numbers of high reacting samples and 
therefore freeze thaw did not seem to be a problem.  A patient was classed as untreated if they 
had not received chemotherapy treatment in the last 6 months or surgery in the last 18 months.  
Patients with multiple cysts were excluded from the study.  The positive control was a pool of 
highly responding sera from individuals infected with CE1, CE2, CE3 and CE4 type cysts (4 
samples per cyst type, n=16 individuals). Details of cyst were provided by US images and/or 
notes.   
Patients with different cyst morphologies were selected for this study.  A flow chart describing 
the inclusion criteria for sample selection is shown below Figure 5-1 
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Figure 5-1:  Selection criteria for serum samples 
 
The classification of cyst types observed (CE1-CE4) was based on matching the ultra-
sonographer’s images and notes to the initial classification system of hydatid cysts (WHO-
IWGE, 2003).  It is acknowledged that this system has been updated by splitting CE3 cysts into 
CE3a and CE3b, but this was not established at the time of serum collection and therefore is 
not employed. Among those selected, 33 patients had CE1 cysts, 19 had CE2 cysts, 21 patients 
with CE3 cysts and 27 patients had CE4 cysts.  Cyst locations are shown in Table 5-1. 
 Cyst 
Type 
Numbers of 
Patient 
Liver Lower 
abdo
men 
Omen
tum 
Kidne
y 
Spleen 
CE1 33 24 3 3 2 1 
CE2 19 11  8   
CE3 21 15 1 5   
CE4 27 24 2 1   
Table 5-1:  Cyst Morphology and Localization    
5.2.2 ELISA analysis 
ELISA analysis was done to determine total serum immunoglobulin (IgG(w)) and IgG1 and 
IgG4 subclass antibodies expression in response 5 recombinant and 1 native parasite antigens. 
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These had been previously purified and optimised in chapter 3.  The optical density was 
calculated as the average of duplicate samples with the blank subtracted.  Duplicate samples 
that had more than 10% difference were repeated. 
5.2.3 Cut off results  
Traditionally, ELISA cut-off values are calculated by averaging a panel of known negative 
controls and adding two or three standard deviations, the Gaussian approach (Allan et al., 
1990).  In this study, negative cut off points were calculated as the mean optical density plus 2 
SD of control negative sera samples (Ito et al., 2002; Jiang et al., 2012).  The sera were chosen 
from 50 patients who were CE-negative but had blood taken for other unrelated conditions e.g. 
malaria and typhoid; but the details of the conditions were not available.  It is acknowledged 
that this may have influenced the immune responses. The patients all gave consent for their 
serum to be used for scientific research.  The lowest reactive samples from 20 individuals in 
Turkana ultrasound results was used.  The negative cut off point of expression of total IgG and 
IgG subclasses 1 and 4 for different recombinant antigens were calculated with the results 
shown in Table 5-2. 
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Antibody (Antigen) MEAN O. D Standard Deviation CUTOFF 
Total IgG (HSP70) 0.117 0.060 0.237 
Total IgG (EF1) 0.090 0.075 0.241 
Total IgG (FABP1) 0.108 0.052 0.212 
Total IgG (TPx) 0.079 0.055 0.189 
Total IgG (AgB) 0.065 0.031 0.127 
Total IgG (HCF) 0.156 0.120 0.397 
IgG1 (HSP70) 0.081 0.037 0.155 
IgG1 (EF1) 0.097 0.059 0.216 
IgG1 (FABP1) 0.082 0.022 0.125 
IgG1 (TPx) 0.062 0.015 0.093 
IgG1 (AgB) 0.098 0.034 0.167 
IgG1 (HCF) 0.188 0.076 0.341 
IgG4 (HSP70) 0.074 0.032 0.138 
IgG4 (EF1) 0.079 0.035 0.149 
IgG4 (FABP1) 0.076 0.033 0.143 
IgG4 (TPx) 0.080 0.038 0.156 
IgG4 (AgB) 0.074 0.030 0.134 
IgG4 (HCF) 0.154 0.091 0.336 
Table 5-2:  ELISA negative cut off values  
A pool of 10 highly responding positive sera were used a positive control.  All sera were stored 
at -20°C prior to being assayed 
5.2.4 Statistical analysis 
Data were analysed using scatter computer graphics software (GraphPad Prism version 6, 
SanDiego - CA USA) and SPSS statistical package version 23 (SPSS Inc Chicago, IL).  
Differences between total IgG and IgG subclasses based on the same antigen were compared 
using chi-square test.  Statistical significance was considered at P-value ≤ 0.05 unless otherwise 
stated. 
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5.3 Results 
5.4 Specificity of total IgG and IgG subclasses. 
Test for specificity was done using 21 sera samples from individuals found in the same 
community as test cases but known be to disease free.  Specificity was calculated as sum of 
negative cases shown by the particular antigen, divided by total number of cases and multiplied 
by 100.  Table 5-3 shows the specificity of total IgG and IgG sub classes in response to 
different antigens.  All antigens showed good specificity of between 90 and 100%. 
Antibody HSP70(%) EF1(%) FABP1(%) TPx (%) AgB (%) HCF 
(%) 
Total IgG 95 95 95 95 90 95 
IgG1 95 90 100 100 95 95 
IgG4 100 95 100 95 95 100 
Table 5-3:  Specificity of total IgG and IgG sub classes in response to different antigens 
 
5.4.1 Differential antigen recognition with changes in cyst type 
One hundred CE cases were evaluated for antibody responses towards 6 different antigens with 
total serum IgG and IgG subclasses IgG1 and IgG4.  Of these 33 harboured CE1 cysts, 19 had 
CE2 cysts, 21 had CE3 cyst and 27 had CE4 cysts.  All the cases had been previously confirmed 
and cyst type determined by ultra sound.  
5.4.1.1 Antigen Recognition Towards CE1 Cyst Types.  
Sera from 33 untreated individuals diagnosed with CE1 cysts were tested using ELISA against 
5 recombinant antigens and 1 native antigen to detect levels of total IgG and IgG subclasses 1 
and 4 immune responses.  The diagnostic performance of different antigens was assessed and 
graphed in Figure 5-2 to Figure 5-5  
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Figure 5-2:  Expression of Total IgG in responses to echinococcal antigens in patients with CE1 cysts  
 
Figure 5-3 shows the above data in a box and whisker plot as a comparative representation  
 
Figure 5-3:  Total IgG Expression in responses to echinococcal antigens in patients with CE1 cysts 
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Figure 5-4:  Expression of IgG1 in responses to echinococcal antigens in patients with CE1 cysts  
 
 
 
Figure 5-5:  Expression of IgG4 in responses to echinococcal antigens in patients with CE1 cysts 
ELISAs determining total IgG (IgGw) expression in response to HSP70 in CE1 cases showed 
a seropositive rate of 67% (22) with an average OD of 0.398.  The diagnostic value was 
improved to 88 % with both subclasses IgG1 and IgG4 with a higher average O.D of 0.430 and 
0.45 respectively.  The differences between total IgG and the subclass seropositive rates were 
highly significant with IgG1 (χ² = 9.1, p = 0.008) and IgG4 (χ² = 9.1, p = 0.008). Also, the 
seropositive rates between IgG1 and IgG4 were significant (χ² = 16.8, p = 0.003).  
Total IgG expression in response to EF-1β/δ was poor with only 30 % (10) of the cases 
confirmed as positive. It also had low average OD at 0.220nm but the spread of immune 
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responses was minimal with one highly responding outlier. These responses were marginally 
improved with IgG1 which confirmed 42 % (14) were positive and markedly improved with 
IgG4 where 64% (21) of the cases were seropositive.  The average optical density in IgG1 and 
IgG4 responses were 0.216 and 0.255 respectively.  The difference between total IgG and 
subclass IgG1 seropositive rates were highly significant (χ² = 13.3, p < 0.001) and IgG4 (χ² = 
18.2, p = 0.005) and IgG1 vs IgG4 was also highly significant (χ² = 13.9, p < 0.001).  
Total IgG expression towards FABP1 were also poor with only 45 % (15/33) seropositivity 
and average titre value of 0.241.  Better diagnostic value was found with subclass responses 
where 91% (30) were seropositive with IgG1 and 85% positive with IgG4.  The average 0D 
was also improved with 0.258nM with IgG1 and 0.238 with IgG4.  The difference between 
total IgG and subclass IgG1 seropositive rates were not significant (IgG(w) vs 1gG1, p = 0.23, 
IgG(w) vs IgG4 (p = 1) and IgG1 vs IgG4 was also not significant (p = 0.53). 
Better diagnostic values with total IgG were achieved with TPx with positive responses at 73% 
(24) with average OD of 0.304.  Similarly, diagnostic value was improved by using subclasses 
and positive responses with IgG1 were 100% (33) with average OD of 0.366 and IgG4 88 % 
(29) with average OD of 0.336.  The difference between total IgG and subclass IgG1 
seropositive not significant (χ² = 3.2, p = 0.24) but was significant with IgG4 (χ² = 10.86, p = 
0.02) and IgG1 vs IgG4 was not significant (χ² = 5.3, p = 0.16). 
Total IgG expression in response to AgB was 70% (23) with an average OD of 0.342.  With 
subclasses, 94% (31) were seropositive with IgG1 with average OD of 0.411 and 97% (32) 
with IgG4 with an average OD of 0.472.  The difference between total IgG and subclass IgG1 
seropositive rates was highly significant (χ² = 33.01, p = 0.02) but not significant with IgG4 (χ² 
= 15.9, p = 0.061) and IgG1 vs IgG4 was also not significant (χ² = 15.9, p = 0.061). 
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Responses of total IgG towards HCF showed a sero-positive rate of 88% (29) and average OD 
of 0.864.  Reponses of IgG1 showed 91% (30) seropositivity and IgG4 94% (31) with an 
average OD of 0.882 and 0.869 respectively.  The differences between total IgG and subclass 
IgG1 seropositive rates were not significant (χ² = 15.98, p =0.119) and IgG4 (χ² = 7.220, p = 
0.061) and IgG1 vs IgG4 was significant (χ² = 15.98, p = 0.061). 
 
Therefore, specific IgG1 subclass was predominant in responses AgB while specific and IgG4 
responses were the predominant towards TPx.  Responses towards HSP70 and EF1 were 
significantly different between all antibodies while those against FABP1 and HCF had no 
statistical significance differences across all antibodies tested.  
5.4.1.2 Antigen recognition towards CE2 cyst types 
Sera from 19 untreated CE2 cases was tested using ELISA against 5 recombinant antigens and 
1 native antigen to detect levels of total IgG and IgG subclasses 1 and 4 immune responses.  
The diagnostic performance of different antigens was assessed and graphed in Figure 5-6 to 
Figure 5-8Figure 5-8:   Expression of IgG4 in responses to echinococcal antigens in patients with CE2 cysts  
.  
Figure 5-6:  Expression of total IgG in responses to echinococcal antigens in patients with CE2 cysts  
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Figure 5-7:  Expression of IgG1 in responses to echinococcal antigens in patients with CE2 cysts 
 
 
Figure 5-8:   Expression of IgG4 in responses to echinococcal antigens in patients with CE2 cysts  
Assays for total serum IgG antibody showed that 58% (11) of CE2 cases were sero-positive in 
response to HSP70 with an average O.D of 0.33. assays for subclass IgG1 showed a 
seropositivity of 79% (15) with a mean O.D of 0.36 and IgG4 79% (15) of the cases to be 
seropositive with an average O.D 0.331. The differences between total IgG and the subclass 
seropositive rates were significant with IgG1 (χ² = 16.9, p = 0.018) and IgG4 (χ² = 6.9, p = 
0.018). Also, the seropositive rates between IgG1 and IgG4 were significant (χ² = 19, p < 
0.001). 
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In CE2 cases, similar to CE1 cases, the poorest performing antigen against total serum IgG was 
EF-1β/δ where six patients (32 %) showed positive response with a mean O.D of 0.212. 
subclass IgG1 had similar results at 32 % (6) mean O.D of 0.121 and unlike in CE1 cysts, 
subclass IgG4 did not improve the performance very much with a seropositivity 42 % (8) and 
a mean O.D of 0.183.  The difference between total IgG and subclass IgG1 seropositive rates 
were highly significant (χ² = 19, p < 0.001) and IgG4 (χ² = 12.2, p = 0.005) and IgG1 vs IgG4 
was also significant (χ² = 14, p = 0.01). Total IgG responses in response to FABP1 showed a s 
68 % (13) seropositivity with an average O.D 0.224.  With the subclasses, IgG1 had a 
seropositivity of 95 % (18) and a mean O.D of 0.233 while IgG4 had a seropositivity rate of 
89% (17) and an average OD of 0.199.  The difference between total IgG and subclass IgG1 
seropositive rates were not significant (χ² = 2.3, p = 0.32) and IgG4 (χ² = 0.531, p = 0.105) and 
IgG1 vs IgG4 was also significant (χ² = 8.9, p = 0.422).  
Antigen TPx showed a good diagnostic performance with responses to total IgG at 84 % (16) 
with average O.D of 0.281, responses with IgG1 100% (19) average O.D of 0.403 and 
responses of IgG4 at 84 % (16) with average O.D of 0.390.  The difference between total IgG 
and subclass IgG4 seropositive not significant (χ² = 0.825, p = 0.422) 
Total IgG expression in response to AgB was 89% (17) with an average OD of 0.412.  With 
subclasses, 89% (17) were seropositive with IgG1 with average O.D of 0.421 and 89% (17) 
with IgG4 with an average OD of 0.446.  The difference between total IgG and subclass IgG1 
seropositive rates was highly significant (χ² = 19, p < 0.006) but not significant with IgG4 (χ² 
= 8.9, p = 0.105) and IgG1 vs IgG4 was also not significant (χ² = 8.9, p = 0.105). 
Responses of total IgG towards HCF showed a sero-positive rate of 88% (29) and average OD 
of 0.864.  Reponses of IgG1 showed 91% (30) seropositivity and IgG4 94% (31) with an 
average OD of 0.882 and 0.869 respectively.  The differences between total IgG and subclass 
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IgG1 was highly significant (χ² = 19, p = 0.006) and IgG4 (χ² = 19, p = 0.006) and IgG1 vs 
IgG4 was also significant (χ² = 19, p = 0.006). 
5.4.1.3 Antigen recognition towards CE3 cyst types 
Sera from 21 untreated CE3 cases was tested using ELISA against 5 recombinant antigens and 
1 native antigen to detect levels of total IgG and IgG subclasses 1 and 4 immune responses.  
The diagnostic performance of different antigens was assessed and graphed in Figure 5-9 to 
Figure 5-11. 
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Figure 5-9:  Expression of total IgG in responses to echinococcal antigens in patients with CE3 cysts. 
 
Figure 5-10:  Expression of IgG1 in responses to echinococcal antigens in patients with CE3 cysts 
 
Figure 5-11:  Expression of IgG4 in responses to echinococcal antigens in patients with CE3 cysts  
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In CE3 cases, expression of total serum IgG antibodies in response to HSP70 was lower than 
the active CE1 and CE2 cysts and only 38% (8) of the cases were sero-positive with an average 
O.D of 0.317. there was improvement in diagnostic value with the use of subclasses and IgG1 
showed seropositivity of 62% (13) with a mean O.D of 0.31 and IgG4 a seropositivity of 80% 
(17) of the cases and average O.D 0.294.  The difference between total IgG and subclass IgG1 
seropositive rates were significant (χ² = 7.95, p = 0.006) but not significant with IgG4 (χ² = 
3.04, p = 0.12) and IgG1 vs IgG4 was also not significant (χ² = 0.297, p = 0.618). 
As with the active cysts, the poorest performing antigen with total serum IgG remained EF-
1β/δ where 4 patients (19 %) showed positive response with a mean O.D of 0.192. The response 
remained poor with subclass IgG1 at 23 % (5) with a mean O.D of 0.198 but improv ed greatly 
with IgG4 to 67 % (14) with mean O.D of 0.228.   The difference between total IgG and 
subclass IgG1 seropositive rates were significant (χ² = 15.78, p < 0.001) but not significant 
with IgG4 (χ² = 2.42, p = 0.255) and IgG1 vs IgG4 was also not significant (χ² = 3.28, p = 
0.123). 
Another poor performance with total IgG was found with FABP1 where 33% (7) seropositivity 
was found with FABP1 with an average O.D 0.218.  With the subclasses, responses of IgG1 
FABP1 picking up all the cases at 100 % (21) and a mean O.D of 0.213 and IgG4 76 % (16) 
with average O.D of 0.208.  The difference between total IgG and subclass IgG1 seropositive 
rates were not significant. 
Expression of total IgG in response TPx were 62 % (13) seropositive with average O.D of 
0.250, 100 % (21) and had an average O.D of 0.278 in IgG1 responses and 76 % (16) with 
average O.D of 0.244 with IgG4 responses.  The difference between total IgG and subclass 
IgG1 seropositive rates were not significant. 
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Responses of total IgG towards AgB were moderate at 67 % (14) average O.D of 0.353. while 
seropositivity with IgG1 was 81% (17) and IgG4 was 100% (21). The difference between total 
IgG and subclass IgG1 seropositive rates were significant (χ² = 21, p = 0.005). 
The best performing antigen with total IgG was HCF recognising 81% (17) with average O.D 
of 0.806 which a similar result with an average and 0.862 IgG1 and 90 % (19) of the cases, 
having an average O.D 0.750 with IgG4. The difference between total IgG and subclass IgG1 
seropositive rates were not significant. 
The best performing antigen was TPx against IgG1 antibodies as it picked up all the cases. The 
poorest performing antigen with CE3 cases was EF1α/β though the performance was improved 
with IgG4 antibodies compared to total serum IgG and IgG1 similar to CE2 and CE1 cases.  
5.4.1.4 Antigen recognition towards CE4 cyst types 
Sera from 27 untreated CE4 cases was tested using ELISA against 5 recombinant antigens and 
1 native antigen and the levels of total IgG and IgG subclasses 1 and 4 immune responses 
assessed. The diagnostic performance of different antigens was assessed and graphed in Figure 
5-12 to Figure 5-14. 
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Figure 5-12:  Expression of total IgG in responses to echinococcal antigens in patients with CE4 cysts 
 
Figure 5-13:  Expression of IgG1 in responses to echinococcal antigens in patients with CE4 cysts 
 
Figure 5-14:  Expression of IgG4 in responses to echinococcal antigens in patients with CE4 cysts 
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The responses of total serum IgG antibody in CE4 cysts showed that 52% (14) were sero-
positive in response to HSP70 with an average O.D of 0.421.  Responses of IgG1 antibody with 
the 27 cases improved the diagnostic value, similar to all the other cyst types to 70% (19) with 
a mean O.D of 0.433. and with IgG4 antibody to 78% (21) with average O.D of 0.377. The 
difference between total IgG and subclass IgG1 seropositive rates were significant (χ² = 12.24, 
p = 0.001) but IgG4 was not significant (χ² = 3.84, p = 0.067) and IgG1 vs IgG4 was also 
significant (χ² = 10.67, p = 0.04). 
The poorest performing antigen with total serum IgG was EF1 where 7 patients (26 %) showed 
positive response with a mean O.D of 0.207. This was also found in response towards IgG1 at 
41 % (11) with a mean O.D of 0.221 but the diagnostic performance of EF1 was the best with 
CE4 cysts at 74 % (20) with mean O.D of 0.209. The difference between total IgG and subclass 
IgG1 seropositive rates were significant (χ² = 13.74, p < 0.001) but with IgG4 was not 
significant (χ² = 7, p = 0.137) but IgG1 vs IgG4 was not significant (χ² = 0.22, p = 0.022). 
Seropositivity with FABP1 was 56 % (15) with an average O.D 0.243. Improved performance 
was observed in all other antigens with IgG1 being seropositive for 89 % (24) the cases and a 
mean O.D of 0.241. and with IgG4 seropositive for 85% (23) with average O.D of 0.231 The 
difference between total IgG and subclass IgG1 seropositive rates were not significant (χ² = 
4.21, p = 0.075) but was significant with IgG4 (χ² = 3.04, p = 0.028) and IgG1 vs IgG4 was 
also significant (χ² = 19.4, p = 0.001). 
Responses of total IgG to TPx were 85 % (23) seropositive with average O.D of 0.266. The 
best performing antigen was TPx with 96 % (26) of seropositive cases and an average O.D of 
0.383 Seropositive cases with TPx reduced to 85 % (23) with average O.D of 0.368.  The 
difference between total IgG and subclass IgG1 seropositive rates were not significant (χ² = 
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5.97, p = 0.148) but with and IgG4 was highly significant (χ² = 27, p < 0.001) and IgG1 vs 
IgG4 was not significant (χ² = 5.97, p = 0.148). 
The best diagnostic antigen with total serum IgG was AgB with a seropositivity of 89% and 
IgG1 response rate was 85% (23), mean O.D 0.357 and IgG4 picked up 81% (22) with an 
average O.D of 0.444. The difference between total IgG and subclass IgG1 seropositive rates 
were significant (χ² = 19.4, p < 0.001) and IgG4 (χ² = 14.85, p = 0.003) and IgG1 vs IgG4 was 
also significant (χ² = 9.28, p = 0.013). 
HCF was seropositive for 74% (20) with an average O.D of 0.839 responses to HCF were 
similar to FABP at 89% (24) with mean O.D of 0.837 Second best performing antigen was 
AgB and HCF which picked up 81% (22) each with an average O.D of 0.444 and 0.811 
respectively. There were no significant differences in antibody responses across all the 
antigens.  The difference between total IgG and subclass IgG1 seropositive rates were 
significant (χ² = 10.547, p = 0.026) and IgG4 (χ² = 14.8, p < 0.025) and IgG1 vs IgG4 was also 
significant (χ² = 14.8, p = 003). 
Overall, a logistical linear regression model was fitted to analyse the performance of all the 
antigens with different cyst types.  It was found that expression of IgG1 in response to HSP70 
were significantly different in CE1 cyst compared to all other cyst types (p = 0.041). In CE2 
cysts, expression of IgG4 in response EF1 were not significantly level (p = 0.062). expression 
of total IgG in response to HSP70 was also significantly different in CE3 cysts (p=0.09) while 
in CE4 cysts it was the expression of IgG4 in response to AgB (p = 0.015).  A summary of 
differences in significance is shown below Table 5-4 
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CE1 
Antigen IgG (w) vs IgG1 IgG (w) vs IgG4 IgG1 vs IgG4 
HSP70 0.008 0.008 0.003 
EF-1β/δ  0.001 0.005 0.001 
FABP1 0.23 1.0 0.53 
TPx 0.24 0.02 0.16 
AgB 0.002 0.61 0.061 
HCF 0.119 0.61 0.061 
CE2 
Antigen IgG (w) vs IgG1 IgG (w) vs IgG4 IgG1 vs IgG4 
HSP70 0.018 0.018 0.01 
EF-1β/δ  0.001 0.005 0.01 
FABP1 0.32 0.105 0.422 
TPx 0.422 0.422 0.422 
AgB 0.006 0.105 0.105 
HCF 0.006 0.006 0.006 
CE3 
Antigen IgG (w) vs IgG1 IgG (w) vs IgG4 IgG1 vs IgG4 
HSP70 0.006 0.12 0.618 
EF-1β/δ  0.001 0.255 0.123 
FABP1 - - - 
TPx - - - 
AgB 0.005 - - 
HCF - - - 
CE4 
Antigen IgG (w) vs IgG1 IgG (w) vs IgG4 IgG1 vs IgG4 
HSP70 0.001 0.067 0.04 
EF-1β/δ  0.001 0.137 0.022 
FABP1 0.075 0.028 0.001 
TPx 0.148 0.001 0.148 
AgB 0.001 0.003 0.013 
HCF 0.026 0.025 0.003 
Table 5-4:  Differences between different antigens in diagnosis 
Significant differences between the expression of IgG1 and IgG4 subclasses were seen in 
responses to HSP70 and EF1 in CE1, CE2 and CE4 cysts. Antigen B and TPx also showed 
significant differences in expression of the 2 subclasses of IgG in cases harbouring CE4 cyst. 
As a diagnostic approach in CE, detection of IgG1 responses to TPx had the best value with 
seropositivity of between 96 and 100%. 
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5.4.2 Variation of Immune Reponses with Different Cyst Types 
Performance of serological tests varied with pathological stage of CE and the antibody used.  
The CE-specific IgG subclasses (IgG1-4) showed a better performance than total IgG (Figure 
5-15 to Figure 5-17).  
 
Figure 5-15:  Level of total IgG responses in different cyst types 
 
Figure 5-16:  Level of IgG1 responses in different cyst types 
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c) 
Figure 5-17:  Level of IgG4 responses in different cyst types. 
Expression of total IgG in response to a panel of 6 antigens.  Active CE1 and CE2 cysts were 
more seropositive to all the antigens than inactive CE3 and CE4 cysts but CE1 and CE2 cyst 
had the largest number of patients that were seronegative.  Every cyst type showed some 
seronegative cases.  Over 70 % of all cases were seropositive towards 3 or more antigens but 
20% of the cases were false negatives by all the antigens.  
Expression of IgG1 subclass in in response to the same panel of antigens showed good 
diagnostic potential for CE4 cysts where 74% of the cases were seropositive to all 6 antigens 
compared to 42 % in CE1, 32% in CE2 and 24% in CE3 cases. Performance of IgG1 compared 
to total IgG was superior and over 90% of all the cases were seropositive for 3 or more antigens. 
About 99% of the cases were seropositive towards 4 or more antigens but 1 CE4 patient was 
seronegative in all the tests.  
Responses of IgG4 showed the best diagnostic value for CE1 and CE3 cysts in response to all 
6 antigens tested compared to the performance of IgG1 and total IgG. The same CE4 patient 
that was non-responsive with IgG1 was also seronegative with IgG4, but no other case was 
missed out by the subclasses. Compared to IgG1 responses where all but 1 case were 
seropositive with 4 or more antigens, there was a wide variation in responses with IgG4 and 
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only 80% of the cases were positive for 4 or more antigens.  In diagnosis, IgG1 was found to 
be the best subclass antibody. 
5.4.3 Variation of Immune Reponses with Different Patients 
To assess the breath of the serological profile of patients harbouring different cyst types, 
expression of antibodies total IgG and subclasses IgG1 and IgG4 in response to a panel of 6 
different antigens were assessed.  There were 33 patients harbouring CE1cysts, 19 with CE2 
cysts, 21 with CE3 cysts and 28 with CE4 cysts.  For each patient, 18 tests were carried out for 
each serum sample (Figure 5-18 to Figure 5-21).  The highest responding patients showed a 
positive response in all 18 tests while some patients were seropositive for only 4 tests. 
 
Figure 5-18: Number of seropositive tests, from a total of 18 in each patient among CE1 
cases 
 
Figure 5-19:  Number of seropositive tests, from a total of 18 in each patient among CE2 
cases 
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Figure 5-20:  Number of seropositive tests, from a total of 18 in each patient among CE3 
cases 
 
Figure 5-21:  Number of seropositive tests, from a total of 18 in each patient among CE4 
cases 
Some patients showed positive responses to all 18 tests.  These were 15% with CE1 cysts, 26% 
with CE2 cyst, 9% with CE3 cysts and 11% with CE4 cysts.  
The group that had the highest number of highly responding patients was CE1 with 66% 
seropositive in 15 or more of the tests. In cases with in CE2 cysts there was 42% seropositive 
response for 15 or more tests, 38% in CE3 cyst and 55 % in CE4 cases.   
All CE1 patients showed seropositive results to 7 or more tests and all CE3 patients showed 
positive results to 8 or more tests. On the other hand, one CE2 patient had positive results to 
only 4 tests while one CE4 case was seronegative to all tests.  
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5.5 Discussion  
Serological diagnosis of CE depends on numerous factors, including cyst location, type, 
number and size.  A great challenge in serological diagnosis is finding simple inexpensive 
methods for large scale sero-epidemiology.  The main aim of this chapter was to generate a 
comparison of E granulosus antigens and to assess their diagnostic value as well their efficacy 
in defining cyst status.  
Diagnostic tests are judged on their ability to recognise true disease.  False positives are a 
problem with CE and studies have shown variations in diagnostic value with different 
populations.  For example, total IgG-ELISA tests with HCF showed a low false positive results 
with specificity of between 87.5% in healthy Indian donors to 100% in Italian donors (Chirag 
et al., 2015; Tamarozzi et al., 2013). However, in Turkana this was shown to be up to 50 % 
(Craig, 1986).  Cross-reactivity with other parasitic diseases such as alveolar echinococcosis 
(AE), cysticercosis, schistosomiasis and fascioliasis is quite high in patients (Moro et al., 2009; 
Zhang et al., 2011).  Hydatid cyst fluid has also been shown not to be a good antigen for patients 
follow-up during the clinical management of CE (Moro et al., 2009), and anti-HCF IgG 
antibody reactivity may remain high many years after successful cyst removal (Galitza et al., 
2006).  
The antigens chosen for this work included EgFABP1, EgEF-1β/δ, EgHSP70, EgAgB and 
EgTPx that had been purified as described in chapter 3.  We also included native HCF 
comparison purposes.  Carmena et al. (2006) reviewed the diagnostic performance of different 
recombinant antigens and previous studies suggested they might be differentially expressed in 
different cyst types.  They may therefore have potential use in diagnosis of fertile, deteriorating, 
unstable and viable parasite respectively.  
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Diagnosis was based on the detection of total serum IgG as well as specific IgG subclasses 
IgG1 and IgG4 antibodies.  Detection of antibodies IgG isotopes rather than total IgG has also 
shown promise in follow-up in relation to cyst activity and relapses.  Both IgG2 and IgG4 may 
be related disease evolution, and relapses (Benabid et al., 2013; Celik et al., 2009).  Other 
studies have shown that IgG4 responses are mainly against CE1, CE2, and CE3 cyst types 
while IgG1, IgG2, and IgG3 were the predominant responses against CE4 and CE5 (Carmena 
et al., 2006; McManus et al., 2012).  However, Sub class IgG are more under-detected in CE 
patients than total serum IgG (Cappello et al., 2013; Tawfeek et al., 2011).  As a diagnostic 
tool, compared to total serum IgG, detecting IgG subclasses improved the diagnostic 
performance of our tests with nearly all the antigens.  Significant differences in expression of 
IgG1 and IgG4 was only found in response to some antigens (Figure 5-22 to Figure 5-24).  In 
cases of CE1 cysts, IgG4 was the highly expressed in compared to IgG1 in response to HSP70 
and EF1.  All other antigens showed no significant differences.  This was different from what 
was found in cases with CE4 cysts where IgG1 was the prominent antibody in response to 
HSP70, EF1 and HCF.  This was also found by Tenguria et al. (2014) who stated that IgG1 is 
expressed highly in inactive cysts while IgG4 is more expressed in active cysts.  However, this 
trend was not found with AgB which showed higher IgG4 antibodies in CE4 cysts.  The 
diagnostic performance for HCF in detection of total IgG in ELISA is between 64.8% and 
100% (Ahn et al., 2015; Akalin et al., 2014; Akisu et al., 2006).  False negative results may be 
due to variability in antigenicity of HCF depending on source (Rahimi et al., 2011) or the 
infecting  E. granulosus  genotypes, e.g. G1 and G2 genotypes from Europe express higher 
quantities of antigen B2 in HCF compared to those from China (Jiang et al., 2012).  In this 
study, HCF with total IgG had a sensitivity of 83% overall.  Sensitivity to active CE1 and CE2 
cysts was 88% and 89% respectively but this reduced to 81% and 74 % in CE3 and CE4 cysts.  
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The, diagnostic value of HCF was improved with IgG subclasses to 91% and 89% with IgG1 
and IgG4.  
 
Figure 5-22:  Diagnostic performance of total IgG 
 
Figure 5-23:  Diagnostic performance of IgG1 
 
Figure 5-24:  Diagnostic performance IgG4.   
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Antigen B (AgB) considered one of the most valuable E. granulosus antigens in diagnosis.  The 
high immunogenicity of AgB presents an important diagnostic value for CE with sensitivity 
ranging from 60% to 85% in ELISA (Carmena et al., 2006; Virginio et al., 2003).in similarity 
to our study, Chen et al. (2014) found antigen B to be predominant with CE2 and CE3 cysts 
and also that expression of total serum IgG in response to AgB was lowest in CE1 cases with 
70% seropositive rate.  The diagnostic potential of AgB was improved with subclass IgG 
antibodies and it was the best diagnostic antigen overall for all cyst types. Responses of AgB 
IgG subclasses showed a positive diagnostic rate of over 85% in diagnosing all cyst types.  
Immune responses towards E. granulosus EF-1β/δ antigen were most inferior in the panel with 
an overall sensitivity of 27%.  Detection of EF-1 β/δ by total IgG was 27 % in our study while 
Ortona et al. (2001) found it to be 41%. On the other hand, the sensitivity to EF-1 β/δ when 
recognised by IgG4 in our study was 63 % compared to their 18.3 %. There were more 
seropositive cases in patients harbouring transitional CE3 and inactive CE4 cysts than active 
CE1 cyst.  This was similar to (Ortona et al., 2003) who found that elevated levels were 
recorded in patients with inactive cysts while lower titres were found in patients with active 
cysts.  A study by (Rigano et al., 1995) and another by Ortona et al. (2001) found that IgE was 
also significantly correlated to EF-1 β/δ. This and other literature point towards EF-1 β/δ 
release as being an indicator of cysts deterioration.  We did not test for IgE responses but in 
our study, there were significant differences in recognition of EgEF-1 β/δ by different 
antibodies where IgG1 vs. IgG4 showed a p < 0.000, total IgG vs.  IgG1 (p = 0.12) and total 
IgG vs. IgG4 (p=0.12).  The best immune responses in recognition of EgEF-1 β/δ were IgG4.  
High expression of IgG4 is associated with active cysts and chronic disease (Boctor et al 1990).  
The antigen EgEF-1 β/δ may skew the Th1/Th2 cytokine balance towards a Th2 polarization 
CE patients (Ortona et al., 2001).  This polarization has been associated with susceptibility to 
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CE (Rigano et al., 1995) suggesting that EgEF-1 β/δ has a role in inducing allergic reactions 
and susceptibility to human CE. 
Heat shock protein has been identified as a dominant parasite immunogen and antibodies 
that recognize parasite HSP70 have been found in sera from patients with schistosomiasis, 
leishmaniasis and trypanosomiasis (Chen et al., 2017).  Recognition of EgHSP70 by IgG 
and IgG subclasses has been associated with patients harbouring stable or younger or 
where the cyst had undergone trauma (Zhuo et al., 2017).  In our study, the diagnostic 
value of total serum IgG in recognition to HSP70 was poor in cases with CE3 (38% 
seropositive rate) and CE4 cysts at 52% seropositivity and was marginally improved in 
CE2 cysts at 58% seropositivity and CE1 cysts at 67% seropositivity.  A similar  antibody 
reactivity to HSP70 was detected in the sera using immunoblotting technique where of 
60% were detected for total IgG, 83% were positive with IgG1 and 31% were 
serodiagnosed using IgG4 (Ortona et al., 2003).  In our study, both IgG1 and IgG4 showed 
an improvement in diagnosis compared to total serum IgG with 76% with IgG1 and 82% 
with IgG4.  
A protein Thioredoxin Peroxidase TPx was previously described after isolation from E. 
granulosus cDNA library (Li et al., 2004).  It was found to be an important factor for 
protoscoleces survival and defence against oxidative damage in the host during development 
(Wang et al., 2018).  In our study, responses of total IgG to TPx had a sensitivity of 76 % 
overall.  Detection of IgG1 in response to TPx improved the diagnosis to 99 - 100 % 
seropositive results for CE1, CE2 and CE3 cysts and 96% for CE4 cysts.  Overall, this was the 
best diagnostically valuable antigen found in this study for both active and inactive cysts.  Other 
ELISA findings in patients with both active and inactive disease suggest that the EgTPx protein 
is of potential interest in the host–parasite relationship. A study by Wang et al. (2018) showed 
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that silencing of EgTPx protein impaired the differentiation of protoscoleces into metacestodes 
both in vivo and in vitro through reducing parasite viability when subjected to oxidative stress.  
Some studies (Li et al., 2004; Margutti et al., 2008) dismiss it as a serologically unhelpful 
suggesting its role in immunomodulation of responses to E. granulosus or formation of 
antibody– antigen complexes.  In contrast, we found EgTPx very effective in the 
immunodiagnosis of CE, a result that was also found by (Zhang et al., 2013). Responses of 
IgG4 subclass against TPx was 82% overall. There was little insignificant variation between 
cyst types. 
Various classes of serum antibodies are found in patients with CE.  Studies on different 
antibody responses show that IgG1 and IgG3 antibodies may correlate with inactive or stable 
disease and IgG4 and IgE antibodies correlate well with active or progressive disease 
(Manzano-Román et al., 2015).  In our study, IgG subclasses recognized different hydatid cyst 
fluid antigens.  Responses to HSP70 in inactive CE3 and CE4 cysts were greater with IgG4 
than IgG1. Also, responses of IgG4 towards AgB in CE1, CE2, CE3 cysts were higher than 
IgG1 and EF1 was markedly increased with IgG4 in all cyst types.  In contrast, responses to 
TPx and FABP1 were higher with IgG1 compared to IgG4.  It is possible that there is a 
preferential recognition of different antibodies to different antigen molecule.  This has also 
been reported in other studies where IgG1 preferentially recognized antigen 5 and IgG4 
recognize antigen B or other immunomodulatory molecules (Rigano et al., 2004; Wen et al., 
1994)3 Wen and Craig, 1994).  
Differential expression of antibodies according to cyst type was only found in response to some 
antigens and cyst in our study.  There were however differences in antigen recognition in 
different antibodies and TPx was better recognised by IgG1 while AgB was better recognised 
by IgG4.  Like other studies total IgG showed the least diagnostic performance compared to 
subclass IgG1 and IgG4 (Lawn et al., 2004) and had false negatives in all cyst types.  The best 
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performing antigen with CE1, CE2 and CE3 cysts was found to be TPx in determining 
expression of IgG1 antibodies as it resulted to no false negatives. The poorest performing 
antigen overall was EF-1β/δ though the performance was improved with IgG4 antibodies 
compared to total serum IgG and IgG1 
Despite availability of well-defined purified and recombinant antigens, use of any single one 
in the field has proved suboptimal.  One of the limitations is the complexity of immune 
responses in different individuals and populations.  We demonstrated the differences in 
immune responses in different cases in the same community.  This difference would be much 
wider in different populations.  The solution of serodiagnosis may lie in using a combination 
of tests which proved more accurate in this study where despite variability in immune 
responses, there was only one false negative.  
Although antibodies do not appear to be effective disease resolution, they may reflect 
functional purposes. Rigano et al (1995) found that patients who had high serum levels of 
specific IgG4 responses and low IgG1 responses towards HCF had poor response to 
chemotherapy while those who had low IgG1 responses compared to IgG4 responses had 
favourable responses to chemotherapy. In another study, high IgG4 responses were associated 
with chronic, symptomatic cases while high IgG1 responses were associated with acute and 
asymptomatic cases (Shambesh et al, 1997).  
Serological tools to support imaging technique diagnosis and follow-up of CE patients would 
be desirable. It would be of even greater use if it contributes to the identification of cystic stages 
to assist in clinical management.  This objective was not well demonstrated by the panel of 
antigens in our results. The reasons for this may be the small size of our sample, differences in 
immune responses between our subjects and those assessed in other studies or differences in 
quality of antigens produced 
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5.6 Conclusion  
In general diagnosis, detection of IgG1 responses to TPx had the best value with seropositivity 
of between 96 and 100%.  
In differential diagnosis, the difference between responses of subclasses IgG1 and IgG4 
towards HSP70 was found to be a good indicator for active or inactive cysts.  
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6 IMMUNOLOGICAL FOLLOW – UP  
6.1 Introduction 
Antibody levels have been shown to fluctuate during the course of an infection depending on 
rate of development, antigenicity, transmission dynamics and sensitivity to chemotherapeutic 
agents (Daeki et al., 2000).  Different antigens have been associated with those changes and 
studies on their use as markers for cyst fertility, viability or instability have been done (Carmena 
et al., 2004). 
Tests based on antibodies against crude antigens have poor specificity and sensitivity in 
diagnosis and little or no use in follow-up of patients.  Recombinant antigens have good 
potential for both diagnosis and follow-up, but lack of standardization is still a problem. The 
challenge persists on developing a reliable universal serology standard for the diagnosis and 
monitoring of CE patients.  The answer may also lie in a panel of antigens as opposed to one. 
A typical active cyst is filled with clear fluid containing viable protoscoleces.  The cyst may 
remain in this state for many years with or without growth in size.  Cysts may also 
unpredictably change in morphology by regressing and losing integrity, either naturally or after 
chemotherapy.  This loss of integrity allows host cellular or bacterial infiltration and may lead 
to partial deterioration or death of the cyst.  It is also possible that the cyst retains partial 
viability and may progress at a future date (Rogan et al., 2006).  .  
Ultrasound images in post-treatment follow-up may not give the whole picture and cysts 
undergoing micro-alterations in structure may not be detectable (Solomon et al., 2017).  A 
means of predicting an imminent change in cyst morphology at a cellular/immunological level 
is needed. This would be particularly useful in monitoring treatment outcome during follow-
up.  Antibody levels fluctuate during the course of infection depending on structural changes 
to the cyst wall and the level of interaction between the cyst and the host immune system.  
160 
 
These variations may be different in response to drug treatment and may be indicative of 
outcome. In a study by Stojkovic et al. (2009) CE1 patients that showed a particular response 
to albendazole treatment had a 50-75% cyst inactive or disappeared within 2 years post 
treatment.  One of the main drawbacks in serodiagnosis is that residual antibodies linger for 
months to years even after surgical cure giving rise to perpetual false positive results (Feng et 
al., 2010). 
Ultrasound as a diagnostic tool would be complemented by a robust detection system of 
fluctuations in serum antibodies if they are useful in predicting the possible outcome of disease.  
Antibody fluctuations are a response to varied release of extraneous antigenic materials from 
the parasite (Mariconti et al., 2016).  These fluctuations may be related to treatment, transition 
from one cyst morphology to another and changes in body immunity e.g. coinfection.  During 
follow-up, discrete changes in the cyst may go undetected.  Also, there may be no visible 
change in cyst morphology, but immunological indictors may be present. Cysts may transition 
from the inactive CE4/CE5 stages to active CE1 or CE2 cysts (Stojkovic et al., 2009) and 
immunological events may accompany these changes making serology especially important in 
follow-up after initial treatment (McVie et al., 1997).   
The potential of finding antigens that are differentially expressed by defined cyst stages would 
give serology a potential usefulness in the description of cyst activity thus guiding clinical 
management of CE patients  (Fotoohi et al., 2013).  Effective serological tests for CE diagnosis 
would be more profitable if they could define and support cyst status and evolution (active: 
CE1, CE2, and CE3b, transitional: CE3a, or inactive: CE4 and CE5).  The rationale is that in 
the host, intact healthy viable cysts should only elicit antibody responses to antigens that are 
native to cyst fluid (Nunnari et al., 2012).  Cysts that have become damaged by natural causes 
or as a result of chemotherapeutical intervention are expected to trigger a more varied antibody 
response.  
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Specific antibody responses against many helminth infections have been reported including 
filariasis, cysticercosis and schistosomiasis with evidence of differential responses towards 
chronic infection where IgG4 responses are raised and acute infections where IgG1 responses 
are elevated (Atmadja et al., 1995; Mutapi et al., 2011).  In CE, clinically expressed cases 
indicate a significant raise in IgG1 and IgG4 antibodies (Mourglia‐Ettlin et al., 2016) and 
albendazole treated patients with good therapeutic and clinical outcome showed significantly 
lower serum specific IgG4 and higher IgG1 compared to no responders with poor outcome 
while untreated asymptomatic cases also showed lower IgG4 compared to clinically expressed 
cases (Rigano et al., 2004).  
In chapter 4, five recombinant Echinococcus granulosus antigens, EgFABP1, EgEF1α/β, 
EgHSP70, EgTPx and EgAgB and one native antigen HCF, were purified and assessed 
for performance as a tool of diagnosis for different cyst types.  All these antigens showed 
variation in immune responses in different cyst types as well as IgG subclasses.  The study 
now focusses on the use of these antigens in following up patients to assess their 
immunological potential as markers for disease progression or regression.  Their reactivity 
towards total serum immunoglobulin IgG and its subclass antibodies IgG1 and IgG4 with 
sera obtained sequentially from patients harbouring cysts that either progressed or 
regressed over time was assessed.  
The aim of this chapter was to link morphological changes in cysts to antibody profiles during 
long-term follow-up of individual patients with albendazole therapy. 
Antibody levels fluctuate during the course of infection depending on structural changes to the cyst wall 
and the level of interaction between the cyst and the host immune system.  These variations may be 
different in response to drug treatment and may be indicative of outcome.  We hypothesised that this 
variations in antibody profiles may be useful in prediction structural changes in cysts. 
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6.2 Materials and methods  
6.2.1 Sequential sera analysis  
Serum samples collected in the endemic Turkana area by AMREF personnel during the years 
of surveillance were assessed for suitability of use in sequential sera analysis.  A total of 9 
cases that had at least five samples in enough quantities were selected for this study.  Of these, 
2 had cysts whose morphology did not change during follow-up, 4 cases changed from active 
to inactive while 2 patients harboured cysts that changed from inactive to active cysts with 
time. The sequential sera samples were used to test reactivity of previously purified 
echinococcal antigens.  REgHSP70, REgFABP1, REgTPx, 
REgEF1-β/δ, REgAgB and native 
HCF antigens towards total serum immunoglobulin IgG and sub-classes IgG1/IgG4 antibodies 
in patients harbouring cysts which underwent morphological changes and others that did not. 
6.2.2 Experimental procedure 
All ELISA assays were carried out as described in chapter 3.  Antigen concentrations were 
determined using Bradford assay and optimal working concentrations by checkerboard assays  
Patients were classified according to the morphological changes that occurred during the 
months of follow-up. Nine patients were followed up for between 2 and 45 months. Variations 
in total IgG and sub classes IgG1 and IgG4 antibody levels in sera were monitored through 
their recognition of 6 different antigens described above.  Patients were classified in to 3 groups 
depending on changes in cysts morphology during follow-up period. Three groups were 
described.  Group 1 (P1 – P3) had cysts that did not change throughout follow-up, group 2 (P4 
– P7) had cysts that transitioned from active to inactive and group 3 (P8 – P9) had cysts that 
changed from inactive forms back to active by the end of follow-up (Table 6-1)  
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Cyst Morphology Change Patient Number Changes that took place during follow-up 
Unchanging Cysts   P1 CE1       
P2 CE3       
P3 CE1       
Changing Cysts Active to Inactive P4 CE2 CE4     
P5 CE2 CE3     
P6 CE2 CE4     
P7 CE4 CE2 CE3   
Inactive to Active P8 CE3 CE1 CE4 CE1 
P9 CE2 CE3 CE4 CE3 
       
*P1, P2 and P3 did not change, P4, P5, P6 and P7 changed from active to inactive, P8 and P9 
changed from active to inactive 
Table 6-1:  Characteristics of the cyst changes in followed up cases 
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6.2.3 Results 
6.2.3.1 Changes in serum antibody levels in cases with unchanging cysts 
Sequentially collected sera from 3 patients harbouring cyst type that did not change during 
follow-up were assessed for variations in immune responses.  One case received albendazole 
treatment at the start of follow-up and the other 2 at different times in the course of follow-up.  
ELISAs determining total IgG and IgG subclasses 1 and 4 expression in response to different 
echinococcal antigens are described in Figure 6-1 through- Figure 6-3. 
The most responsive antibody was total IgG which showed optical density twice as high as that 
of the subclasses 1 and 4.  With patient P1, the trends were similar in all antibody types.  Follow 
– up started at treatment.  Immune responses to all antigens showed an increase during the first 
week of treatment and continued to rise in the second week of treatment.  Halfway into 
treatment at 2 weeks, all responses started to decrease at different rates apart from those towards 
FABP1 and TPx which only start declining at the end of treatment.  Responses towards HSP70 
show an increase at the end of treatment while those towards HCF remain largely the same a 
month post treatment.  
Patient P2, harbouring a CE3 cyst that did not change, was followed up for 87 months. As in 
patient P1, all antibodies showed similar trends in response to different antigens. There were 
little fluctuations before chemotherapy. Post chemotherapy, the greatest variation in response 
was seen in to FABP1 where the antibody titres of both IgG1 and IgG4 doubled. There was 
marginal increase in responses to other antigens  
Unlike the untreated CE3 cases where the antibody titres did not change much prior to 
treatment, the CE1 case P3 showed great variability of responses towards HSP70, HCF, FABP1 
and AgB.  There were also differences between antibodies.  Responses of total IgG towards 
HSP70 showed an increase before chemotherapy.  They had declined one week into 
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chemotherapy and increased again after the end of treatment to levels lower than prior to 
treatment. This was not the case with IgG1 and IgG4 where levels showed little fluctuations. 
Responses of IgG1 towards FABP1 showed a marked increase from start of follow up to 2 
months post chemotherapy and thereafter declined sharply. This was not seen with the other 
antibodies.  Responses towards AgB and HCF showed similar trends and with IgG1, the trends 
were opposite that of FABP1 where the antigen titres of AgB and HCF increase while that of 
FABP1 declined  
Overall, AgB, EF1-β/δ and TPx antigens showed low responses towards total IgG antibodies 
in all 3 patients while HSP70 showed high responses in one CE1 patient and average responses 
with other CE1 and CE3 case. Post chemotherapy, levels of FABP1 were elevated significantly 
in 2 patients   
ELISAs determining total IgG showed a significant variation in response to FABP1 (p = 0.028).  
Responses of IgG1 and IgG4 were significant towards AgB (p = 0.044).  With total IgG, 
recognition of TPx and EF1-β/δ remained seronegative but were marginally positive with IgG1 
and IgG4. 
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a 
Figure 6-1:  Changes in antibody responses in unchanging CE1 cyst followed for 2 
months. 
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b 
Figure 6-2:  Changes in antibody responses in unchanging CE3 cyst followed for 8 months  
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c 
Figure 6-3:  Changes in antibody responses in unchanging CE1 cyst followed for 12 months 
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6.2.3.2 Active to inactive  
Four patients (P4 - P7, Figure 6-4 to Figure 6-7). who had cysts that changed from active to 
inactive during were followed – up for between 7 and 16 months.  Changes in expression of 
total IgG, IgG1 and IgG4 over time towards a panel of antigens was assessed.  All the cases 
received chemotherapy during follow-up.   
In contrast to cysts that did not change, there was a marked difference in total IgG levels in 
response to HSP70 increasing by an average of 50% in two patients and decreasing by a similar 
margin in the other 2.  IgG1 and IgG4 responses all showed an increase though one patient was 
seronegative with IgG1 and showed reduction in IgG4 responses throughout follow-up. 
Responses of all antibodies tested to EF1 showed seronegative at the start but sero converted 
to positive with IgG4 in 2 cases. Total IgG expression in responses to TPx was also 
seronegative  
Two patients, P4 and P5 were followed up before and after chemotherapy and for the other 2 
follow-ups started from the date of first chemotherapy. Before treatment, the trends of the 2 
untreated patients differed in that P4 had stable or increasing antibody titres whereas P5 had 
stable or decreasing titres. In P4 the increasing antibodies were in recognition of HCF and AgB 
and for P5 the decreasing ones were in recognition to FABP1 and HSP70. In both patients there 
were slight fluctuations in levels of antibodies against TPx, EF1 and FABP1. 
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Figure 6-4:  Changes in antibody responses in cysts changing CE2 – CE4  
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Figure 6-5:  Changes in antibody responses in cysts changing from CE2 – CE3.  
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Figure 6-6:  Changes in antibody responses in cysts changing from CE2 – CE4. 
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Figure 6-7:  Changes in antibody responses in cysts changing from CE4 – CE1 – CE3.  
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Following chemotherapy, titres for all antibodies increased before returning to levels seen 
before treatment, an observation similar to responses seen in unchanging cysts with exception 
to AgB and HSP70. One patient, P5, antibody levels continued to decrease to levels below 
those found before treatment. For patients who received 2 doses of chemotherapy, (P4, P6 & 
P7), 2 changed from CE2 to CE4 (P4 and P6). There was an interesting outcome for the P7 
where the inactive cyst CE4 became active CE2 after 1 dose of chemotherapy.  
The second dose of chemotherapy did not produce an increase in the levels of antibody titres 
compared to the first dose. The cysts that had transitioned from active to inactive (P4, P6 &P7) 
after the first dose remained in the same state. However, P7 which had transitioned from 
inactive CE4 to active CE2 responded to the second dose of chemotherapy by transitioning 
back to inactive CE3. 
Overall, cysts that changed to CE4 cysts showed a decline in antibody titres towards all 
antigens while those that changed to CE3 cysts showed less decline in titres levels.  There was 
less than 20 % change in antigen titres from start to end of follow-up though there were many 
fluctuations between the two dates especially post chemotherapy.  Compared to cysts that did 
not change, responses to AgB and HSP70 were higher in inactive cysts compared to active 
ones.  
6.2.3.3 Inactive to active 
Two patients (P8 & P9, Figure 6-8 and Figure 6-9) transitioned from inactive to active and were 
followed up for 6 and 45 months respectively.  In the 2 cases, the cysts transitioned between 
active and inactive but were active at the end of follow-up. The plots below show the variations 
over the follow up period. Patient P8 received 1 dose of chemotherapy and patient P9 received 
2.  
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Figure 6-8:  Changes in antibody responses in cysts changing from CE4 – CE1 – CE3.  
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Figure 6-9:  Changes in antibody responses in cysts changing from CE1 ~ CE3 
 
Patient P8 had a CE3 cyst which transitioned in to a CE4 after treatment and returned to a CE1 
cyst 3 months after treatment. The greatest response was towards HCF followed by AgB.  The 
titre levels before treatment showed a remarkable rise up to 2 weeks during treatment and then 
fell sharply in the last 2 weeks of treatment. All the antigen titre levels increased again and 
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showed levels higher than or equal to the pre- treatment levels.  They were still rising at the 
end of the follow-up period and the cyst returned to a CE1 cyst. 
In Patient P9 Pre-treatment levels were stable except for HSP70 which gradually decreased 
until chemotherapy and HCF with IgG1 came down slightly.  During chemo, all antigen 
responses generally went up but of significant increase was HSP70 and continued to increase 
with no other intervention over the next 10 months.  This trend was reversed over the next 10 
months down to pre-treatment levels.  Over the next 15 months, all antigen titres started to 
increase again with HSP70 being of greater significance.  This increase accompanied the 
change of the cyst from an inactive CE4 to a transitional CE3.  
6.2.3.4 Summary of immunological changes during follow-up 
As an overall assessment, and the first and last titres were used to calculate the differences in 
antibody expression towards different antigens.  All cysts cases were assessed together, and 
amber colour indicates the cysts that did not change, green the cysts that changed from active 
to inactive forms and red the ones that regressed from inactive forms to active forms.  Different 
facets in each box indicates the different antibody expression. 
In response to HSP70, the greatest differences in responses were seen within 3 patients (Figure 
6-10).  One case of a deteriorating cyst had titre levels increase 9-fold with total IgG, 6-fold 
with IgG1 and 3-fold with IgG4.  Two other cases with improving cysts also had between 2- 
and 3-fold increases in expression of both total IgG and the subclasses IgG1 and IgG4. There 
was a decline or no change in responses towards all the cases that had unchanging cysts and 
one case of deteriorating cyst  
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Figure 6-10:  Differences in antibody expression towards HSP70 in 9 individual patients.  
Key: Amber colour indicates the cysts that did not change, Green the cysts that changed from 
active to inactive forms and Red the ones that regressed from inactive forms to active forms.   
 
Similar towards responses with FABP1, the greatest variation between initial and final titres was in 
responses of IgG1 (Figure 6-11).  Among those with unchanging cysts, there was a big variation in 
responses but those with deteriorating cysts showed a general increase while those with improving cysts 
showed either reduction or no change in titre level apart from one case who had increasing levels.   
 
Figure 6-11:  Differences in antibody expression towards FABP1 
Key: Amber colour indicates the cysts that did not change, Green the cysts that changed from 
active to inactive forms and Red the ones that regressed from inactive forms to active forms.   
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Responses towards EF1 were similar in all cases showing differences of ±25% overall apart from those 
who had deteriorating cysts where one case increase and one decreased (Figure 6-12).  The increase 
was more than double with total IgG and more than 3 times with IgG1 and IgG4 while the responses of 
the other patient declined by half or less. 
 
Figure 6-12:  Differences in antibody expression towards EF1 
Key: Amber colour indicates the cysts that did not change, Green the cysts that changed from 
active to inactive forms and Red the ones that regressed from inactive forms to active forms.   
 
In response to TPx, differences in expression total IgG overall were minimal apart from one 
deteriorating cyst that showed an increase of 35% (Figure 6-13).  There were no noticeable differences 
according to changes in cyst morphology.  Variations seen with IgG1 and IgG4 did not have value in 
follow-up as there were no obvious trends.  
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Figure 6-13:  Differences in antibody expression towards TPx 
Key: Amber colour indicates the cysts that did not change, Green the cysts that changed from 
active to inactive forms and Red the ones that regressed from inactive forms to active forms.   
 
Antibody responses to AgB showed the best promise in follow-up (Figure 6-14).  The cases of 
deteriorating cysts both showed increase in antibody responses especially total IgG and IgG1 and the 
cases of improving cysts showed reduction or similar levels of IgG except 1. The unchanging cysts 
were more variable in responses. Overall, total IgG responses showed good qualities for follow-up.  
 
Figure 6-14:  Differences in antibody expression towards AgB 
Key: Amber colour indicates the cysts that did not change, Green the cysts that changed from 
active to inactive forms and Red the ones that regressed from inactive forms to active forms.   
 
181 
 
In response to HCF, the greatest differences in responses were seen with IgG1 where 1 patient had 3 
times the original titre value and another 2 patients more than doubled them (Figure 6-15).  There was 
reduction in expression of total IgG in all the cases who had cysts that became inactive apart from 1.  
All cases with deteriorating cysts showed increase in titres but some cases with unchanging and 
improving cysts had increases in titres too.   
 
Figure 6-15:  Differences in antibody expression towards HCF 
Key: Amber colour indicates the cysts that did not change, Green the cysts that changed from 
active to inactive forms and Red the ones that regressed from inactive forms to active forms.   
 
Antibody titres fluctuated throughout follow-up with levels significantly increasing after 
treatment and consequently decreasing.  Some patients harbouring unchanging cysts as well as 
cysts considered to be improving showed increases in antibody titres in some patients.   
6.3 Discussion 
This chapter evaluate whether there was a longitudinal link between antibody profiles of 
individual patients and morphological changes in cysts.  We sought to associate antibody 
responses of total serum IgG and IgG subclasses 1 and 4 to outcome of disease in follow-up.  
The usefulness of immune responses in monitoring cyst progression is not unequivocal but 
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some patients showed promise.  Usefulness of native antigens is hampered by the long 
persistence of antibodies in patients after surgical removal or those with non-active cysts (Li et 
al., 2004).  Some recombinant antigens have shown better correlation with specific antibodies 
against defined active cyst types after surgical treatment.  Examples include EgAgP29 (Nouir 
et al., 2009) and the heat-shock protein 20 (Vacirca et al., 2011) which showed a low level of 
specific antibodies against EgB2 and EgHSP20 with EgB1 in the presence of inactive cysts.  
However, some CE patients did not recognize those antigens (Piccoli et al., 2014).  Successful 
immunological monitoring of long-term CE cases would serve as an alert to a clinician before 
radiological and clinical manifestation reducing morbidity 
Nine patients were followed up in this study.  Of these, 3 were classified as having unchanging 
cysts whose morphology remained the same throughout follow-up even after chemotherapy. 
Four cases were classed as having active disease at the start of follow-up that transitioned to 
an inactive disease by the end.  A third group of 2 cases had an inactive disease at the start of 
follow- up which then relapsed back to active disease.  All patients received chemotherapy and 
there were marked immune responses post treatment without exception.  Post treatment, there 
were differences in outcome where some cysts regressed, others progressed while some did not 
change at all.  Reasons for this remain unknown but immunological factors, compliance to 
chemotherapy and age may play a role. We sought to provide immunological data which can 
be related to post treatment course of CE and provide a pointer to prognosis.  Serological tests 
should show increase in relapsing cysts, no variation in unchanging cysts and show significant 
or gradual decline in successful treatment (Horton, 2018).  
In unchanging cysts, ELISAs determining the expression of total IgG and IgG subclasses 1 and 
4 in response to HSP70 showed an increase.  Total IgG responses towards FABPI, HCF, EF1-
β/δ, TPx and AgB remained the same or showed marginal decline while IgG1 and IgG4 
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responses showed variable results.  The fact that cysts did not change during follow-up even 
after chemotherapy evidences the fact that chemotherapy does not always lead to improvement.  
These results support the findings in chapter 2 where questions on efficacy of chemotherapy 
were raised (Page 98).  Continued rise in responses towards FABP1 2 months after 
chemotherapy in a CE3 cyst might indicate transition back to an active cyst since other studies 
have associated FABP1 with active cysts.  
Four cases had cysts that transitioned from active to inactive forms.  Responses of total IgG 
towards AgB showed a decline while all the other responses were variable. In 3 cases, 
responses of total IgG towards HSP70 increased in 2 cases but remained the same or declined 
in the other 2 cases.  
In clinical practice, relapse of CE is difficult to detect early.  Two patients relapsed in this study 
from inactive to active cysts.  In one of these patients, there was marked increase in responses 
to HSP70, EF1-β/δ, TPx, AgB and HCF while the second patients showed increase in responses 
towards HCF and AgB.  A correlation between HCF and AgB with relapsing disease seemed 
likely.  Intermittent dosing was used as a treatment regime.  It has been argued to cause 
tolerance and reduce efficacy in subsequent doses and may be accompanied by parasitic growth 
and deterioration during treatment interruptions (Horton, 2018).  This may explain the scenario 
in patients P8 and P9 where retrogressive cyst changes were seen after treatment and previously 
inactive cysts became active again after chemotherapy. A similar trend was found in P7 
although the cyst was inactive again after a second dose of chemotherapy.  
Due to variations in titre levels during follow-up, the initial and the final levels were used to 
define a more precise measure of immunological follow-up criteria.  Ratios of initial and final 
titres during the follow-up period were used and the trend assessed.  In the cases of unchanging 
cysts as well as cysts considered to be improving, increases in antibody titres in contrast to 
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expectation were seen in some patients.  These cases may have been recurrences that had not 
become clinically or morphologically detectable or may have been cases of multiple 
undiagnosed cysts.  It is also possible that though these antigens had been found useful in 
diagnosis, they were unhelpful in follow-up in a significant number of cases.  The follow-up 
period was short, and the sample was small but there were variations in antibody responses to 
different antigens.  This maybe an indication that there is a differential expression of antigens 
and a longer follow-up period with more samples may define these expressions better. 
Overall, only responses of total IgG towards AgB showed distinct differences according to 
changing cyst morphology and seemed applicable in follow-up.  They increased in all the cysts 
that became relapsed, declined with all the cysts that became inactive and remained stable in 
all the unchanging cysts.  The trends of other responses of different antibodies to different 
antigens were not as obvious but may have become more pronounced given longer follow-up 
and larger sample sizes. Other studies have shown that immune responses may linger even after 
surgical cure (Manzano-Román et al., 2015) but in other studies, they do decline with inactive 
disease and sometimes disappear though this have been shown to take years(Naik et al., 2016) 
From chapter 4, many patients showed false negative results, and, in this chapter, this was 
followed further in followed- up patients.  Total IgG responses towards EF1-β/δ and TPx 
remained negative throughout follow-up but were positive with IgG4.  In a patient with an 
unchanging cyst, total IgG responses towards FABP1 declined to seronegative as did those of 
IgG4 towards HSP70. A third patient with CE3 unchanging cyst was highly responsive with 
all antibodies showing positive responses.  
In the group where cysts changed from active to inactive, all immune responses towards EF1-
β/δ were sero-negative 
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The results in this study showed that antibody levels persist post chemotherapy and this may 
be because cure was not achieved. In other studies where serology was used in follow-up, 
surgically cured patients have shown persisting IgG antibodies in 5 years of follow-up 
sometimes even showing increases (Manzano-Román et al., 2015) 
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7 ANTIGEN DETECTION 
7.1 Introduction 
 
The diagnosis of CE is generally based on radiological and ultrasound examinations along with 
immunodiagnostic methods (Parija, 1998; Sadjjadi, 2006).  Many immunological assays have 
been developed to detect anti-hydatid cyst antibodies in the serum with variable degrees of 
success.  Drawbacks associated with antibody detection in diagnosis of CE include sub-optimal 
performances of the available tests, difficulties with the standardization of antigen, inability to 
readily distinguish between past and present infections, significant numbers of false negatives 
and cross reactions with other cestodes (Doiz et al., 2001; McManus et al., 2012).  Moreover, 
in villages where Echinococcus is endemic, up to 26% of the general population was 
seropositive for HCF antigens with only about 6% infected (Craig et al., 1986).  Use of 
circulating antigens rather than antibodies as a diagnostic tool has been demonstrated in 
helminth infections (McManus et al., 2012), and it circumvents many of the problems above. 
Evidence points that circulating hydatid antigens are found in the serum only when there is an 
active infection with levels continually decreasing after a successful surgical removal or 
chemotherapy (Devi et al., 2003; Sarkari et al., 2015). 
As a diagnostic tool, antigen detection requires antibodies that can be either commercially 
obtained or produced in house.  Commercial antibodies can be used against a broad range of 
antigens including proteins, carbohydrates, short peptides, hormones and nucleic acids (Delves 
et al., 1997).  Antibodies can be monoclonal i.e. those secreted by a single clone of B 
lymphocytes usually from immunized mice, or polyclonal i.e. those produced by a mixture of 
B lymphocytes, usually from immunised rabbits (Leenaars et al., 2005). Choice between 
polyclonal or monoclonal antibodies is dependent on time and money.  Polyclonal antiserum 
187 
 
can be obtained within 4-8 weeks while monoclonal antiserum takes 3-6 months to produce 
(Leenaars et al., 2005). Another advantage of using polyclonal antibodies is the ability to 
recognise multiple epitopes on the antigen leading to better detection. Multiple antibodies also 
bind to the antigen at different epitopes, amplifying the signal and many research questions, 
polyclonal antibodies suffice. 
To measure the amount of antigen in the sera, Sandwich ELISA, which measures the quantity 
of antigen between 2 layers of antibodies was used. The first antibody, capture antibody, is 
bound to a solid phase on the microtiter plate and then incubated with the solution containing 
the antigen. A second antibody conjugated to enzyme, conjugate antibody, is then incubated 
and a substrate is added.  The amount of substrate hydrolysed is proportional to the amount of 
antigen in the test solution(Gottstein, 1984).  
Commonly used enzymes for conjugate antibodies are horseradish peroxidise, alkaline 
phosphatise and β-galactosidase. Horseradish peroxidise (HRP) has the advantage of being 
cheaper, readily available and has a high turnover rate.  Substrates used with HRP include 
3,3’,5,5’-tetramethylbenzidine hydrochloride (TMB) which has the advantage of detecting low 
levels of enzyme, is non-mutagenic and non-carcinogenic ((Mesulam, 1978)). 
The aim of this chapter was to evaluate the relevance of antigen detection in immunodiagnosis 
of CE. 
Use of circulating antigens rather than antibodies may show better result as a diagnostic tool 
as evidence shows that circulating hydatid antigens are found in the serum only when there is 
an active infection.  The hypothesis was that variations in antigen profiles can predict structural 
changes in cysts. 
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7.2 Materials and methods  
7.2.1 Antibodies 
Several capture and conjugate antibodies previously purified and stored in a -80°C freezer at 
Salford University, UK were tested for an antigen recognition ELISA. These antibodies had 
been purified from sera obtained from rabbits immunized in Libya or China between 2 October 
2000 and 23 October 2003. The rabbits had been immunized with either Echinococcus 
granulosus crude whole worm extract, excretory-secretory (ES) preparations or with a saline 
wash of intact E. granulosus worms  (van Kesteren et al., 2015), ). 
7.2.2 Testing immunoreactivity of rabbit sera in ELISA 
A total of 8 rabbit sera was tested for use a capture and conjugate antibody for this experiment.  
Different combinations were tested for optimal responses.  To determine working 
concentrations, a checkerboard ELISA was prepared as described below. 
A 4HBX plate (Fisher Scientific, Loughborough, UK) was coated with 1:400 hydatid cyst fluid 
(HCF) diluted in BCB (carbonate bicarbonate) buffer (Sigma-Aldrich, Dorset, UK) leaving 2 
wells as blanks.  The plate was incubated overnight at 4°C then washed three times with 0.1% 
PBS 
buffer (1 Phosphate Buffered Saline tablet (Fisher Scientific, Loughborough, UK) per 100ml 
distilled water, 0.1ml Tween.  All the wells, except blanks, were then blocked with 0.3% PBS 
(1 Phosphate Buffered Saline (Fisher Scientific, Loughborough, UK) tablet per 100ml distilled 
water, 0.3ml Tween with 5% milk powder and incubated for one hour at room temperature. 
The contents of the plate were discarded, and the plate washed three times with 0.1% PBS.  A 
volume of 200μl of purified IgG from the sera of selected hyperimmune rabbits and normal 
rabbit rerum (the control) in 0.3% PBS and milk solution (1:25 dilution) were pipetted into the 
first column of wells, and subsequently serially diluted, to give concentrations ranging from 
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1:25 to 1:25600.  After a one-hour incubation at room temperature, the contents of the plate 
were discarded, and the plate was again washed in 0.1% PBS.  Apart from the blanks, 100μl of 
alkaline phosphatase labelled conjugate antibody (anti-rabbit IgG alkaline phosphatase, 1:2000 
dilution, from Sigma-Aldrich, Dorset, UK) was added to each well, and incubated for one hour 
at room temperature. After this incubation the plate was again washed in 0.1% PBS and 100μl 
of PNPP (p- nitrophenylphosphatase, Fisher Scientific, Loughborough, UK) was added to each 
well (including blanks) and the plate was allowed to develop for 20 minutes.  The plate was 
then read using a Tecan® Sunrise plate reader at 405nm. Sera R5 showed the best results for 
capture antibody while R91 was best for conjugate antibody.  
7.2.3 Sandwich ELISA  
Sandwich ELISA was performed to detect the amount of circulating antigen in human sera.  
Optimal concentration of rabbit anti-HCF IgG (5 μg/ml) was diluted in coating buffer and 100 
μl of solution was placed into a 96-well ELISA plate followed by incubation at 4℃ overnight.  
The excess antibody was removed by washing the plate 5 times in PBS-Tween 20, pH 7.4 
containing 0.05% Tween 20). After washing, 100 μl of blocking buffer (3% skimmed milk) 
was added and the plate was incubated for 1.5 hr at RT.  Following the washing steps, sera 
from surgically confirmed CE patients along with samples from healthy people as negative 
controls was added into the wells and the plate was incubated for another 1.5 hr. After a 
washing step, 100 μl of horseradish peroxidase-conjugated anti-HCF IgG was added and the 
plate was incubated for 1 hr at RT. After being washed as before, the plate was incubated with 
chromogen/substrate (100 μl/well of 4 mg/ ml OPD, 0.025% H2O2 in 0.1 M citrate buffer, pH 
5.0), The absorbance at 490 nm was monitored with a microplate reader (Bio-TEK- ELX-800). 
The cut-off point was set as 2SD above the mean of control samples. 
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7.3 Results 
7.3.1 Usefulness of circulating antigens in diagnosis 
A total 124 serum samples from proven hydatid patients from Turkana were tested for 
circulating antigens (cAg). Of these 34 harboured CE1 cysts, 42 had CE2 cysts, 21 had CE3 
cyst and 27 had CE4 cysts.  All the cases had been previously confirmed and cyst type 
determined by ultra sound. The diagnostic performance antigen detection was assessed (Figure 
7-1). 
 
  
Figure 7-1.  Circulating Antigens seropositivity in different cyst types 
 
The results showed a significant variation in the level of cAg according to cyst type. The active 
cysts showed much higher titres of cAg than the inactive cysts. Overall hydatid cyst antigens 
were detected in 72.6 % (90) of the cases.  In patients with CE1 cysts, antigen levels were 
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seropositive for 91.1 % (31/34) while in CE2 cases there were detectable cAg in 81% (34/42) 
of the patients.  The levels were lowest in CE3 cases where only 42% (9/21) of the cases were 
seropositive for circulating antigens but number increased in CE4 cysts and 59 % (16/27) were 
seropositive  
7.3.2 Assessment of circulating antigens for clinical follow-up 
Sequential sera taken from untreated CE patients were assayed using ELISA for circulating 
antigens.  The groups were divided in to 3, according to the cyst morphological changes during 
follow-up.   
Eight patients with unchanging cysts were followed up for between 11 and 12 months.  There 
was fluctuation in antigen levels over the months (Figure 7-3) but the first and last readings 
showed little difference (Figure 7-2).  One case of improving cyst declined slightly. 
 
Figure 7-2 : Changes in levels of circulating antigens in unchanging cysts. 
Green represents CE1 cysts, amber CE2 cysts and red CE3 cysts.  
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Figure 7-3.  Fluctuations in levels of circulating antigens in Unchanging Cysts. 
The above shows little variation in antigen concentration (OD range between 0.1 and 0.32) 
There were no obvious trends according to cyst type.  Titres with the CE3 cyst fluctuated the 
least and had the same levels at the end of follow-up as at the start.  The cases with CE2 cysts 
showed very little difference in titre levels with less than 0.1 nM change between the first and 
last titre.  There were great variations during follow-up in all cases. 
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Figure 7-4.  Changes in serum antigen concentration over time in improving cyst. 
All the cases of improving cysts showed reduction in antigen titres. One case was seronegative 
all through follow-up while 2 cases became seronegative during follow-up.  One case 
deteriorated rapidly while all the others had gradual decline (Figure 7-4). 
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Figure 7-5.  Changes in serum antigen concentration over time in deteriorating cyst. 
 
 
Figure 7-6.  Changes in antigen concentrations over time in deteriorating cyst. 
Serum antigen concentration in deteriorating cysts was followed up on 3 cases.  One case 
decreased drastically, one case increased slightly, and the other patient did not show much 
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variation.  The trends with deteriorating cysts did not show any value in follow-up (Figure 7-5 
and Figure 7-6). 
Unlike antibody titres, chemotherapy did result in greatly changes in circulating antigens titres.  
Though most patients did not have detectable circulating antigen in their sera, those that did 
showed little variation during follow-up. There was no correlation between circulating antigens 
and antibody levels in this study though in one patient P4 there were opposite trends between 
circulating antigen and antibody responses towards FABP1 (Appendix 2,  Figure 10-1 and 
Figure 10-2). 
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Discussion  
Sero-diagnosis as a tool in clinical and epidemiological diagnosis and follow-up is especially 
important in Turkana due to lacks a macro diagnostic hospital and has nomadic population.  A 
combination of ultra-sound imaging and serology gives the best diagnostic efficacy.  Use of 
specific antibody detection results in sub-optimal sensitivity and specificity with unacceptably 
high rates of false negatives (Sunita et al., 2007). The level of antibody titres varies according 
to cyst properties such as size, location and type as well as patient properties such as age and 
immuno-competence.  Antibodies against anti- E. granulosus may not be adequately raised for 
immuno-diagnosis but may persist long after cure as seen in surgically removed cysts leading 
to wrong diagnosis  (Todorov et al., 1979). 
Circulating E. granulosus antigens are only detectable in the serum during active infection with 
levels decreasing gradually after successful chemotherapy or surgical removal of the cyst (Devi 
et al., 2003).  The passage of antigens from the cysts into peripheral circulation, formation of 
immune complexes and the subsequent clearance of both from circulation is ill understood.  In 
this study the levels of circulating antigens in the sera of CE patients harbouring different cyst 
types was assessed.  Positive responses in 72.5% had a better diagnostic accuracy than antibody 
detection in CE1 and CE2 cysts. Other studies have shown diagnostic accuracy of between 33-
85%, with ability to detect anti- E. granulosus antibody (Gottstein, 1984; Ravinder et al., 1997). 
Low sensitivity was found in CE3 and CE4 cysts of the antigen detection assay. This may be 
due to inactive cysts releasing fewer antigens in the serum or formation of immune complexes 
which cannot be easily detected by assays. Some active cysts were also missed out in diagnosis 
and a reason for these maybe small intact cysts not releasing sufficient antigens detectable in 
the serum. 
The findings of this study showed that antigen detection may be a useful diagnostic method for 
CE patients. Although the antibody detection had better sensitivity, antigen detection showed 
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good diagnostic value for active cysts CE1 and CE2. It may also be a useful tool in assessment 
of the efficacy post treatment.   
Levels of circulating antigen were assessed during follow-up for up to 12 months in both treated 
and untreated cases. Levels of antigen titres were commensurate with variations in cyst type 
though in some cysts that did not change, antigen titres fluctuated during follow-up.  In cases 
where the cysts progressed for inactive types, a fall in the level of circulating antigens declined 
slowly in response.  The same was found in patients that underwent successful chemotherapy.  
Serological assessment of chemotherapeutic responses is difficult due to variabilities in tests, 
patient and parasite.  Indirect tests including cAg and antibody levels have shown suboptimal 
results in determining viability.  The level of immune responses mounted is dependent on the 
patient’s immune competence, cyst location, number, type and size.  Additionally, live and 
dead cysts maybe present in one patient at the same time. Parasite factors may include 
differences in species, virulence and geographical origin. 
Antibody responses may be affected by circulating antigen (CAg) or circulating immune 
complexes (CIC) taking up the some or all of circulating antibody and making it undetectable. 
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 conventional analysis (Craig et al., 1984), (Craig et al., 1986). 
7.4  Conclusions  
Antigen ELISA showed value as a diagnostic tool in hydatid cysts has better sensitivity in 
active cysts. Serology adds accuracy to diagnosis as an alternative technique in the field  
Circulating antigens were found to be unhelpful in follow-up 
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8 GENERAL DISCUSSION 
Human cystic echinococcosis is a serious cyclo-zoonotic disease caused by the metacestode of 
Echinococcus granulosus. The parasite affects any body organ and pathology is typified by 
long term growth of unilocular cysts which may contain thousands of protoscoleces, each with 
the potential of generating another cyst upon rupture. Echinococcosis causes a substantial 
disease burden and an excess of 1 million people live with the diseases at any one time and the 
cost is estimated to be US$ 3 billion annually in for treating cases and losses to the livestock 
industry (Battelli, 2009). 
With very some exceptions, the direction of disease progression was as predicted by the WHO 
CE ultrasound classification.  CE1 cysts were significantly associated with younger people and 
therefore early infection and the progressive cyst changes were age increased. These 
observations are consistent with the findings of Brunetti et al. (2010), suggesting that the 
classification is correct in that early class cysts (CL, CE1, CE2) are fertile and progressive 
while late class cysts (CE4, CE5) are degenerative  though they can revert to an earlier active 
state.  If it is assumed that CE4 and CE5 cysts are older than CE1 cysts, then in communities 
where CE1 cysts dominate transmission from dogs is likely to be more recent that in 
communities where CE4 and CE5 cysts predominate (Rogan et al 2006). The progressive 
decline of CE1 cysts and the increase in average age at first infection was an indication that the 
control program was effective.  
Treatment of human hydatid cases involves chemotherapy with albendazole or surgery, either 
radical endocystectomy or a more conservative procedure PAIR.  In our study, many cases 
were left untreated and observed. Chemotherapy was offered to the cases that had symptomatic 
and progressive cysts as a first line of treatment.   
The course of CE is indolent, and cysts may have incubation periods of months to years.  The 
growth rate is generally estimated to be between 1 – 5 cm per year (Craig et al., 1986).  Our 
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study had considerable variation in the development of cysts ranging from spontaneous 
disappearance to increases of 13 cm in one year.  Evidence of spontaneous cure was observed 
in 7.9% of the cases that did not receive treatment. Previous studies in Tibet, Kenya and 
Argentina reported natural degradation in 18.9 %, 13.6% and 21% (Craig et al., 1986; Larrieu 
et al., 2004; Li et al., 2010).  The number of cases followed up without intervention was small, 
mostly due to ethical issues as well as requirement for treatment when the cysts showed 
progressive changes.  Besides self-cure, 32% of untreated cysts also showed improvement 
without intervention.  These observations have great implications on assessment of patients 
and choice of therapy. This is especially pertinent in Turkana where the facilities are 
rudimentary and incidents of protoscoleces dissemination during surgery resulting to multiple 
cysts is high ((McPherson, 1986),  Cooney et al., 2004)  
Albendazole treatment stabilised cysts and arrested further progression in morphology and size 
rather than cure them.  In our study, intermittent dosing was done, and number of courses 
limited to 3 in most patients though some received up to 8.  In studies where continuous dosing 
was done, better outcomes were achieved (Barnouti, 2015).  It is also possible that intermittent 
dosing in our study caused disease progression during rest period, a concept introduced by 
Junghanss et al. (2008) as some cases showed deterioration after treatment. Chemotherapy was 
used more frequently than any other form of intervention mostly due to lower logistical and 
technological costs as well as the possibility of improvement or cure without more invasive 
procedures.  Three or more doses were found to be more effective on CE1 and CE2 cysts but 
not so much with CE3 and CE4 cyst. It would be recommended that a symptomatic CE3 or 
CE4 cyst gets a different kind of intervention if they have not shown enough improvement after 
the second dose.  
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Percutaneous treatment under ultrasound guidance provides an alternative to radical surgery or 
long-term chemotherapy treatment.  The results of PAIR during the 12-month follow-up were 
favourable with 13% cured, 65% inactive and 21.2% showing regenerating cysts with an 
average of 4 days hospital stay similar to a study by Rajesh et al. (2013). Compared to surgery, 
there was poorer outcome with PAIR but with a reduced hospital stay and less post-operative 
complications. Better outcome may have been achieved in combination with chemotherapy. 
Radical surgery is recommended for more complex cyst stages containing daughter cysts those 
features and similar to the other therapies, long term treatment is necessary (Thota et al., 2018).  
In our study, endocystectomy had the best overall outcome with 89.1% considered cured and 
11.9% considered recurrences after 12 months of follow-up. Complications after treatment 
were more in the surgical group with the most common being bacterial infection in the residual 
cavity, continued morbidity due post-operative sequalae and 3 mortalities.  Use of 
chemotherapy alongside surgery improved the cure rate from 86.9% to 93.5%. 
Evaluation of recurrence is also difficult because surgical spillage may not become apparent 
until years later. It is also not possible to distinguish between recurrence and new infection and 
we assumed recurrence when a new cyst appeared in the residual cavity. Some patients already 
being followed up had cysts elsewhere in the body.  In our study, we treated these as 
reinfections, but they could have been recurrences and our data maybe rather optimistic. Our 
follow-up period was also limited. The recommendation is to follow-up until the whole residual 
cavity is reabsorbed and in many of our cases with PAIR that was not achieved, and the cysts 
were considered inactive.  
Diagnosis of CE is mainly confirmed through ultra sound sometimes in combination with 
anamnesis, clinical history and serological testing.  Immunodiagnosis of CE is still problematic 
and commercially available tests show suboptimal performance.  Factors that complicate 
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serodiagnosis include lack of standardized immunodiagnostic assays, discrepancy in antigen 
preparation and performance in different laboratories, cyst characteristics like genotype, size, 
stage and location and patient characteristics like age and immuno-competency. Serological 
test for CE have been negative in human immunodeficiency virus (HIV)-positive cases 
(Coupland et al., 2012). Serological assays still have a complementary role and research may 
improve diagnostic performance soon.  False positives are one of the biggest problems in 
serodiagnosis.  Available tests do not differentiate between past (cured or calcified cyst) from 
present (active or progressive) infection because antibodies have been shown to linger many 
years after surgical cure (Nouir et al., 2008; Piccoli et al., 2014).  Performance of serological 
tests may also be dependent on the pathological stage of CE (Mariconti et al., 2014) and a 
single defined molecule may not be sufficient for diagnosis of all stages of CE.  
We set out to explore the value of a panel of recombinant antigens for immuno-diagnosis and 
assess variations in antibody responses to cyst morphological changes. Purified parasite 
Antigens EgFABP1, EgHSP70, EgTPx, EgEF1-β/δ and EgAgB were assessed diagnostic value 
using 100 sera samples from Turkana Kenya.  Results showed difference in antigen reactivity 
towards total IgG, IgG1 and IgG4 isotype subclass antibodies. Although antibodies do not 
appear to be effective disease resolution, they may reflect functional purposes. Rigano et al 
(1995) found that patients who had high serum levels of specific IgG4 responses and low IgG1 
responses towards HCF had poor response to chemotherapy while those who had low IgG1 
responses compared to IgG4 responses had favourable responses to chemotherapy. In another 
study, high IgG4 responses were associated with chronic, symptomatic cases while high IgG1 
responses were associated with acute and asymptomatic cases (Shambesh et al, 1997).  
Higher IgG4 levels were found in active cysts CE1 and CE2 in response to HSP70 and EF1-
β/δ compared to levels of IgG1, while higher IgG1 titres were found in inactive CE4 cysts 
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compared to IgG4.  This was also found by Tenguria et al. (2014) who stated that IgG1 is 
expressed highly in inactive cysts while IgG4 is more expressed in active cysts. Daeki et al 
(2000) also found higher IgG4 levels to be associated with active cysts.  In contrast, responses 
of IgG4 towards AgB was significantly higher in CE4 cases.  Potential to link of the US images 
to immunological markers is needed especially during the cyst stages that are “silent” post-
treatment when the cyst changes may go undetected (von Sinner et al., 1991).  To the clinician, 
information on developmental pathway of disease with a means of predicting, instability or 
transition from degeneration to regeneration would be helpful in choice of intervention. The 
levels of subclass IgG activity with different cyst types showed discriminatory recognition in 
HSP70, EF1 and AgB between active and inactive cyst types.  These immunoserological 
differences are especially helpful in characterisation of CE during field study 
The purified parasite antigens were assessed for their usefulness as immunological markers for 
disease characterisation in long term follow-up. Antibodies fluctuate throughout the course of 
infection in response to varied release of extraneous antigenic material.  Some cysts may have 
arrested development and not change for long periods while others may progress unpredictably 
and show much disparity in structure (Rogan, et al., 2006). In the current study, levels of 
immunoglobulin in a defined panel of CE patients’ sera showed discriminatory antibody 
responses in recognition to some recombinant antigens according to cyst changes. The study 
substantiates the premise that chemotherapy always elicits a wide range of responses towards 
different antigens.  The responses peaked one to two weeks from start of treatment and 
generally declined gradually.  This maybe an indication that at 2 weeks, chemotherapy 
treatment begins affecting cyst integrity causing release of extraneous antigenic material and 
leading to increased immune responses.  From 2 weeks post treatment, it may be possible that 
the cyst losses viability or immune suppression occurs, and this is indicated by decrease in the 
immune responses in most cases to pre-treatment levels. The prognosis is considered 
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favourable if the decline continuous past pre-treatment levels and in cured cases become 
seronegative.  The antibody levels persisted in all the cases followed up. This was post-
chemotherapy, and this may be because cure was not achieved. In other studies where serology 
was used in follow-up, surgically cured patients have shown persisting IgG antibodies in 5 
years of follow-up sometimes even showing increases (Manzano-Román et al., 2015) 
Use of circulating antigens rather than antibodies as a diagnostic tool reduces false negatives 
and cross reactions with other cestodes (Doiz et al., 2001; McManus et al., 2012).  Circulating 
E. granulosus antigens are only detectable in the serum during active infection with levels 
decreasing gradually after successful chemotherapy or surgical removal of the cyst (Devi et al., 
2003).  Antigen detection was found to be very useful in diagnosis of active cysts where 86% 
of CE1 and CE2 cases were seropositive and only 50.5% of inactive CE3 and CE4 were 
seropositive.  
Taken together, findings of this study indicated that the antigen detection assay might be a 
useful method for diagnosis of patients with active hydatidosis. Also, the antigen detection 
assay might be a useful approach for assessment of the efficacy of treatment especially after 
removal of the cyst.  
8.1 Conclusions 
Evidence of spontaneous cure was observed in 7.9% of the cases that did not receive treatment.  
Besides self-cure, 32% of untreated cysts also showed improvement without intervention. 
Treatment should only proceed on deteriorating cysts after a period of observation.  
Second and third dose of chemotherapy is unhelpful in treatment of CE3 and CE4 cysts and a 
different intervention should be considered if the first dose does not give favourable outcome. 
The best tool in general diagnosis of CE is IgG1 responses to TPx with a sensitivity of 98% 
overall 
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Serological responses to each antigen may differ in individual patients and that reactivity may 
be useful in predicting disease progression or regression.  
Antigen diagnosis is useful in diagnosis of active cysts but found no use in follow-up 
8.2 Future work  
This study showed some immunological complexity associated with hydatid cysts in diagnosis 
and their variations during transformation from one cyst-type to another during follow-up. 
However, the sample size was small and follow-up period was short.  More intensive studies 
proving repeatability and consistency of our findings are essential. Other Limitations included 
insufficient patient data and missing US images. Further work would include a more 
comprehensive set of sequential patient sera and partnerships with other countries where 
human hydatidosis endemic. Test for cross reactivity of the antigens used with other helminths 
would also be helpful to determine specificity. 
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10 APPENDIX 
10.1 Patient data collection sheet 
 
 
 
Id number 15 30 12 8 
location Lowarengyah Lokichoggio Lokichoggio Lokichoggio 
age 15 30 52 21 
sex  Male  Female Female  Female 
tribe  Toposa  Turkana  Turkana Turkana 
Previous surgery  Yes No  No  No 
Location of Surgery  Kakuma       
Sample date 02/05/1991 24/01/2003 05/04/1989 10/09/1985 
visit 3 2 7 1 
Follow-Up period (months) 55 0 65 0 
US Result Hydatid Hydatid Hydatid Hydatid 
Cyst Nature Multiple cysts Single cyst Multiple cysts Single cyst 
Multiple cyst number     2 cysts   
Cyst in other location         
WHO classification R liver CE2 CE3 CE3   
WHO Classification L liver         
WHO Classification R Kidney         
WHO Classification L. Kidney         
WHO Classification spleen       CE1 
WHO Classification mesentery CE1       
WHO Classification L. abdomen     CE4   
WHO Classification eye         
WHO Classification muscle         
WHO Classification Lung         
WHO Classification other   CE1     
Size Cyst in R Liver large   Large   
Size Cyst in L liver         
Size Cyst in R kidney         
Size Cyst in L Kidney         
Size Cyst in Spleen       medium 
Size Cyst in Omentum mesentery large       
Size Cyst in lower  abdomen     medium   
Size Cyst in abdominal  wall         
Size Cyst in  eye         
Size Cyst in  muscle         
Size Cyst in  lung     large   
Size Cyst in other  location         
Treatment No Yes no No 
Status of  cyst     No   
Treatment  PAIR         
Result of  PAIR         
Treatment Surgery   endocystectomy     
Type of surgery         
Findings at surgery         
Result after surgery         
Albendazole after surgery         
Type of treatment Albendazole   Yes     
Dosage   1 dose     
Number courses         
Result after treatment Cyst in R Liver   No cyst visible     
Result after treatment Cyst in L liver         
Result after treatment Cyst in R kidney         
Result after treatment Cyst in L Kidney         
Result  after treatment Cyst in Spleen         
Result after treatment Cyst in Omentum Mesentery         
Result after treatment Cyst in lower abdomen         
Result after treatment Cyst in abdominal wall         
Result after treatment Cyst in eye         
Result after treatment Cyst in muscle         
Result after treatment Cyst in lung         
Result after treatment Cyst in other location   recurrence     
Further Information Surgery recommended   Self-cure  No change 
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10.2 Variations in circulating antibodies and circulating antigens during follow-up 
a) 
Figure 10-1: Comparison between circulating antigen and circulating antibody titres in 
Unchanging cysts 
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Figure 10-2:  Comparison between circulating antigen and circulating antibody titres in 
cysts hanging from active to inactive.  
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